Genomics
for Good
2022 Corporate Social Responsibility Report

Genomics for Good

Table of Contents
Illumina

At Illumina, we are driven by the power of genomics to positively
impact the world and shape a more sustainable and equitable
future for all.
Our third annual Corporate Social Responsibility Report describes the evolution of
our environmental, social, and governance (ESG) program from January 1 throughDecember 31, 2021.
This report reflects the progress we have made and looks to the future withour continued commitment to deepen our impact on human health by serving as achampion for patients, our communities, our people, and our planet.

1

Integrating Environmental Sustainability

38

Introduction ................................................................................1

Strategic Approach and Impact..................................................39

A Message from Our CEO............................................................ 2

Climate Action............................................................................... 41

2021 Highlights ............................................................................4

Facilities.........................................................................................43

Illumina Overview . .................................................................... 5

Products.........................................................................................45

Understanding Genomic Fundamentals..................................... 6

Value Chain....................................................................................47

About Illumina................................................................................ 7

Sustainability Applications...........................................................49

Illumina Impact at a Glance.......................................................... 8
Business Overview....................................................................... 9

Nurturing Our People

51

CSR Strategy.............................................................................10

Strategic Approach and Impact..................................................52

Q&A with Our CFO...................................................................... 10

Our People.....................................................................................54

CSR Governance..........................................................................11

Diversity, Equity, and Inclusion....................................................56

Connecting CSR Strategy to Our Business.............................. 12

Investing in Our People................................................................ 61

Our CSR Strategy: Creating Unique Impact............................. 13

Caring for Our Employees............................................................65
Workplace Health and Safety......................................................67

Expanding Access to Genomics

14

Strategic Approach and Impact.................................................. 15

Operating Responsibly

Innovation and Affordability......................................................... 17

Strategic Approach and Impact.................................................. 71

Equitable Access and Data Diversity..........................................20

Corporate Governance.................................................................73

Improving Reach............................................................................2570

Ethics and Compliance................................................................. 74
Human Rights................................................................................ 77

Empowering Our Communities

30

Data Security and Privacy............................................................78

Strategic Approach and Impact.................................................. 31

Public Policy...................................................................................80

Strategic Philanthropy................................................................. 33

Responsible Supply Chain........................................................... 81

Engaging Our People....................................................................34
Inspiring Future Generations.......................................................35

Appendix

85

Reporting Overview......................................................................86
Key Performance Indicators........................................................87
Indices (GRI, SASB, TCFD, SDGs)............................................. 100
Assurance Statements............................................................... 109
Disclosures.................................................................................... 111
Singapore leaders celebrating 2021 International Women’s Day#ChoosetoChallenge #IWD2021

Illumina

AccessIntroduction | Illumina Overview | CSR Strategy

Community

ESG at Illumina

Environment

Patient

Community

PeopleEnvironment

A Message from Our CEO
We entered 2021 full of hope for a recovery from the pandemic, at the dawn of a new era of genomic
medicine, and a recognition of the incredible opportunities for us to rebuild a healthier, more inclusive, andmore sustainable global community.
In the past year, we saw countless examples of resilience, perseverance
and progress as we continued to respond to the pandemic, push for greater
equity, and protect our planet through genomic innovation.
Genomics has revolutionized response to the pandemic and the future ofhealthcare. The speed of development, and the high efficacy and safetyof mRNA vaccines have been an unprecedented medical and scientifictriumph. Genomics has now gone mainstream, and will be an increasingly
critical part of public health, from fighting and preventing pandemics torevolutionizing diagnosis, treatment, and prevention of disease. We believe
the life-changing benefits of genomics should be available to the many,
not the few.
Guided by our Mission, we are taking action through our businessstrategy to Expand Access to Genomics, Empower our Communities,
Integrate Environmental Sustainability, Nurture our People, and Operate
Responsibly. We are working to expand access by enabling innovation anddriving affordability, by broadening the reach of the genomic ecosystem,and ensuring equitable access with representative data to drive greater
health equity.
This past year the world crossed a significant milestone for genomic testing,with over one billion people across 45 countries reimbursed for genomic
tests, cancer therapy selection, genetic disease diagnosis, and non-invasive
prenatal testing. We aim to reach two billion covered lives by 2026. Throughinnovation and investments in R&D, we are unlocking new possibilities forclinicians to power personalized medicine, improve patient outcomes, anddrive down overall healthcare costs.

Integrity

PeopleIntegrity

Appendix

Appendix

Genomics has
revolutionized responseto the pandemic and thefuture of healthcare.”

We expanded our operations with applications that build on thetransformational impact genomics can provide for human health andthe economics of healthcare. Our software portfolio has evolved to help
geneticists and clinicians diagnose rare disease patients with Artificial
Intelligence (AI) technologies that provide genomic interpretation at scale.
In 2021, we acquired GRAIL, and it remains subject to an ongoing merger
review in the European Union. It is being held and operated separately.
We believe our acquisition of previously-spun off GRAIL will ultimately
accelerate access and adoption of a breakthrough multi-cancer early
detection blood test. GRAIL’s Galleri® blood test can detect more than 50
types of cancer in asymptomatic patients, with the potential to improve
patient outcomes and provide leaps forward in the fight against cancer.
By empowering our communities through philanthropic support, we areworking to bridge the gaps for areas in need. In 2021, we committed$60 million of in-kind product contributions for a Pathogen Genomic
Initiative (PGI) to help create a comprehensive pathogen genomic surveillance
network to build critical public health capabilities. In its foundational year, wedelivered close to $5 million in product donations to Africa and Southeast
Asia. We also committed $120 million of product donations to support thelaunch of the iHope™ Genetic Health initiative with a target of half of the
donations outside the US and at least one-third dedicated to patients in
Africa. The new effort aims to rapidly scale access to clinical whole genome
sequencing at labs across the world and reach thousands of rare disease
patients a year in resource-limited communities.

Francis deSouza, CEO

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

2

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

A Message from Our CEO

We deepened the integration of environmental
sustainability with our updated climate action
plan and Net Zero commitments. We set ambitious
science-based emission reduction targets for our
entire value chain as part of our overall businessstrategy to minimize climate risk, build climate
resilience, and identify opportunities. In September,
our targets were officially verified by the Science
Based Targets initiative (SBTi). This year, we
reduced our global carbon emissions from ourdirect operations by 24%.
The exponential growth of Illumina provides
expansive opportunities for our employees.
Nurturing our people and creating an environmentof inclusion is foundational to our current andfuture success. We continue to advance diversity
and inclusion to create a culture of equity andbelonging in our workplace, community, suppliers,and business partners. In 2021, we achieved 17%
spend to diverse suppliers in the US. We expanded
our employee resource groups with over 4,000
employees participating in diversity, equity, andinclusion programming and we are proud to haveagain confirmed a net zero gap in pay.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTAs macro-trends resulting from thepandemic continue to shape thelabor market, we are well-positioned
to attract top talent looking for a
purpose-driven company, strong
business performance, flexible
working conditions, and a
responsible corporate citizen.”
Our current employees continue to report in quarterly
surveys high Trust and Engagement Indexes of90%, with 93% reporting they are proud to work forIllumina, and 92% reporting they believe Illumina
values diversity. Our efforts are ongoing and weare committed to increasing the representationof women and ethnic and racial minorities in our
workforce and leadership.

Operating responsibly as good corporate
citizens, we do business in a way that reflects
the very best of Illumina and honors the trust thatpatients, our employees, customers, community,
and shareholders put in us. Our role as a genomics
pioneer brings with it the responsibility to enable
innovation for good with the technology we create,
and the data collected is used safely, ethically,
and responsibly.
Our holistic reporting strategy is designed toprovide transparency on how environmental,social, and governance (ESG) topics affect ourbusiness internally, and how we impact theenvironment, and society externally. This year, we
refreshed our materiality assessment to confirm themost material ESG issues and to remain attuned toour stakeholder feedback on where we can makethe most impact. We continue to align our ESG
reporting to the Global Reporting Initiative (GRI),
the Sustainable Accounting Standards Board (SASB)
standards, and the Task Force on Climate-related
Financial Disclosures (TCFD). We remain focusedon supporting the United Nations Sustainable
Development Goals and the principles of theUnited Nations Global Compact.

As we look to the future, we view our CSR program
through the lens of continuous improvement and wewill continue to strive to be the best employer, thebest environmental steward, and the best corporate
citizen we can possibly be.
Many thanks to our partners, collaborators, and to
the incredible researchers and clinicians we serve. A
special thanks to our employees for helping Illumina
thrive, for giving back to our communities, for taking
care of one another, and bringing our Mission to life.
Together, we are advancing genomics to improve
human health and beyond.

Francis deSouza
Chief Executive Officer3

Illumina

AccessCommunity

Introduction | Illumina Overview | CSR Strategy

ESG at Illumina

Environment

Patient

Community

PeopleEnvironment

Integrity

PeopleIntegrity

Appendix

Appendix

2021 Highlights

Expanding Access to Genomics

Empowering Our Communities

Integrating Sustainability

Nurturing Our People

Operating Responsibly• 1 billion covered lives• $14.5M total donations• Maintained a zero net pay gap• $5M in-kind donations supporting
year 1 implementation of the Pathogen
Genomics Initiative• 1,345 causes supported• Committed to Net Zero in our operationsand value chain by 2050

• 100% Illumina facilities participatedin third-party audit programs• 30,000 medical education
learners reached• $120M committed to launch iHope™
Genetic Health• 31% Employee Participation ingiving and volunteer programs• 59% of global electricity consumption
came from renewable sources• >315,000 STEM learners• Completed first Scope 3 assessment• >9,500 volunteer hours donated• $700K donations for sustainability andenvironmental justice initiatives• 18 new genomic companies fundedthrough Illumina for Startups• 84% of our strategic supplierscommitted to minimize theirenvironmental footprint• 50% minority representation in the
US workforce• 45% global female workforce• 5% increase in female executive
leadership representation in last
three years• >4,000 participants in employee
resource group programming• Human Rights Impact
Assessment initiated• Published first annual
Transparency Report• Developed and disclosed Ethical
AI Principles• 17% diverse supplier spend• 24% reduction of global carbon
emissions from our direct operations

2021 Recognition

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

4

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

Illumina Overview
As an engine of genomics innovation, we areenabling tomorrow’s discoveries5Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

Understanding Genomic
Fundamentals
What causes a cancer cell to mutate? How do you
identify a novel virus like COVID-19 and create a
vaccine? How do we safeguard the world’s foodsupply? What effect does climate change have on
biodiversity? The answer to these and thousandsof life’s most pressing questions can be found in
the world of genomics.

01

A Genome
Set of genetic instructions.

Only a handful of genes differ fromperson to person. We are 99.9%
genetically identical.

02
03

Small section of DNA that make up
the functional unit of heredity.

DNA

All living things have DNA.

Instructions in a genome withunique chemical code to guide
growth, development, and health.
Two twisting, paired strands.

04
There are 3 billion letters(bases) in the human genome.

05

06 Illumina Technology

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Genes

Bases
The DNA found in living organisms is
made up of nucleotide bases. These fourchemical units are abbreviated A, C, G, T.

Genome Sequencing
Ability to read the billions of letters of
the DNA, find variants, and help develop
testing, treatment, and personalized
medicine.

Our pioneering technology unlocks the power of the
genome’s potential on fighting infectious disease,diagnosing cancer, creating sustainable agriculture,and researching biodiversity.

First sequence of the full humangenome cost $3 billion. Today,
Illumina achieves a $600 genome.

6Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

About Illumina
Genomics is the single most important revolution of our time.
Illumina is a global genomics and human healthcompany powering the future of personalized
medicine and beyond. At Illumina, our efforts haveturned ideas into innovations impacting millions ofpeople and unlocking discoveries across the field ofgenomics. The results are all around you—in the careyou receive, the decisions you make for your family,
the environment, and the food you eat. Yet, we know
we are just getting started.
We have the great honor of continuing the legacyof the Human Genome Project by providing new
insights into the genetic code and having a profound
impact on scientific research and healthcare. We area leader in genomics, innovating at the intersection of
biology, technology, and health.
We are re-imagining what is possible with
unprecedented advances in next-generation
sequencing. As a genomics pioneer, we have proven

Our Mission:

through focused and continued innovation how
unlocking the power of the genome can exponentially
improve the human condition. Our ability to drive
patient outcomes has made us a trusted partnerin healthcare.
Today, we are providing tools that enable the next
generation of researchers and clinicians to usher inthe future of personalized medicine. In agriculture
and the environment, we’re developing microarrayand sequencing technologies that will help ourplanet and food system support a rapidly growing
human population, conduct research on biodiversity,and study climate change impacts.
Driven by our Mission, we are committed to making
our technology more affordable and accessible,
realizing health equity for billions around the world.
Illumina is not just a company at the forefront of a
global genomics movement, we are at the center ofa global health transformation.

Improve Human Health by
Unlocking the Power of the Genome
Our Values:

Innovation isin our DNA

We are relentless inthe creation of great
products

We collaborate
deeplyWe move fast andembrace change

We areopen

Illumina Innovation Vectors

Oncology

Reproductive Health2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Genetic Disease

Research/Applied Genomics

Infectious Disease

Drug Discovery

Proteomics

7

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

Illumina Impact at a Glance
OUR LOCATIONS

9,191

employees

women

55%
men

50%

64

$209M

$4.5B

$885M

20%

>20,000
cumulative
sequencing
installed base24%

Scope 1 and 2
CO2e reduction

average hours
training per person

R&D investment>8,000

total Illumina
customers

59%

renewable
electricity

US Minority Workforce: Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Americas
Baltimore, MD, US 4
Foster City, CA, US 3, 4, 6
Hayward, CA, US 2, 4
Madison, WI, US 2, 4, 6
San Diego, CA, US 1, 2, 3, 4, 5, 6
São Paulo, Brazil 4

minority1 representationin US workforce

Zero Net
Pay Gap

2021 revenue

1

45%

Greater China
Beijing, China 4
Shanghai, China 4
Taipei, China 4

diverse supplier
spend

total revenue
invested in R&D

140

countries receive
our products$14.5M
donatedHeadquarters
San Diego, CA

EMEA
Berlin, Germany 4
Cambridge, UK 4, 5, 6
Eindhoven, Netherlands 4, 5
Evry, France 4
Istanbul, Turkey 4
Mechelen, Belgium 4
Moscow, Russia 4
Rennes, France 4
Steenoven, Netherlands4, 5
Tel Aviv, Israel 4

Asia Pacific
Melbourne, Australia 4
Osaka, Japan 4
Seoul, South Korea 4
Singapore 2, 4, 5, 6
Tokyo, Japan 4

1 Headquarters, 2 Manufacturing, 3 Clinical, 4 Commercial, 5 Distribution Center, 6 R&D

8Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

Business Overview
Financial Performance

$4.5B

R

71%

Consumables
Library prep and proprietary sequencing kits such

$3.2B

$3.3B

$3.5B

G
CA
r
ea
-y

5

$2.8B

$2.4B

%
14

Revenue Details

as flow cells and reagents for our sequencing andRevenue$4.5B

microarray instruments

12%

17%

2021

2020

2019

2018

2017

2016

Instruments

Service and Other

Our sequencing systems span the full range

Warranties and maintenance contracts for systems

of applications as well as a microarrayand services undertaken in our labs, revenue from

instrument to support genotyping

intellectual property fees, in vitro diagnostic licensing,milestones, and informatics

Sequencing systems for virtually every application and every lab

iSeqTM 100

MiSeqTM and MiSeq DxTM

Affordable, simple,

Speed and simplicity forand powerfultargeted and small genome
sequencing

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTNextSeqTM 550, NextSeqTM
550Dx, and NextSeqTM
1000 and 2000
Deeper, larger studies on abenchtop platform

NovaSeqTM 6000
Flexible, scalable NGS
system for virtually any
application9

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

Driving Long-Term Business Value through ESG
Q & A with our Chief Financial Officer, Sam Samad

Q: How do Illumina environmental, social, andgovernance (ESG) goals fit into the overall financial
strategy of the company?

A:

Furthering our ESG strategy is directly tied
to furthering our business strategy. Stewardshipof our fiduciary responsibility includes a strongemphasis on managing risk, driving performance,and ensuring business integrity. ESG provides alens to evaluate opportunities that incorporate thevoice of all our stakeholders.
There is tremendous data that supports the links
between ESG strength with better business outcomes
across several financial metrics. The financial links to
ESG are about investment and value. ESG is not just a
cost center...it is a center of value creation.
We are investing into more sustainable facilities,
products, and our value chain. These investments arelinked to our core business and to the UN Sustainable
Development Goals for climate, innovation, and ofcourse...health and well-being.
We have made ESG a strategic priority in how we dobusiness. As CFO, I am looking for ways to ensure weare protecting the long-term value of the company andthat includes both financial and non-financial inputs
related to risk and opportunities.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTWe are committed to ensuring adequate investment
in ESG programming, applying consistent andtransparent reporting standards, requiring
accountability on key ESG metrics, and utilizing ourenterprise risk management approach.
ESG issues cover the span of our organization and has
successfully been integrated in our business. For the
Finance organization, it has been a natural expansionof our existing governance on cost optimization,accountability, risk analysis, internal monitoring,
reporting transparency, and data assurance.

Q: What do you see for the future of ESG and

how is Illumina positioned?

A:

As CFO, I believe investing in our ESG initiatives
can drive growth, create innovation, and contributeto our long-term success. I foresee that ESG willcontinue to link to customer satisfaction, the ability
to attract and retain top talent, create operationaland financial benefits, and help us understand risk
and opportunities. Illumina has a great foundation inplace, and we will continue to evolve and advance
our ESG strategy for the future.
By engaging and empowering all our stakeholders,
including customers, business partners, employees
and communities, we will continue to build
resilience, create long-term value and supportscience that advances public health and the healthof our planet.

I believe increased recognition on theimportance of ESG will drive mandatory reportingand more investment to support shifts to a carbon
free economy.
At Illumina, we are already participating incomprehensive and voluntary reporting that
represents the most material topics for ourcompany and our industry. We are committed
to transparency in our reporting and are well
positioned for the evolving regulatory reporting
requirements around the globe.

Sam Samad, CFO

ESG is not just a cost center…it isa center of value creation.”10Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

CSR Governance
We govern CSR at the highest level with oversight from the full Board of Directors (Board).

CSR is integral to how we do business. Our
governance structure facilitates accountability,transparency, and continuous improvement.

• This strong leadership supports the management of material environmental, social, and governance issues, including climate
action, diversity, equity and inclusion, human rights, cybersecurity, and ethical, responsible business practices• The Board provides oversight and receives updates on current performance and future strategic plans at least annually or more
frequently if material changes occur• Select ESG targets are included in annual corporate goals and influence executive compensation through the management
performance scorecard• Learn more about our Board governance, member tenure, independence, and diversity in the Integrity chapter

Board ofDirectors

CSR Executive Steering Committee

Giving Governance• Chaired by CFO• The Illumina Corporate Citizenship Steering Committee
has oversight on philanthropic contributions from Illumina.
Membership is comprised of the CEO, CFO, General Counsel,
Chief Medical Officer, and Chief People Officer• Comprised of senior leadership team from across organization• Provides guidance on CSR strategic plans and practices

CEO + Executive Leadership
CSR Executive Steering Committee
Giving Governance• Approves major ESG programs and monitors progress toward2030 and 2050 targets• Members include Chief Medical Officer, General Counsel, Chief ofGlobal Operations, Chief People Officer, Chief Technology Officer,
Chief Marketing Officer, and Global Head of CSR• The Illumina Corporate Foundation Board governs the philanthropy
associated with the Illumina Corporate Foundation, a separate
entity and private foundation. The foundation board is comprisedof Illumina senior leaders including the CEO, CFO, General Counsel,
Chief Medical Officer, Chief People Officer, and VP Treasury• The CSR function is responsible for strategy development, program implementation, and ESG reporting
CSR Functional Group

Supporting CSR Working Groups
Executive Diversity Council | Environment, Health & Safety Steering Committee | Quality Council
Public Policy Committee | Sustainable Product Core Team | Supply Chain Sustainability• The CSR functional group focuses on long-term value creation and risk mitigation• CSR programs are embedded into our business through several supporting cross-functional working groups• These teams work to operationalize and integrate CSR in each of their respective programs& Responsibility Working Group | Supplier Diversity Governance Committee• We offer employees the ability to directly participate in our CSR program through a variety of grassroots efforts
Employee Engagement Groups
Sustainability Green Teams | Illumina Cares Volunteer Champions | Employee Resource Groups

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT• These teams provide a wealth of ideas and support for activation at local levels all aimed to link our CSR efforts
back to our Mission

11

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

Connecting CSR Strategy
to Our Business
Stakeholder Engagement

Our first materiality1 assessment was conducted
in 2018, engaging a range of internal and external
stakeholders to assess ESG issues important to ourbusiness and our ability to create impact.

ents
Pati

Suppl
iers
Co
pa mm
rtn u
e

el
ann
Ch rtners
pa

Emp
loye
es

ty
ni s
r

H
pr e

re
ca s
th er
al vido

In 2021, we engaged with an external consultancy
firm to refresh our materiality assessment. This
gave us an opportunity to confirm the mostmaterial ESG issues and remain attuned to ourstakeholder feedback on what is most importantto our business, our stakeholders, and where wecan make the most impact.

CSR peergroups

rs
to
bu
tri
Dis

Inv
es
tor
s

Government& regulations

The updated assessment revealed the themes ofaccess, diversity, and sustainability increased inleveling from the previous assessment. Groupingof themes was updated to align with reporting
frameworks and relevant industry naming convention.
There was no change in leveling of data privacy,
philanthropy, human capital, or health and safety.
Based on the updated materiality assessment, ourcurrent CSR focus areas remain relevant, are stillreflective of the most material topics for Illumina, andconfirm appropriate prioritization of existing efforts.

2021 Materiality Results
Environmental

No
np
rof
its

We engagea wide rangeof stakeholders

Customers

We are committed to operating with transparency andopen communication to develop trusted relationships
with all our stakeholders. Since the creation of our
CSR program, we have routinely gathered feedback
on environmental, social, and governance (ESG)
topics from our stakeholders. As part of our ongoingengagement, we have used a variety of ways to gather
feedback and gauge interests including customer
surveys, employee surveys, industry trade group
participation, and guidance from relevant frameworks
such as the UN Global Compact and Sustainable
Development Goals. In addition, we continue to
use external benchmarking such as the Dow Jones
Sustainability Index, CDP, Gender Equality Index, andCorporate Equality Index to identify areas of focus
and opportunities.

Materiality Assessment RefreshSocialGovernance• Genomic Literacy• Data Privacy & Security • Access to Healthcare• Ethical Use of Genomics& Genomics• Sustainable Products• Biodiversity• Community& STEM Education

tr yus
Ind derslea& Philanthropy• Human Rights

Our strategy and reporting approach aligns with international ESG frameworks and a commitment to providing

Impact to Business

transparency on our progress.

• Customer Engagement& Patient Voice• Pricing & Affordability• Employee Health& Safety• Market Presence& Innovation• Product Safety& Quality• Diversity, Equity& Inclusion• Sustainable Facilities(climate, emissions,energy)• Responsible & Sustainable
Supply Chain• Corporate Governance,

Business Ethics& Transparency• Human Capital (attraction,
development, retention,
engagement)• Fair Labor Practices

Importance to Illumina Business

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

1

In this report, we use the terms “material” and “materiality” to refer to topics that reflect Illumina’s meaningful environmental, social, and governance impact. The use of such terms shall not be deemed to constitute anadmission as to the materiality of any information in this report for purposes of applicable securities laws or any other laws of the United States, nor are we using them as they are used in the context of financial statements
and financial reporting.

12

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Introduction | Illumina Overview | CSR Strategy

Our CSR Strategy: Creating Unique Impact
As a mission-driven company, our CSR strategy focuses on delivering sustainable long-term value by addressing the most significant andmaterial environmental, social, and governance areas. We align our priorities and targets to support the 17 United Nations Sustainable
Development Goals and have identified eight we can most uniquely impact.
We are committed to integrating environmental
stewardship into the way we operate. We recognize theimportance of the environment in creating a healthy,
sustainable future for all.

Harnessing extraordinary talent and helping
them thrive allows us to make world-changing
leaps in human health and beyond. Our aim
is to nurture a culture of care that is fueledby supporting one another, promoting
collaboration, inspiring innovation, andfostering diversity, equity, and inclusion.

By sharing our time, talent, and technology,
we aim to inspire, support, and empower
patients, our communities, our employees,
and the next generation.

Our role as a genomics pioneer
brings with it the responsibility toenable innovation for good, ensuringthat the technology we create andthe data we collect are used safely,
ethically, and responsibly.

We aim to drive down the cost of
sequencing, expand access to genomic
technology, and increase the diversityof data to bring the transformative
benefits of genomics for all.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTGUIDING PRINCIPLE
We believe that pursuing our Mission to improve human health extends beyond bringing innovation to market.
We have a responsibility to ensure that everyone can benefit from unlocking the power of the genome.
It is in our DNA to lead with sustainable, responsible, and proactive corporate citizenship.

13

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Expanding Accessto Genomics
14

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Expanding Access to Genomics:

Our Strategic Approach
We are committed to expanding access to the transformative benefitsof genomics. We are driven by our conviction that genomics should beavailable to the many, not the few.
Overview

Our Objectives

Genomics has the power to save lives and vastly improve the human condition. As a leader in genomics,
we are focused on driving down the cost of sequencing, expanding access to diagnostics technology,
and increasing the diversity of genomics data to realize health equity for billions of people aroundthe world.

Enabling Innovation and Affordability

We are proud to help scientists make major discoveries as we make sequencing more accessible andaffordable. While developments in genomics have led to enormous breakthroughs in human health,implementation has been almost entirely restricted to more developed nations.

• Reduce the cost of genome sequencing

To successfully fulfill our Mission to improve human health, we must expand access to genomic
technology and precision medicine, regardless of social status, income, or geographic location. We
must continue to bridge the gaps to ensure inclusion of data that represents our global diversity.

• Support philanthropic opportunities• Advance product innovation• Invest in strategic acquisitions, partnerships,
and collaborations

Ensuring Equitable Access and Data Diversity• Increase diversity of genomic data
• Champion patient advocacy
Improving Reach to Broaden the Genomic Ecosystem• Provide genomic literacy education
for health care professionals

Global health inequities highlighted during this pandemic haveintensified the urgency of enabling access to genomic testing
for all. Our genomic knowledge should reflect the beautiful
diversity of humankind and make sequencing more accessible,
so that patients in all communities can benefit.”• Engage with regulators, payers, andgovernment authorities• Catalyze genomic startups

Contributing to the UN SDGs

Phil Febbo, Chief Medical Officer

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

15

Access

Illumina

Community

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Expanding Access to Genomics:

Measuring Our Impact
2030 Targets

2021 Highlights

Achieve $100 genome

Achieve 2 billion covered lives by 2026

2021 PROGRESS

2021 PROGRESS$600

1 billion

2021 Recognition

20%

revenue invested in R&D

covered lives

Support 50,000 patients throughphilanthropic iHope

TM

programming

2021 PROGRESS

1,150

Support >200 genomic startups
2021 PROGRESS

63

$120M

committed to launch iHopeTM
Genetic Healthstartups since inception

patients

Activate Pathogen Genomics Initiative

Reach at least 25,000 medical education

donations enabling our $60 million

learners annuallycommitments by 2027
2021 PROGRESS$5M

2021 PROGRESS

18

new genomic companies fundedthrough Illumina for Startups

30,000learners

in-kind donations

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

16

Access

Illumina

Community

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Enabling Innovation and Affordability
As a genomics pioneer, we have proven through focused and continuous innovationthat unlocking the power of the genome can exponentially improve the human condition.
There is urgency to our Mission because we understand thattoday’s discoveries have the potential to help tomorrow’s
patients. Our ability to drive patient outcomes has made us atrusted partner in healthcare. Today, we’re providing tools thatenable the next generation of researchers and clinicians tousher in the future of personalized medicine.
Innovating at the intersection of technology, biology, andhealth, we are re-imagining what’s possible for clinicians,
transforming how they detect, diagnose, and treat cancer aswell as other rare, infectious, and genetic diseases.
Unprecedented advances in next-generation genetic sequencing(NGS) are enabling patients to make more informed choices thatcan change lives. That’s why we create cutting-edge technologies
that diagnose patients more quickly, more accurately, and morecost efficiently. Every technological breakthrough that increases
yield, improves product quality, or reduces the cost of sequencing
leads to the potential to improve lives.

Innovation for Every Stageof Workflow
As we continue to unlock the power of the genome, the amountof data generated from NGS is rapidly expanding. To reach the fullpotential of genomics in healthcare, there is a need not only foraccessible sequencing and data creation, but also for advanced
systems to easily analyze that data. In 2021, we made significant
improvements to our platforms and product pipeline to provide
ultra-rapid, highly accurate, comprehensive, and scalable analysisof this data.

Transforming Genomic
Data into Catalysts
Launched in 2021, Illumina Connected Analytics (ICA)
is a new integrated bioinformatics solution providing acomprehensive, private, cloud-based data platform. ICA
empowers customers to manage, analyze, and explore large
volumes of multi-genomic data in a scalable and flexible
environment with security and privacy at its core. Harnessing
the technology brought from the 2020 acquisition of
BlueBee, ICA provides users the flexibility to run custom
analyses and access our DRAGENTM Bio-IT Platform.

50x
5x

faster*lower data footprint**

Next-Generating Sequencing Workflow

Library Prep

Sequencing

Data Analysis

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Aggregation

Exploration

Sharing*mapping/variant calling for whole-genome sequencing**from compression

17

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Enabling Innovation and Affordability

Cost Per Genome

Driving Affordability
We’ve helped take the cost of sequencing the
genome from $3 billion to $600, putting our dreamof a $100 genome within reach. We aim to make ourtechnology affordable and accessible to as many
patients as possible, while setting high standards forthe ethical use and security of data.

2003$3,000,000,000
2006$20,000,000
2007$2,000,000
2008$200,0002010$10,000

2014$1,000

Launch of our NovaSeqTM
6000 v1.5 Reagent Kit

2020

$600

$100

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTCOVID-19 Focus:

Bringing Pandemic Surveillance Beyond
Big Cities Through Innovation
Increasing surveillance for detection of emerging and prevalent variants is critical to the global
efforts to control the virus. Many countries are sequencing positive cases of COVID-19 andreporting variants to support public health management. Most genomic data is coming from large
genomic centers where labs have the capacity for high-throughput sample processing, while
countries with limited resources have low submissions to COVID-19 surveillance networks.
With the debut of the COVIDSeq™ Assay, smaller labs are better enabled to participate in the
global surveillance for the pandemic to identify SARS-CoV-2 virus mutations and provide criticalinformation on the epidemiology of new variants.
The COVIDSeq™ Assay provides low- and mid-throughput labs access to de-centralized
surveillance on a smaller scale so they can sequence and identify viral variants—a critical enabler
for public health agencies managing the COVID-19 pandemic. Learn More

Processing Power to Fight the Pandemic
DRAGEN™ (Dynamic Read Analysis for GENomics) Bio-IT
Platform uses hardware technology to provide ultrarapid
analysis, further improving quality and reducing secondary
data analysis time—all with the goal of enabling insightsfrom sequencing data faster. We continue to provide theIllumina SARS-CoV-2 Data Toolkit at no cost to the global
research community in support of efforts to combat
the pandemic.

1.25 million
samples processed through
COVIDSeq™ protocol andanalyzed through DRAGEN™
with the COVIDSeq™
BaseSpace Sequence Hub app

117

>75%

from Illumina instruments

were performed on Illumina instruments

countries providing sequencing dataof COVID-19 data submissions to GISAID

18

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Enabling Innovation and Affordability

Powering the Future of Personalized Medicine Together
Enabling innovation and driving affordability goes beyond delivering sequencers
and data. It includes delivering insights and accelerating the paradigm shift toward
genomic sequencing as a standard of care to improve patient outcomes and drive
down overall healthcare costs.

Accelerating the Identification of Genetic Disease Through Innovation in Partnership
In some cases, the diagnostic odyssey to identify genetic disease is a race against time, when an early
diagnosis can dramatically improve patient outcomes, save a child’s life, or help a patient live a healthier life.

In addition to our internal innovation engine, we leverage strategic acquisitions, partnerships, andcollaborations to further support our Mission, drive affordability, and expand access to genomics for all
so that the potential of personalized medicine can be realized.

Cancer is a disease of the genome and treatment will increasingly leverage NGS-based tests—from
early detection and diagnoses to therapy selection and monitoring. We are committed to innovating anddiversifying our oncology product portfolio and partnerships. The continued expansion of our TruSight
Oncology pipeline complements our acquisition of multi-cancer early detection company GRAIL.

Emedegene

A Diagnostic BreakthroughEmedgene (pronounced: imagine), helps geneticists and clinicians to diagnose rare disease patients byoffering artificial intelligence technologies that provide genomic interpretation at scale. Adding Emedgene
technology into our software portfolio will provide valuable data insights to clinicians for more personalized
treatment decisions.

Our TruSight™ Software Suite, powered by DRAGEN™ variant-calling, is making it possible for labs to
cut through millions of variants to find the one (or two) that is making someone ill, and in turn, result infast‑tracking the right treatment for patients.

GRAIL
In 2021, we closed on the acquisition of GRAIL,
a previous spin-off of Illumina. GRAIL is focused onlife-saving early detection of multiple cancers—all
through a simple blood test in a doctor’s office.
GRAIL’s Galleri® blood test can detect more than
50 types of cancer in asymptomatic patients. Our
acquisition of GRAIL will accelerate access andadoption of this life-saving test worldwide. The
acquisition is subject to ongoing legal proceedings
and pending the European Commission’s ongoingmerger review. GRAIL is currently being held andoperated as a separate company, with oversightprovided by an appointed, independent monitoring
trustee during the European Commission’s ongoingmerger review.
2022 CORPORATE SOCIAL RESPONSIBILITY REPORTOur partnership with Kartos Therapeutics led to the co-development of a project to create a next‑generation,
sequencing‑based companion diagnostic. The new companion diagnostic will use whole blood as adiagnostic sample type, enabling the detection of blood cancers such as leukemia and lymphoma.
By leveraging our technology and harnessing the expertise with commercial partnerships, we continue toadvance the Illumina commitment to develop standardized, globally distributable tools for precision medicine.

Partnerships with a Common Goal
Oncology partnerships announced in 2021 included Bristol Myers Squibb, Kura Oncology, Myriad Genetics, Gilead, and Merck.
Partnerships can magnify impact and enhance common goals. The following partnerships reflect examples of collaborations
and our approach to creating the connective tissue uniting industry.
• Access to Comprehensive Genomic Profiling Coalition• Blood Profiling Atlas in Cancer Consortium• Coalition for Access to Prenatal Screening• DNA Data Storage Alliance• European Confederation of Pharmaceutical Entrepreneurs• Genomic Medicine Sweden• German National Action League for People with Rare Diseases• Harvard Pilgrim Health Care• International Consortium on Acute Leukemia• Medical Genome Initiative• University of Melbourne Genomics Hub• Weill Cornell Medicine and New York-Presbyterian Hospital

19

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Ensuring Equitable Access and Data Diversity
Genomics has been integrated into clinical practice at a faster rate than almost any innovation in thehistory of medicine, but inequities still exist. Implementation has been almost entirely restricted to moredeveloped nations, and 70% of the genomes we have today are of Caucasian descent.
Genomics is creating a path toward personalized medicine and inspiring hope worldwide, but there is avital need to make genomic technology and precision medicine available to all, regardless of their social
status, income, or geographic location. To ensure that genomes can be interpreted in the appropriate
context of global diversity, we aim to increase the equity of representation in genomic data. With equitable
representation in the data, therapies and solutions can be attuned to a broader set of genomes, decreasing
this bias in our medicine for the future.

Commercial Initiatives: Genomic Diversity Projects
Several countries worldwide have initiated large scale population genomics projects as well as large
collaborative efforts to increase diversity in human genetics. We are proud to be a part of these commercial
initiatives that are bringing more focus to cover the diversity of world ancestries and ensure that genomic
representation is part of equitable health care in the future.

Qatar Genome Program
Today, less than 1%1 of the genome
inventory represents ancestries from
Arab and Middle Eastern populations. With thisunderrepresentation in genetics data, the ability tobenefit from genomic applications is limited. The
Qatar Genome Program (QGP) aims to correct that.
This group is using Illumina technology to sequence
individuals from the general population of Qatar.
Insights from phase one of the QGP, which
sequenced 6,045 individuals, identified more than
88 million variants, of which 24 million are novel.
2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Based on sequencing data, the results highlighted
the value of advancing genetic studies in the Araband neighboring Middle Eastern populations. This
will significantly improve our understanding of
global patterns of human variations, human history,
and genetic contributions to health and diseases
in diverse populations.

Human Heredity and Healthin Africa
The African genome is the oldest humangenome, with Africa containing moregenetic diversity than any other continent. It isestimated, however, that fewer than 3% of analyzed
genomes come from Africans, creating a gap in the
representation of genetic information for healthand diagnostic research. There is an enormous
opportunity to utilize genomics to benefit African
populations and to inform global health.

Shanghai Genomics Alliance
Launched in 2021, the Shanghai
Genomics Alliance brings together
allies from across the industry. Over 50 industry
and governmental partners have come together
to collaborate in the genetic testing field in China.
The Alliance is committed to improving the level ofinnovation in the field of genetic testing technology
in China, accelerating the industrializationof technology, and promoting collaboration
among members.

The Human Heredity and Health in Africa (H3Africa)
consortium, led by African scientists for the
African people, facilitates fundamental research
into diseases on the African continent while also
developing infrastructure, resources, training, andethical guidelines to support a sustainable African
research enterprise.
Illumina supports H3Africa’s efforts with an open
human consortia. The consortia helps biomedical
researchers work together to design and run
customer genomics assays. The H3Africa assays2
use novel, genome-wide content from individuals
across African populations, built on the MEGA Arraybackbone. These studies use genetic, clinical, andepidemiologic methods to identify hereditary andenvironmental contributions to health and disease.

1

Genetics for all. Nature Genetics (2019)
NIH provides funding to H3Africa as part of the Common Fund Global Healthinitiative; the use of any company, commercial product and/or service by
H3Africa grantees does not imply endorsement by NIH.

2

20

Access

Illumina

Community

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Ensuring Equitable Access and Data Diversity

Philanthropic Initiatives: Genomic Data That ReflectsEveryone, Everywhere
Democratizing sequencing can enable families,
communities, and whole countries to harness thebenefits of Next-Generation Sequencing (NGS).
By doing so we can help to expand the genomics
infrastructure in underserved areas and support thediversification of data.
We are proud to support projects that increase thediversity of genomic data, invest in philanthropic
opportunities, and champion patients.

Supporting Native American
Genomic Research
Native BioData Consortium (NBDC) is the first
nonprofit research institute led and staffedby indigenous scientists and tribal community
members in the US. Since its inception in 2018, theJoe Yracheta
Board Vice President, Native BioData Consortium
Cheyenne River Indian Reservation

consortium’s goal has been to ensure that Native
people can benefit from advances in genetics andhealth research. NBDC’s broader vision is to store
and study research samples that not only pertain
to human health, but also environmental andagricultural health.

Ensure genomes canbe interpreted in theappropriate context ofglobal diversity

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Close the gap in
under resourced
communities

Broadening Genetic Research into
Cancer Origins
The New York Genome Center (NYGC)
Polyethnic-1000 Project (P-1000) focuses on cancer
care inequities in underserved populations, with theobjective of democratizing and broadening access tothe power and potential of cancer therapies.

Increasing Global Access to Genomics

Increase diversity andequity of representationin genomic data

Native American communities have been among thehardest-hit groups by the COVID-19 pandemic in the
United States. To empower the Native community’s
response to the current pandemic and help them
prepare for future risks, we supported the donationof a NextSeq™ 550, consumables, and training
to the Cheyenne River Sioux Tribe. In addition
to COVID-19 surveillance, NBDC will be able tostudy other diseases that disproportionately affecttheir population, such as diabetes, cardiovasculardisease, and colon cancer. The donations will enable
NBDC to keep samples and data local so that thefindings can ultimately benefit the communities they
serve, empower the Native community response tothis pandemic, and help them prepare for future risks.

Ensure everyone has accessto lifesaving treatments
tailored to their individual
health needs

Cancers are diseases of the genome, caused andinfluenced by genetic variation whether inherited or
acquired by environmental and behavioral factors.
Significant research has identified the genetic
variations that contribute to the start and progressionof cancers. These studies, however, have been limited
largely to patients of Western European descent andhave focused on inherited, as opposed to acquired,genomic variation.
Illumina has committed $2.4 million of in-kindproduct donations to support this initiative and help
to identify differences between ethnicities that may
account for disparities in occurrence, response totreatment, and survival for different cancer types.
Learn more about the P-1000.

COVID-19 Philanthropy in India
In May 2021, Mumbai was at the epicenter of adevastating wave of COVID-19 in India. In response,
Illumina donated sequencers, reagents and support
valued at US$1 million to the Molecular Diagnostic
Reference Laboratory at Kasturba Hospital, runby the Municipal Corporation of Greater Mumbai.
This donation was aimed to expand SARS-CoV-2
sequencing capabilities in the State of Maharashtra,
supporting the broader genomic surveillance effort
across India.
Learn more in the Community section.

21

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Ensuring Equitable Access and Data Diversity

Measuring iHope™ Impact

Bringing iHope™ to More Families Around the WorldThe Illumina iHope™ program will change thetrajectory of genomic medicine worldwide, helping
patients who may have otherwise been invisible.
Families of children with undiagnosed genetic
diseases often face an uncertain and unpredictable
future. These diagnostic odysseys may include
years of multiple inconclusive tests, surgeries,
and procedures.
In high income countries, these patients often remain
undiagnosed for up to seven years, while in low- andmiddle-income geographies, many families neverknow the cause of their child’s suffering. iHope™ isa philanthropic effort that provides comprehensive
whole genome sequencing (cWGS) to underservedfamilies around the globe. It was created in 2017,bringing together a wide range of organizations
aimed to shorten the diagnostic odyssey, inspire
hope by increasing access to genomics, and pilot
the approach for potential scale.

In 2021, we announced an expansion of the programwith a $120 million commitment over the next
five years to support the launch of the iHope™
Genetic Health program under the auspices of thenonprofit Genetic Alliance. The expanded programis designed to provide cWGS to tens of thousands ofunderserved families across the globe.
iHope™ Genetic Health was created to be a flagshipprogram for Genetic Alliance, a global nonprofit
focused on advancing genetics to benefit humanhealth, to create networks of clinics, and laboratories
equipped with the necessary genome technology
to provide precision genomic diagnoses to patients
suffering from rare genetic disease.

Where We’ve Been

1,150

patients impacted since inception

40%
60%

1

change management after cWGS

24

iHope™ clinical sites worldwide

Where We’re Going$120M

Our vision is agenome for every
patient that needs
one, and a networkof partners who will
help them on every
part of their journey
to better health.”
Ryan Taft, PhD
Illumina iHope™ Lead and
VP, Scientific Researchcommitment over the next five years>50%

patients to be impacted by 2030

50,000

Learn more about Illumina iHope™ andiHope™ Genetic Health

By establishing iHope™
Genetic Health, weare expanding ourcommitment to ensurethat the benefits
derived from wholegenome sequencing areavailable to as many
people as possible, as
quickly as possible,
regardless of disease,geography or income.”
Francis deSouza
CEO, Illumina

1/3+

directed toward patients in Africa

percent of genetic disease affects
young people

Francis S. Collins, M.D., Ph.D.
National Institutes of Health Director

patients receive diagnosis after cWGS

300 million

people affected with a genetic disease

I applaud this important initiative toimprove access to this life-changing
technology. Access to medicine should
always be a right, not a privilege.”

As the mother of two children, diagnosed
with a genetic condition, I can’t rest until
we build equitable systems to meetthe needs of all who experience thediagnostic odyssey.”
Sharon Terry
Genetic Alliance CEO

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

1

Derived from >1000 cohort

22Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Ensuring Equitable Access and Data Diversity

PGI Impact Year 1: Africa

Boosting Pathogen Genomics Surveillancein Low- and Middle-Income Countries
Building pathogen genomics capabilities
globally protects the health of everyone,since a threat in one place can quickly
become a threat everywhere.
That’s a driving idea behind the creation of
the Pathogen Genomics Initiative (PGI), a
collaboration between industry partners, theBill & Melinda Gates Foundation, NGOs, andPublic Health Agencies. PGI aims to integrate
pathogen genomics and bioinformatics into publichealth surveillance, outbreak investigations, andimproved disease control and prevention. The
partnership is designed to expand access to nextgeneration genomic sequencing (NGS) tools andexpertise to strengthen public health surveillance
and laboratory networks across low-and-middleincome countries for COVID-19, as well as otherepidemic threats and endemic diseases such as
AIDS, tuberculosis, malaria, cholera, and otherinfectious diseases.

The initiative aims to create a comprehensive
ecosystem for sustainable implementation of NGS
for pathogen surveillance.
Expanding access to pathogen sequencing will aid increating a global pandemic early warning system byenhancing geographic coverage and catalyzing efforts
to detect new epidemics before they spread widely
and to monitor their transmission in real-time for a moretargeted and precise response. Pathogen sequencing
will also contribute to research and development
efforts for new vaccines, diagnostics, and treatments
for current and emerging infectious diseases.
Illumina has committed $60 million over the next
five years with in-kind donations, including NGS
platforms, reagents, and training support.
The initiative will bring us closer to the vision of anearly warning system to detect new epidemics andapply genomics to benefit all.

Use and integration of advanced technologies such as next-generation
sequencing into surveillance and emergency response programmes facilitates
public health decision-making for better outcomes, as evidenced in two Ebola
virus disease outbreaks and the current COVID-19 pandemic.“
John Nkengasong, Director of Africa CDC
believes strengthening genomic surveillance systems is key for early notification and control of these outbreaks.

Africa Pathogen Genomics Initiative
Africa PGI is a four-year collaboration between the
Africa CDC Institute of Pathogen Genomics, the U.S.
Centers for Disease Control, the Bill & Melinda Gates
Foundation, Microsoft, Illumina, and other industry
partners. The initial Africa PGI commitment included$20 million and led to the expansion of a
global model.

$3M

3x

12

$20M

delivered in 2021

countries

committed overfour years of in-kindproduct donations

15

11

organizations

Africa Centre of Excellence for Genomics of Infectious
Diseases (ACEGID) Training 2021

Expanding PGI to Southeast Asia
In 2021, we announced an expansion on our Africa
PGI commitment with an additional $40 million
of product donations over the next five years
to low-and middle-income countries, starting inSouth Asia. The PGI commitment will help create acomprehensive pathogen genomic network aroundthe world, building critical public health capabilities
in areas of need.

$60M

increase in monthly
deposited sequences
to GISAID

new sequencers

PGI Impact Year 1: Southeast Asia

$1.8M

3

3

11

delivered in 2021

countries
India, Bangladesh,Indonesia

new sequencers

organizations

Illumina commitment to PGI over five years
23Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Championing Patients
We are building a global community of genomics revolutionaries to help solve some of the most complex
challenges of today. We seek the scientists, researchers, educators, clinicians, and patient ambassadorsthat are passionate about the responsible use of genomics to change and save human lives.
Together, we can guide the world into this new era innovating healthcare with patients at the center of it all. Patients are our constant source of inspiration to fulfill our
Mission to unlock the power of the genome. We continue to advocate for the best clinical care for patients across the globe in these unprecedented times, actively
engaging with medical organizations and governments to ensure that the genetic disease community has not only hope but also a voice. Arming patients with more
information and knowledge empowers them to make better decisions about their health.

Illumina Patient Ambassadors

The Childhood Dementia Initiative

The Clearity Foundation

Illumina Patient Ambassadors are a coalitionof patients and family members dedicated toincreasing awareness of the importance ofgenetic testing. Connecting families to a wider
community of people with similar experiences helps
provide support and strength during the search
for a diagnosis and can improve patient care andmanagement. By sharing personal stories about
their disease journey, the group can educate andmotivate an entire ecosystem of support.

Around the world, 700,000 children and young
people are suffering from genetic disorders thatcause childhood dementia. The Childhood Dementia
Initiative is a new organization in Australia thatrecognizes September 22 as Childhood Dementia
Day. They are raising awareness and working toward
treatments and better care to improve the quality oflife of children with dementia.

When it comes to cancer, knowledge is power, andsequencing can provide life-saving insight. The
Clearity Foundation provides ovarian cancer patientswith information on treatment and test options aswell as emotional and social support.

At Illumina, we joined their It’s time to FACE it
campaign, and we invited our employees to show
their support by getting messy with face paints.

The Clearity Foundation introduced comprehensive
genetic profiling to Michelle and her wife Denise.
Through the profiling, they found that one of her
genetic markers has a potential response with new
drug treatments. Genetic profiling has provided new
targeted treatment for Michelle and hope for the future.

The Miller Family, Illumina Patient Ambassadors

Renee Gallagher, Illumina Executive Sales Specialist, Australia

Michelle and Denise#IlluminatingRareDisease
Our employees are passionate about the rare diseasecommunity. They understand the power of genomics
to help end a patient’s diagnostic odyssey and support
their care management.
Since 2008, Rare Disease Day events have taken placearound the world on the last day of February to raiseawareness about rare disease, and highlight its impact
on patients’ lives. Each year, employees participate
in a campaign by posting photos connected to thetheme. For every photo posted, the Illumina Corporate
Foundation donates to the chosen charities for theyear. In 2021, we collectively raised over $30,000.
These funds were distributed to charities across ourglobal communities.

Daniel Lv and Family, Illumina Safety Manager, China

24

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Improving Reach to Broaden
the Genomic Ecosystem
We are an engine of genomics innovation—the larger our network,
the greater our collective impact. By contributing to the genomic
ecosystem, we can amplify the power of genomics.
We expand the reach of genomics through genomic literacy, catalyzing genomic startups, advocating for
healthcare coverage and genomics adoption, and empowering patients.

Expanding Genomic Literacy
Illumina is committed to increasing the awareness of genomics in healthcare and the advancement ofprecision medicine. We aim to increase genomic literacy by supporting existing healthcare professionals,
connecting genomic professionals, and inspiring the next generation of scientists, innovators, and researchers.

HCP Impact in 2021

2030 Target
Reach

25,000+health care professional
learners annually

Expandindependent medical education (IME) partnerships
with professional societies and the medical community,
providing education across all clinical segments
Demonstrate>95%

supported medical education
programs increase participant
knowledge and competence2021 PROGRESS>30,000

The American Society of Human Genetics (ASHG) Online
Education for Genetics Professionals
ASHG provides an online learning center where healthcare professionals can access a variety of digitallearning experiences—webinars, workshops, podcasts, and more. In 2021, the Illumina Corporate
Foundation funded support of a new genomics education program. The program reached more than 12,000
professionals, with 36% of participants reporting an actual practice change due to the learning and 62% of
those participants indicated that their implement change improved patient care.

Illumina China NGS Industry Summit
At the first Illumina next-generation sequencing (NGS) Summit inShanghai, genomic leaders discussed the future of oncology andhealthcare. NGS can markedly improve human health, enablingearlier diagnoses, more precise pathogen monitoring, and better
outcomes for cancer patients. Key themes also included theimportance of accountability, collaboration, and the need to build
a greater ecosystem to support NGS.

Connecting Genomic Professionals at Illumina SPARK Event
Nearly 20 years since the Human Genome Project revolutionized healthcare, we convened leaders andinnovators from around the world at this first-ever global idea forum, SPARK, to recognize the remarkable
contributions of genomics to date and imagine the breakthrough innovations of tomorrow. Together, we
spotlighted the efforts to make genomics-led precision healthcare a global reality for all and created a spacefor changemakers to share their experiences and cast a vision for what’s next.
Bill Gates; Nobel Laureates Dr. Jennifer Doudna and Dr. Frances Arnold; NIH Director Francis Collins, MD, Ph.D.;
Dr. Sue Desmond-Hellmann; Dr. Sanjay Gupta; and many more of the brightest minds in the industry gathered
to discuss collaboration in precision medicine, inclusivity in healthcare, future pandemics, and more.

learners reached through IME>15,000

HCPs reached through Illuminasponsored education including over
11,000 from our Greater China region

90%

average self-reported
knowledge change

25

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Improving Reach to Broaden the Genomic Ecosystem

Catalyzing Genomic Startups to Drive Innovation
Genomics startups are playing an increasingly important role internationally in the expansion of the genomic
ecosystems. Illumina aims to catalyze this growth by supporting the Illumina Accelerator program and Illumina
Ventures. The dramatic innovations emerging from these startups are helping to drive down costs and unlocking
new areas of biology and market use.

Illumina for
Startups

Illumina for Startups
Illumina for Startups is our way of accelerating innovation in the entrepreneurial community by partnering withleading venture capital investors and entrepreneurs to create, launch, and grow genomics startups.
Illumina Accelerator is a company creation engine co-located with Illumina research and development sites
in the San Francisco Bay Area and Cambridge in the United Kingdom. Illumina Accelerator provides selectstartups with access to seed investment and business guidance, Illumina sequencing systems and reagents,and fully operational lab space during each six-month funding cycle.

New synthetic biology approaches for a moresustainable future

Impactful diagnostics to detect and prevent
diseaseSoftware and tools to further enable new
insights

Important agriculture and food innovations tofeed more with less

Consumer-driven applications to help us better
understand ourselves

Sequoia Capital
China Intelligent
Healthcare
Genomics Incubator,
Powered by Illumina

Illumina
Accelerator
San Francisco
Bay Area

Scope of Programs
Novel drug discoveries to treat patients

Illumina
Accelerator
Cambridge, UK

2030 Target

The global reach of Illumina Accelerator is demonstrated by ourinvestment in diverse startups from around the globe. This diversity isa testament to the strength and breadth of the talented entrepreneurs
around the world focused on unlocking the power of the genome toimprove human health and beyond.”
Amanda Cashin, PhD, co-founder and Global Head of Illumina for Startups

Achieve2021 PROGRESS

18

$1B

genomic startup supported1

early-stage companies joined

raised in venture

the 2021 global cohort

capital funding

200+
Learn more about our accelerators
1

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

From program inception

26

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Improving Reach to Broaden the Genomic Ecosystem

Illumina Accelerator Spotlight
Genomics Startups in China
In 2021, we joined with Sequoia Capital China, a leading investment
firm, to support the startup genomics ecosystem in China. The launchof Sequoia Capital China Intelligent Healthcare Genomics Incubator,
Powered by Illumina, leverages the expertise of Illumina for Startups
in building genomics companies with the unparalleled track record of
Illumina Accelerator in San Francisco Bay Area and Cambridge, UK.
Sequoia Capital China will dedicate to the genomics incubator its
investment expertise and community of entrepreneurs to advancegenomics founders.
By leveraging this first-of-its-kind platform, we will continue to grow
China’s biotechnology innovation and business presence, as well as
foster groundbreaking discoveries with the aim to help millions ofpatients in China and around the world.
The startups selected for the inaugural funding cycle included:• Mobidrop Biotechnology, a medical
device and research tools company
developing cutting-edge, single-cellsequencing microfluidic technologies
for molecular diagnostics applications• Sequanta Technologies, a multiomics
company committed to building
DNA, RNA, epitome, and proteomics
technology platforms for research andclinical applications
Learn more

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Illumina Accelerator Spotlight
Sustainability
Illumina Accelerator goes beyond investing in healthcare
solutions. We are also passionate about investing in
breakthrough startups pushing boundaries in sustainability.
Genomics startups are pioneering new discoveries in synthetic
biology, materials science, food science, and agriculture tocreate new industries built on products that are better for us,
the planet, and society. Some of these investments include:
Checkerspot, Inc., an advanced materials
company designing and commercializing thenext generation of high-performance andsustainable materials enabled by genomics
and chemistry. Checkerspot is using
microalgae to create a sustainable alternative
to petroleum.
Pluton Biosciences, LLC, a microbial testing anddiscovery research company in
St. Louis, Missouri, is developing
next-generation products forcarbon sequestration, agriculture,pharmaceutical, biomaterials and bioremediation.
Yali Biosciences Inc., a food techcompany from San Francisco Bay
Area, uses synthetic biology andgenomics tools to make climatesmart, sustainable foods.

Illumina Ventures
We further support the genomic startup
community through Illumina Ventures, an
independently managed firm founded in2016. It is focused on assisting startups
that are pioneering genomic applications
and enabling precision medicine. We
provide funding, strategic counsel,
as well as access to the wealth ofexperience and expertise of the world’s
leading genomics solutions provider.
Companies supported by Illumina
Ventures are pioneering everything fromnew applications for advancing humanhealth through genomics to applications
that leverage genomics for sustainability,
biodiversity, climate change research,
food scarcity, and agrigenomics. Learn
more about Illumina Ventures.

Illumina Alumni
Network
In 2021, we launched the Illumina
Alumni Network. With over 7,000 alumni
representing over 600 companies, we arebroadening the genomic ecosystem andcreating a community to forge the futureof genomics together.

27

Access

Illumina

Community

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Improving Reach to Broaden the Genomic Ecosystem

Enabling Equitable Coverage and Reimbursement for
Improved Patient Outcomes and Health Economics
Our ability to help improve patient outcomes has made us a trusted partner in healthcare. Today, we’re providing
tools that enable the next generation of clinicians to usher in the future of personalized medicine, but there
is much work to do to increase awareness of genomic testing, its benefits to patients, the impact on healtheconomics, and translate that into reimbursement policies that establish funding and allow for equitable access togenomic testing.
Illumina is not just a company at the forefront of a global genomics movement. We’re at the center of a global
health transformation. The impossible is possible right now—not decades in the future. Through evidence
generation, education community outreach, collaborations and partnerships, Illumina is committed to advocating
for healthcare coverage and accelerating the adoption of genomics as a diagnostic tool.

United States NGS Coverage Outlook
14%

19%
81%

Non-Invasive
Prenatal
Testing(NIPT)

Somatic
Mutation
Panels(Oncology)

<1%

11%

75%

Whole Exomeand Genome(RUGD)

64%

19%

TargetAchieve17%

2 billion
covered lives globally

Total insured lives: 240M

Total insured lives: 289M

Total insured lives: 240M

All pregnancies covered 193M

All panel sizes covered 217M

WES & WGS covered 42M

Only high risk covered 46M

Only targeted panels 40M

Only WES covered 153M

Not covered 1M

Not covered 32M

Not covered 45M

Outside the US: 598M, 505M, and 309M lives are covered for NIPT, somatic panels, and WES/WGS, respectively

by 20262021 PROGRESS

1 billion
covered lives globally

WES: Whole exome sequencing WGS: Whole genome sequencing CGP: Comprehensive genomic profiling

Learn about our public policy priorities.
2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

28

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Innovation and Affordability | Equitable Access and Data Diversity | Improving Reach

Improving Reach to Broaden the Genomic Ecosystem

In 2021, several studies and programs focused on
the use of whole genome sequencing (WGS) inclinical routine to help diagnose and treat critically ill
infants demonstrating the power for patients and bymeasuring healthcare costs.

Project Baby Bear: Better Outcomes for
Infants with Rare Diseases
Last year, we highlighted Project Baby Bear, thenickname for a $2 million Med-Cal pilot program toprovide rapid whole genome sequencing (rWGS) forbabies in intensive care. In 2021, a study publishedin the American Journal of Human Genetics outlined
the success of Project Baby Bear using rWGS®
to diagnose and guide treatment for infants with
unexplained rare diseases.
Employing the most comprehensive diagnostic
testing available, Rady Children’s Institute for
Genomic Medicine used rWGS to analyze the genetic
code of 184 infants in intensive care who werecovered by Medi-Cal. The results provided doctors
and families with vital information that empoweredthem to make life-altering medical decisions resulting
in shorter hospital stays, targeted personalized careand fewer costly, invasive procedures.
Among the infants sequenced, rare genetic diseases
that explained the baby’s admission to intensive
care were diagnosed in 74 babies or 40% of them.
Guided by the information provided by rWGS,
clinicians were able to provide precision medicine
that changed care for 58 babies, or 32% of them.
In addition to changes in treatment, rWGS resulted

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

in avoidance of other costly procedures suchas tracheostomies or gastric tube insertions,eliminated the need for further testing and led to
fewer days in the hospital.
Encouraged by the early success of Project Baby
Bear, the State of Florida and State of Michigan
have since initiated their own publicly fundedrWGS demonstration projects and several similar
programs have been deployed around the globe.

One Step Closer On the Path toDiagnostic Equity
Illumina scientists collaborated with investigatorsfrom five children’s hospitals to co-author a study
published in the Journal of American Medical
Association (JAMA) Pediatrics. The Illuminasupported study, called NICUSeq, shows theimpact of clinical whole genome sequencing(cWGS) in the ICU.

Expanded Medicaid
Coverage in Michigan
In 2021, the State of Michigan expanded
Medicaid coverage to include rWGS testingfor critically ill infants suspected of having arare genetic condition. By covering the costs
for this testing option, more families will beable to get the answers they need to find theright course of treatment for their children.

The NICUSeq randomized time-delayed trial results
show that use of cWGS outperforms standardof care by two-fold both in terms of diagnostic
efficacy and change of clinical management of
acutely ill newborns suspected of having a genetic
condition. The study showed the importance oflarge-scale genetic testing in newborns, leading toearly diagnosis of genetic conditions and helping
to inform decision-making for physicians andfamilies. Having this type of genetic information
provides immediate and sustainable benefits thathave lifelong value, providing a genetic ‘reportcard’ that can be used to help direct medical care.
The data supports the widespread adoption andimplementation of cWGS for newborns in crisis.
What makes this study important is that it
mirrored real-world infant care, and showed that
WGS is viable as a first-line diagnostic in diverse
communities and healthcare institutions. This study
highlights the reality of a future where genomics isfor all.

Project Baby Bambi: Implementing WGS
for Infants in the NICU in Israel
Through an agreement with Israel’s Ministry of
Health, Illumina is supporting a pilot program ledby the Genetics Institute of the Tel-Aviv Sourasky
Medical Center to implement the use of WGS for
rapid diagnosis in newborns in critical conditions who
are treated in neonatal intensive care units (NICU).
The program is intended to include all NICUs
in hospitals in Israel. Doctors from participating
hospitals will evaluate the use of WGS as a firsttier diagnostic tool to enable faster identificationof disease-causing genetic abnormalities in
infants and identify the correct treatment course.
The project could lead to the creation of national
reimbursement for WGS as a diagnostic tool in
hospitals across Israel.

   Learn More
Illumina press releaseWe can’t claim victory until every family with an
infant or child with suspected genetic or raredisease has access to whole genome sequencing
to increase their probability of receiving potentiallylife-saving care changes and a diagnosis.

29

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Strategic Philanthropy | Engaging Our People | Inspiring Future Generations

Empowering Our
Communities
30

Illumina

Community

AccessEnvironment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Strategic Philanthropy | Engaging Our People | Inspiring Future Generations

Empowering Our Communities:

Our Strategic Approach
We are committed to giving back, creating shared value
through our business, and seeking opportunities to enable
a more equitable and sustainable future for all.
Overview

Our Objectives

Giving back is in our DNA. By investing in our communities and collectively leveraging our skills, passion,time, and resources. Together, we can make a meaningful contribution to creating a better future.

By sharing our time, talent, and technology, we aim to inspire, support, andempower our communities, our employees, and the next generation.

Community Investment Areas• Engage Our People: Create opportunities for employees to give back to thecommunity and feel connected to our Mission• Inspire Future Generations: Deepen the impact of ourgenomic literacy efforts

Equitable access
STEM
Diversity, equity,
education for all and inclusion
to genomics

Disaster
response

Sustainability andenvironmental justiceLocal efforts andemployee interests• Provide Strategic Philanthropy: Partner with nonprofits to address unmet needs
locally and globally in support of our CSR focus areas

How We Give Back
Corporate Giving:Supports key CSR focus
areas with grants andin-kind donations

Illumina Corporate Foundation:
Supports our CSR focus
areas and the employee
match program

Illumina Cares:
Supports employee
volunteerism and the causes
they are passionate about

Fostering a culture that emboldens our employees togive back is integral to our Mission.”Contributing to the UN SDGs

Sharon Vidal, Global Lead Corporate Social Responsibility

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

31

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Strategic Philanthropy | Engaging Our People | Inspiring Future Generations

Empowering Our Communities:

Measuring Our Impact
2030 Targets

2021 Highlights

2021 Recognition

44

Reach 5 million learners through direct
programming and nonprofit donations

1,345

countries

supported causes

2021 PROGRESS

816,170
learners1

Donate >100,000 volunteer hours and increase
the impact of our skills-based volunteering$5M$14.5M

Corporate
Foundation

total donations

2021 PROGRESS>25,000$9.5M

Illumina, Inc.

hours1

Achieve 50% employee participation
through Illumina Cares programs
2021 PROGRESS

Employee Participation in Giving and Volunteer Programs
Volunteering

31%

GivingTotal Participation

40%

employee participation

Achieve 90% positivity rate on employee
surveys evaluating Illumina Cares programming

31%

29%

26%

24%
20%

19%

2021 PROGRESS

96%
1

2019 baseline

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

10%
5%
2019
2019

2020
2020

2021
2021

32

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Strategic Philanthropy | Engaging Our People | Inspiring Future Generations

Deepening Our
Impact ThroughPhilanthropy

COMMUNITY INVESTMENT
FOCUS

APPROACH

SAMPLE PROGRAMMING• iHope™ Genetic Health Initiative $120M in-kind
donations over next five years

EQUITABLE ACCESSTO GENOMICS

Enable access to genomics for patientsin need and increase the diversity ofgenomic data.

• Pathogen Genomics Initiative $60M philanthropic in-kind
donations over next five years• Foundation for Innovative New Diagnostics (FIND) for equitable
Drug-resistant Tuberculosis (DR-TB) test access
Learn more in Access

We focus our community impact strategy
with investments that support our CSR
efforts for patients, our communities, ourpeople, and our planet.
We drive collective impact and leverage our resources to help address
local and global needs with philanthropic activities and nonprofit
partnerships. Our philanthropic efforts leverage cash grants andin-kind donations. To ensure we can make a meaningful difference, ourcommunity investments align to our CSR focus areas and are designed
to target where we can make the greatest impact.

STEM EDUCATIONFOR ALL

Increase genomic literacy and inspire
future generations.

• Illumina Genomic Discoveries• DNA Decoded• Salk Institute Mobile Science Lab• Genomics 101• I Am A Scientist• SD2• Genomic Comic Education Project with Hunzhi
Learn more in Community• Mumbai COVID-19 donation
DISASTER RESPONSE& HEALTH CRISESSupport natural disaster response andglobal health crises.

• CDC COVID-19 surveillance reagent donations• China floods, EMEA floods, US wildfires• Red Cross Sickle Cell Initiative
Learn more in Access• $20M investment to support sustainability initiatives by 2030

SUSTAINABILITY& ENVIRONMENTAL JUSTICE

Invest in sustainability projects and efforts
to protect vulnerable populations as wetransition to a decarbonized future.

• iConserve• Illumina Agricultural Greater Good Initiative• Turtle Survival Alliance• CSUEB Green Biome InstituteLearn more in  Environment

LOCAL EFFORTS& EMPLOYEE ENGAGEMENTEngage in local efforts to address theissues and challenges where we live andwork and support the causes employees
care most about.

• Regional community grants• Local volunteer initiatives
Learn More in Community

Across all our giving investments, we prioritize and promote equitable representation and support for vulnerable populations.
Learn more about our Diversity, Equity, and Inclusion efforts in People.
2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

33

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Strategic Philanthropy | Engaging Our People | Inspiring Future Generations

Engaging Our People
to Make a Difference in
Their Communities

San Diego, US:  Spin4Cures
Crohn’s & Colitis

We strive to create a purpose-driven culture
with opportunities for employees to volunteer
in their community through organizations thatmatter most to them.
Employee Giving and Volunteer Benefits

Beijing, China:
Education for Autism

Montreal, Canada:  Dans La
Rue Homeless Youth

St. Louis, US:  Pedal the Cause
Duxford, UK:  Community Build

Tokyo, Japan:  Breast Cancer
Pink Plank Challenge
San Francisco, US:
Back-to-school drive

Madison, US:
Park Clean-Up

Cambridge, UK:
Habitat Restoration

UK and US: Hope for Hasti

16

Chris Brannigan, father of rare disease patient Hasti, walked barefoot across the UK and the eastern US to raise funds and awarenessto champion the cause of those suffering with rare disease around the world. He was inspired by his daughter who was diagnosed
inspired by Chris’ action and walked with him along portions of his journey in an act of solidarity. Over $13,000 was raised for Hope for
Hasti through our employee donation match program.

$25

Regional Community Grants

new hire seed
donation deposit

Volunteer Rewards
donation earned for eachhour of volunteer work

Melbourne, Australia:
Solar Buddies

with Cornelia de Lange Syndrome (CdLS) when her genomic profile was sequenced with Illumina technology. Illumina employees werehours paid volunteer
time off (VTO)$10Singapore:  Blood
Donation Drive

Virginia, US:
Boys & Girls Club$500

donation match

Shanghai, China:
Family STEM Day

Allocate dollars across regions
for employee engagement

Activate Illumina Cares
Ambassador Network

Engage local employees
to select nonprofit

Notify nonprofits, implement,
and build partnerships

In addition to the strategic corporate philanthropythat supports our CSR focus areas, we empower our
employees with a Regional Community Grant Program.
In 2021, employees helped direct over $500,000 to localorganizations in their communities.
34

Illumina

Community

AccessEnvironment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Strategic Philanthropy | Engaging Our People | Inspiring Future Generations

Inspiring Future
Generations in STEM
We are committed to equitable access to
STEM education, with the goal of empowering
students to envision themselves as futurescientists, innovators, and trailblazers.
Our approach includes direct programming, philanthropy, andemployee engagement with particular investment in minority andvulnerable populations.
The future of our Mission to improve human health is reliant on nurturing
and equipping our future generations. We aim to inspire our youth topursue STEM careers, support educators to bring genomics into theclassroom, and remove barriers for under resourced groups.

Sparking Interest in Genomic Literacy
Engage Our Employees to Inspire the Next Generation toUsher in the Future of Personalized Medicine
Provide access to diverse talent role models, career mentors,
and stories to help break down misconceptions on systemicbias. Lift employee journeys to counteract stereotypes inclassrooms, labs and the workplace through partnerships
with I Am A Scientist and SD2.

2030 Target
Reach

Develop Tools for Educators

Creating an Educational Community

STEM learners

Help educators understandgenomics through curriculum
partners like Discovery Education andBirch Aquarium. Provide ready‑to‑gostandards‑aligned lessons andactivities for teachers and students
to explore genomics applications.

In partnership with Biocom Institute California,
Illumina Genomic Discoveries continues to build
an educational community where teachers canlearn and connect with the world of genomics.
The program provides genomics‑focused
professional development, a real-world
curriculum, in-classroom activations, andindustry connections.

5 million
2021 PROGRESS>800,000
STEM learners
reachedRemove Barriers to Ensure
Equitable Access to STEM
Remove barriers of access byproviding equipment and expertisefor under resourced groups like
Future Kings and GenSpace.

STRAWBERRYDNA EXTRACTION
PROTOCOLd for ‘Experiment’‘Protocol’ is a fancy wor

Inspire Community Partners& Educators
Inspire community partners andeducators to bring genomics into
their classroom by participating in ourannual The Future is Bright campaigncelebrating DNA Day globally.

Cells

are the basic unit of life and makeup all plants,
animals, and bacteria.

Deoxyribonucleic acid, or DNA,

is the molecule that controls everything that
happens in the cell. DNA contains
instructions that
direct the activities of cells and, ultimat
ely, the body.
This activity will demonstrate how
DNA can beisolated from a strawberry using commonhousehold materials.

What you will need:

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

35

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Strategic Philanthropy | Engaging Our People | Inspiring Future Generations

Inspiring Future Generations in STEM

Taking Students from Curiosity to Career
An important element of our philanthropic support is to nurture a diverse and inclusive STEM workforce for the future. We do thisthrough collaborations with a range of community partners to reach and inspire students of all backgrounds.

Advancing STEM Diversity in
Our Hometown

The Future Is Bright
In celebration of DNA Day each year, we host the “Future Is Bright,” amonth-long genomic literacy initiative. Illumina employees connect withstudents by hosting career panels, implementing genomics curriculum,and leading hands-on experiments. This learning opportunity ties together
genomic research, education, and community impact.

2021 Campaign Impact

165

Illumina employees
volunteered

42,000+teachers, students, andlearners reached

210

550+

7

16

classroom events

public-facing events

54%

organizations
participated in themonth-long activities

different countries and
44 of the US states wererepresented

under resourced
community classrooms

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTIn response to systemic issues of racial inequality
found in education and STEM studies, we areproud to be a founding sponsor of San Diego STEM
Diversity, also known as San Diego Squared (SD2).
The organization focuses on creating diversity
in STEM careers by inspiring, supporting, andmentoring San Diego area students at every stageof the talent pipeline.
Illumina has committed $500,000 over three
years to support the program. In 2021, wesponsored four SD2 scholarships totaling$10,000 for minority high school students whoare pursuing a degree in a STEM-related field andtwo $5,000 educator grants for minority STEM
teachers. In addition, Illumina employees engage
directly with SD2 by volunteering their time to
mentor students interested in STEM over an
immersive, 10-week program.

Future Kings
Future Kings delivers immersive STEM programs to middle and highschool boys from underserved communities through a multi-year,
hands-on curriculum, and dedicated mentorship.
In addition to basic lab skills, students receive training on science
communication, entrepreneurship, and a research project. This year,
the cohort of students chose to study why African Americans are more
susceptible to COVID-19 as their capstone research project. To support
their research and commitment to diversity in STEM, Illumina donatedIllumina iSeq technology, consumables, and an education grant for
program support. Learn more about our partnership with Future Kings’
biomedical program.

Jennifer Hairston (left),
Illumina Mentor, and
her SD2 mentee Manal
Mohamed. Every student
who participates in theSD2 program receives anindustry mentor who sharessome life experience and iscommitted to support themfor at least one year.

My vision for Future Kings and my ongoingcommitment to the organization is to breakthe cycle of poverty in African American and
Hispanic communities by introducing students to
STEM professions.”
Dr. Arik King, Future Kings Founder and Executive Director

36

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Strategic Philanthropy | Engaging Our People | Inspiring Future Generations

Inspiring Future Generations in STEM

Sharing Knowledge to Promote STEM
Seeing Is Believing
That’s the idea behind our YouTube seriesof videos that show what it is like to workat Illumina and to introduce students tothe diverse range of careers our industry
offers. Meet our employees

Black Girls Do STEM

Putting the Fun in Sequencing Technology

Marie Kamsi, Illumina Intern, was the
project lead for the nonprofit Black GirlsDo STEM, and has since joined Illumina
full time as a product engineer. Our interns
worked with Black Girls Do STEM to help
them hit their fundraising goal. The interns
developed social media experiences to help
raise awareness of the organization, drive
engagement, and increase donations.

Illumina Greater China and a well-known social media key opinion leader, Hunzhi, partnered tocreate a series of light-hearted comics and videos demonstrating the postive impact of next
generation of sequencing (NGS). Each collaboration, published on WeChat and Weibo, relatesscientific knowledge to daily life to help the general public gain a better understanding NGS andthis value.

We have 16 hours of paid volunteer timeoff. I’ve been helping to coordinate virtual
Genomics 101 classes for young students
and professional development sessions forcollege students. I love giving back to thecommunity that helped me become who
I am today and being able to help promote
representation in STEM fields.”
Tesa Dinio Abad
Illumina Systems Engineering Manager

Every Student Deserves a Chance to See
Themselves in Science
We have partnered with “I Am A Scientist” to support initiatives
bringing no-cost educational resources to the classroom thatchallenge stereotypes and inspire the next generation of STEM
leaders. We believe if a student can see themselves in science,
they can dream it, and they can build their future to be it.

Janina Jeff, PhD, MS
Illumina Bioinformatics Scientist
I Am A Population Geneticist
Learn More

Alexander Bennett, PhD
Illumina Development Engineer
I Am A Mechanical Engineer
Learn More

Cesar Arcasi-Matta
Illumina Research Associate
I Am An Analytical Chemist
Learn More2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

37

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Integrating
Environmental
Sustainability
38

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Integrating Environmental Sustainability:

Our Strategic Approach
Human health and the health of our environment are intertwined, connecting our Mission to improve human healthwith our commitment to operate responsibly and sustainably.
Overview

Our Objectives

We are committed to integrating environmental
stewardship into the fabric of how we operate.
We recognize the importance of the environmentin creating a healthy, sustainable future forall. We view sustainability through the lens ofcontinuous improvement, knowing there will
always be more opportunities for us to protect
our planet and do our part.
Our expanded climate action targets are an
important part of our overall business strategy
to minimize risk associated with climate change,build resilience, and identify opportunities forlong-term sustainable growth.

As the world seeks innovative solutions to tackle
climate challenges and protect our natural
capital, we recognize the incredible opportunity
the field of genomics and our technology
will provide. Currently, our technology isleveraged for studies used around the world
on biodiversity, endangered species protection,
ecosystem conservation, sustainable agricultural
practices, and climate change research.
Unprecedented advances in next-generation
sequencing are benefiting patients, developing
sustainable food supply, and protecting our
natural capital.

Our climate action goals include commitments
for Net Zero emissions across our operationsand value chain by 2050.

Our customers look to us to support them on their sustainability journeys,
and we are responding to that call with action. By investing in sustainable,
responsible operations, we create a decarbonized future that will enable
resilience, innovation, and market differentiation while driving down ouroperational costs.”

Our approach to environmental sustainability prioritizes the implementation of sustainable
solutions in our facilities and products, as well as across our supply and value chain.
Facilities:• Incorporate green building design

Product:• Integrate Design for the Environment• Reduce Scope 1 and 2 emissions• Optimize sequencer power and processing• Increase renewable electricity• Replace chemicals of concern wherever
possible with greener alternatives• Reduce water footprint• Reduce waste to landfill• Reduce petroleum-based plastics• Reduce packaging

Supply Chain & Value Chain:• Reduce Scope 3 emissions• Drive sustainable and responsible
practices in our value chain

Community:• Help ensure a just transition to a decarbonized
future through philanthropy and community
investments• Engage strategic suppliers to reduce
their environmental footprint
Contributing to the UN SDGs

Kevin Pegels, Chief of Global Operations

39

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Integrating Environmental Sustainability:

Measuring Our Impact
2030 Targets1
Achieve Net Zero and reduce
absolute Scope 1, 2, and 3
emissions 100% by 20502,3,4
2021 PROGRESSIn progress

Reduce absolute Scope 1 and 2
emissions 46%2,3,72021 PROGRESS

24%
reduction

Reduce absolute Scope 3
emissions 46%2,4,72021 PROGRESS

36%
increase

2021 Recognition
100% renewable electricity2,5,72021 PROGRESS

59%

90% landfill diversion atcore sites2,82021 PROGRESS

49%
diversion

10% reduction in water
intensity at core sites2,8,92021 PROGRESS

8%

increase

75% reduction in packaging22021 PROGRESSIn progress

Achieve carbon neutrality indirect operations (Scope 1 & 2)
by 20232,3,62021 PROGRESS

24%

100% of strategic supplierscommit to minimizing theirenvironmental footprint
2021 PROGRESS

84%

committed

Invest $20M in charitable
contributions
to sustainability initiatives
2021 PROGRESS$714K

in philanthropic support enabled2030 Targets, unless otherwise specified
Baseline data 20193
Boundary of Scope 1 and 2 greenhouse gas emissions includes sites that represent jurisdictional control plus material locations, accounting for 96% of our total Scope 1 and 2 footprint
4
Scope 3 GHG emissions reductions from the categories: purchased goods and services, capital goods, upstream transportation and distribution, business travel, employee commuting, and investments
5
Illumina commits to increase annual sourcing of renewable electricity from 0.6% in 2019 to 100% by 2030
6
Carbon offset investments are applied in addition to meeting our verified science-based target for the short-term goals to offset the natural gas impact. All offsets are green e certified and nature based solutions
7
Emission reduction targets have been third-party verified by the Science Based Targets initiative in line with 1.5 degree C climate ambition
8
San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre, Netherlands, and Singapore Woodlands
9
Water target is normalized for intensity by square footage
122022 CORPORATE SOCIAL RESPONSIBILITY REPORT

40

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Climate Action
Climate change represents a threat
to human health, the environment,
and the global economy.
With our commitment to responsible and sustainable
practices, we set a long-term target of Net Zero carbon
emissions by 2050 across our operations and value chain
to align with the most aggressive climate action goals of
keeping global warming to 1.5 °C above pre-industrial levels.
On the path to Net Zero, we have established milestonetargets through 2030 including a 46% reduction ofemissions from direct operations and indirect operations
with a focus on the value chain elements associated withpurchased materials and services, transportation anddistribution, investments, business travel, and employee
commuting.
We have also joined other corporate leaders in committing
to decarbonization and demonstrating our commitment toleadership in environmental sustainability.

Our Path to Net ZeroTo ensure we hit critical milestones on our path
to Net Zero, we created short-, medium-, andlong-term targets. These climate commitments
include SBTi verified targets aligned to the
1.5 °C pathway.

2030

2050

• Business Ambition for 1.5 °C

Net Zero• Science Based Targets initiative• We Mean Business Coalition

46% reduction
for Scope 1, 2 & 31
100% renewableelectricity• United Nations Race to Zero

2023
Carbon neutral in
direct operations• The implementation of UN SDG 13:
climate change• Task Force on Climate Disclosure(Scope 1 & 2 beyond
SBTi verified targets)

2020-2030~4% annual
reduction for
Scope 1, 2 & 3

2019
Baseline

As a science-based organization, we are compelled toensure our reduction targets are aligned and verified toa science-based approach. In 2021, our Scope 1, 2, and 3
emission targets were aligned to a 1.5 °C climate ambitionand externally verified by the Science Based Targets
initiative (SBTi). In January 2022, we submitted
our request for verification of our Net Zero targets.

1

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

We have committed to:

SBTi verified

41

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Climate Action

Risks and Opportunities
Climate Risk Management

Natural Capital and Biodiversity

Addressing climate change is critical to achievinga sustainable, just, and resilient future for all. We
are committed to the integration of climate
resilience planning into our enterprise risk
management program. We continue to evaluate
our approach as external conditions evolve,
recognizing that both physical risks, such as
extreme weather, and transition risks such as
regulatory and technological developments,
may affect our operations.

Nature underpins all economic activities andhuman well-being. It is the world's most important
asset. As part of our approach to sustainable andresponsible business operations, we have reviewed
potential risk and opportunities beyond our climate
footprint to incorporate a holistic look at natural
capital and biodiversity. Natural capital assets
are elements in nature that provide the goods
and services that the economy depends on. We
reviewed the links between our potential direct
impacts and dependencies on natural capital.

We also seek ways to increase our climate
resilience. Our approach to manage the physicaland transition risks and opportunities presented
by climate change aligns with the Task Force on
Climate-Related Financial Disclosures (TCFD)
framework. We have updated our TCFD reporting
to reflect to our SBTi verified goals to keep global
warming well below 1.5 °C. Additional details on
our climate scenario insights are located in the
TCFD Index.

   Learn More
Climate Change Position Statement
Net Zero Climate Action Plan
TCFD Index

As the Task Force on Nature-related Financial
Disclosures develops a risk management anddisclosure framework for organizations to reportand act on nature-related risk, we have conductedpreliminary reviews using ENCORE1 as a tool to offer
early insights on potential impact and opportunities.
We used the following parameters for our review:
Sector of Health Care, Sub-Industry of Life Sciences
Tools & Services, and Production Process of Life
Science, Pharma and Biotech.
The impact materiality for our selected subindustries and production process indicated zerovery high materiality, zero high materiality, and only
1 medium materiality rating across the potential
natural capital categories. The medium materiality
rating for our industry was linked to solid waste andthe intersection of ecosystem services associatedwith species (plants, animals, fungi, algae, andgenetic resources).
At Illumina, our existing environmental-related
targets currently include efforts that prioritize
reducing the impact of waste in our facilities, supply
chain, and product. We will continue to monitor
and assess the natural capital elements of ourenvironmental footprint.
As evidence between biodiversity, natural capital,
and the economy become more defined, we
recognize there are opportunities for the applicationof genomics and Illumina sequencing to protect
and innovate in future nature positive economies.
Our technology is currently used in research tounderstand and guide conservation of species, toimplement more sustainable agriculture and foodsecurity pathways, and as a tool for innovation tocreate new synthetic materials that minimize natural
resources use or create alternatives to natural
capital withdrawals.
We are excited about the opportunities Illumina
and the field of genomics can support as we march
toward a more sustainable future.

CDP Disclosure1

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Exploring Natural Capital Opportunities, Risks and Exposure

42Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Sustainable Facilities
Our direct environmental impact in our operations and facilities
represents 13% of our total emissions footprint.1
Creating Sustainable Facilities
We focus on green building design; optimizationof existing energy, water, and waste systems;
and expanding use of renewable energy. We
continually seek initiatives to reduce
our environmental footprint.
• Incorporating green building design into all new
construction projects• Utilizing renewable electricity• Installing green roofs• Using sustainable building materials

Greening Our Labs
We have partnered with My Green Lab® toimprove the sustainability of our laboratories
around the world. In 2022, we will initiate theprocess of certifying five of our global labs
through the My Green Lab® Certification
Program as part of our commitment to
a Net Zero future. Participating in thisprogram will help us identify and implement
sustainability best practices around energy,
water, and waste, while increasing employee
engagement in our labs.

Energy Efficiency
We regularly evaluate energy-efficiency measures and renewable energy projects to reduce ouroperational carbon emissions. Each of our sites maintains a pipeline of energy projects to contribute toemission reductions.

2021 Initiatives• Enrolled in Community Power offering, shifting all three of our San Diego locations to 100% renewableelectricity. All existing San Diego sites will be fully transitioned by the end of 2022 resulting in an estimated1,500 metric tons CO2e reduction annually.
• Replaced two air handler units and two AC units with newer, more reliable, and efficient units at our
Hayward site. This upgrade will save an estimated 243,000 kWh per year, representing 10% of the entire
site’s annual electricity usage.
• Initiated energy audits at our San Diego, Madison, Hayward, Foster City, Cambridge, and Singapore facilities
to further identify opportunities to reduce energy consumption across our global operations.

2021 PROGRESS• Incorporating energy-conservation technologies• Optimizing natural light and opportunities forconnecting employees to the outdoors
Currently, we have four of our core campus locations
around the world that have earned certifications forgreen building practices.

2030 Target100%
renewable electricity

2030 Target 019 baseline22Onsite generation, purchased renewable electricity, and renewable energy credits
3
Scope 1 and 2 emission intensity per million dollars revenue
12022 CORPORATE SOCIAL RESPONSIBILITY REPORT

46%

59%

59%

59%

Renewable
electricity2

11.4

24%

9.8

9.8

Reduction in
Scope 1 and 2
emissionssince 2019
0.6%

2%

5.8

0.6%

2%

SBTi verified
Renewable Electricity Renewable Electricity
targets
2019

11.4

2020

2021
2019

2020

2021

3
Scope 1 and 2 EmissionScope
Intensity
1 and
2 Emiss

2019

2020

2021
2019

reduction Scope 1 and 2
43

2020

Illumina

AccessEnvironment

Community

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Sustainable Facilities

Waste Management

Water Stewardship

We take a hierarchical approach to waste management, where source reduction is the most preferable option, andlandfill is the least preferable. We will continue to prioritize innovative waste management efforts as part of our 2030
landfill diversion target.

We continuously seek opportunities to reduce our water footprint by improving operational
efficiencies and assessing potential risks to protect this vital natural resource. We assessed
our water usage by comparing the locations of our sites with the baseline water stress risk
ranking according to the World Resource Institute and its Aqueduct atlas.2 For facilities thathave been identified as operating in water-stressed regions, we are committed to focusing
additional efforts on water management planning.

Hazardous Waste

Responsible eWaste Disposal

Our hazardous waste management program isdesigned to minimize impact and manage materials
in the most environmentally responsible manner.
The process follows a hierarchy that specifies:
reclamation/reuse, recycling, waste to energy
recovery, fuel blending, wastewater treatment,
incineration, autoclave, and landfill whenalternatives are not available.

Through our waste management
programs, we aim to reduce theenvironmental impact from electronic
waste and ensure responsible
management at end of life. We partnerwith E-Steward, R2, and other certified
recyclers to refurbish, rebuild, andreuse devices to help organizations
around the world.

San Diego Site Waste

140,000 lbs

hazardous waste diverted annually
through waste segregation project

Producer Responsibility
We participate in required compliance schemes for
producer responsibility to ensure proper collection,
management, and disposal. This includes therecycling of packaging, batteries, and waste
electrical and electronic equipment (WEEE). Under
the EU’s Batteries and Accumulators Directive
and Packaging Waste Directive, and regulations
in several EU member states, we comply withrequirements to finance the collection and recyclingof batteries and packaging supplied with our
products at end of life.

2030 Target

90%

landfill diversion at
all core sites1

Water Risk at Core Site Locations2
San Diego, CA

Cambridge, UK

Steenoven, Netherlands

Foster City, CA

Madison, WI

Hayward, CA

Water risk assessment by siteHigh

Low-Medium

How We Tackle Waste

10%

Singapore

Extremely High

2030 Target

reduction in water
intensity at core sites1

Medium-High
Low

Most preferable

Minimizematerials
bound forwaste stream

Avoid or Reduce

Reuse

Return materials
for reuse

RecycleUtilize materials withappropriate recycle streams or
support curbside compostable

Incinerate

Burn waste materials
with energy recovery

Landfill

Collaborate with waste
haulers to ensure targeted
ideal material streams

Least preferable

1
2

San Diego Water Highlights
At our largest location and highest water risk location,
we employ a variety of water conservation applications:• Reclaimed water used for landscape, cooling towers,
and water features• Low flow fixtures• Smart timers for irrigation linked to forecasted
weather conditions• Synthetic grass in amphitheater• Succulent and native plant landscaping
50% of water used at San Diego locations is sourced
from reclaimed water

San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre, Netherlands, Singapore Woodlands.
Water Stress and the Aqueduct Project44

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Developing Sustainable Products• Reduction in reagent size

• Data footprint reduced by 25%• Ambient flow cell shipping• G igabase per hour increased data rates• Biodegradable inserts• Plant based insulated shipping containers• Increased shelf life from 3 to 12 months
on v1.5 RUO kits

• Disassembly optimization for recycling

NextSeq™ 2000 compared to NextSeq™ 550• Improved energy intensity and compression
efficiency of sequencers• 4x smaller reagent size

D
N

LIFE
OF

NG
UT

RI

IB

IO N

Through our DfE approach, we seek to findmore opportunities to shift the standard
linear economy of take, make, waste toa circular economy addressing the full life
cycle of materials and their end of life.

T

U

S

2030 Targets in Progress• 6x faster on board secondary analysis
OCESSING
PR

DI

TR

• 2.5x output• 75% decrease in waste footprint

RES
OU
RC
ES

Design for the Environment (DfE) is our approach to incorporate sustainability and lower the environmental
impact of products through design. Through DfE, we apply environmental criteria to resource selection,
design, packaging, energy use, data processing efficiency, size, weight, stability, shelf life, temperature
requirements, end-of-life management, and more. Insights from these assessments help inform our work
toward our 2030 targets. In 2022, we aim to complete additional product life cycle assessments (LCA) to
inform further opportunities.

NovaSeq™ compared to HiSeq™

E

Design for the Environment

Sustainable Product Highlights

USE

We continue to develop innovations that reduce the environmental
impact of our products, technologies, and solutions. We apply
the principles of environmental stewardship to address impact
throughout the product life cycle.

MANU

C
FA

• Integrate Design for the Environment (DfE)• Optimize sequencer power consumption and processing efficiency• Reduce amount of petroleum-based plastic in new product designs• Replace use of chemicals of concern wherever possible with greener alternatives• Seek additional opportunities to engage in circular economy

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Lowering the Energy Use of
Our Products
We are seeking ways to optimize sequencing power consumption
and processing efficiency to reduce the environmental impactof our products. The DRAGENTM (Dynamic Read Analysis for
GENomics) Bio-IT platform provides accurate, ultra-rapid
secondary genomic analysis of sequencing data. This platform
requires 20x less energy to analyze one whole human genome
compared to the DRAGENTM-GATK.
45

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Developing Sustainable Products

Sustainable Packaging

Returnable. Reusable. Recyclable. Our packaging is more sustainable than ever.

We lead with sustainable, responsible, and proactive business practices,which extend to how our products are developed and produced, and how
we move materials throughout our value chain. Through the integration of
DfE, we continue to assess opportunities to optimize packaging for products
currently on the market and incorporate sustainable packaging design into thedevelopment of new products.
Many of our products are temperature sensitive, which creates uniquerequirements for packaging, shipping, and storage. We utilize a packaging
LCA tool to provide an additional lens to make informed and evidence-based
decisions about packaging materials and designs.

2030 Target

75%

reduction of packaging
from 2019 baseline90%of our secondary andtertiary packaging will
be recyclable, reusable
or compostable

Recyclable Insulated Containers

Returnable Insulated Containers

Reusable Bulk Sustainable Solutions

A move to plant-based paper insulated
containers results in a recyclable solution.

Insulated containers used for refrigerated
and frozen in vitro diagnostic (IVD) productshipments can be returned to us for reuse.

Insulated pallet shippers for frozen andrefrigerated products are validated
for multiple uses and returnable forrefurbishment and reuse.

• 100% curbside recyclable andcompostable using standard paperrecycling streams• Insulated containers for frozen andrefrigerated shipping are made withplant-based renewable materials, which
require less energy and are diverted fromthe landfill• We experienced pandemic-related
supply disruptions with these containers
in AMR and EMEA throughout 2021. We
were able to redeploy the containers in
AMR in October and are again in full use
throughout the region. We will continue
to scale up use in EMEA in 2022 and are
currently evaluating solutions for use
in APAC.

• Returned containers are inspected,
sterilized, reworked, and reused• 70 lbs of tertiary packaging waste
diverted from landfill with each use andsubsequent reuse• Supplier return facilities inspect andrefurbish for return shipments to Illumina• Pallets are modular and break down flatfor easy return of multiple units via landor ocean transport• Supports internal movement networkand customer bulk orders

Additional Packaging Highlights• Elimination of bubble wrap with dunnage paper• Bulk palletized packaging solution for NextSeq™ 500/550• Continued dry ice optimization resulting in 80 kg less dry ice per frozen pallet

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

46

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Sustainable Value Chain2019 Baseline Scope 1, 2, 3

As a global organization, we recognize our environmental
footprint extends beyond our facility walls.

Scope 1
Scope 2

Scope 3 Emissions

2030 Target

In early 2021, we launched our first Scope 3 emission inventory assessment across all relevant
categories for our value chain to better understand the holistic impact of our business and to
identify the greatest opportunities.

Reduction Scope 3

Waste Generated in Operations 0.1%
Upstream Leased Assets 0.6%
End-of-Life Treatment of Sold Products 1%
Fuel and Energy Related Activities 3%
Use of Sold Product 3%

46%

Business Travel
8%

Using 2019 as our baseline, the results revealed that 87% of our global emissions are
attributable to elements in our value chain.
Of the fifteen categories assessed, we selected the most material categories contributing
to our emission inventory. Categories that represented 7% or more were defined as material
and account for 92% of our total Scope 3 footprint. These categories will be the focus of our
reduction efforts:

Employee Commuting
8%2050 Target

Investments
10%

Net Zero

Scope 3• Upstream transportation and distribution• Investments

2021 PROGRESS• Purchased goods and services• Business travel• Capital goods• Employee commuting

Emission change
since 20192021 % of total
emission footprint

Scope 1 and 2:

Scope 1:After reviewing the Scope 3 data, we established targets for reduction. In September of 2021,
we successfully received verification from the Science Based Targets initiative on our emission
reduction approach aligned to a 1.5 °C pathway. Our verified targets include reducing absolute
Scope 3 emissions 46% by 2030 compared to 2019.
We are working with each functional group on projects to continue to drive down the value
chain impact. Initial projects and sample initiatives include updates to our investment policy,
communication campaign to our supplier base, supplier mapping optimization, expanding
green travel policy, and shifting purchased goods from air to ocean freight wherever possible.
We will continue to report on progress as these evolve.
2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Scope 1 + 2
13%

24%

Scope 3:36%

Capital Goods
17%

Material Categories
of Focus

6%

Scope 2:2%

Purchased Goods& Services
31%

Scope 3:

92%

Upstream Transportation& Logistics
19%
47

Illumina

AccessEnvironment

Community

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Sustainable Value Chain

Engaging Our Partners in Reduction Efforts
We consider it business-critical to work with suppliers and partners across our value chain
who share our commitment to the environment.
We engage with strategic suppliers and business partners on climate-related issues andhold them to the same high standards of business conduct that we set for ourselves. We
require strategic suppliers to commit to reducing their own environmental footprint.
Through our strategic suppliers scorecard program, we assess environmental sustainability
commitments made by our suppliers. Our goal is to empower our suppliers to reduce theircollective carbon footprint and encourage transparent reporting on their progress. In turn,this will help us to reduce our overall Scope 3 emissions.

2030 Target
Ensure100%of strategic supplierscommit to minimizing theirenvironmental footprint
2021 PROGRESS

Sustainable Investments Policy
The emissions associated with our investments accounted for 10% of the impact
in our value chain in our 2019 baseline study and was one of the top five areas
contributing to our Scope 3 greenhouse gas inventory. Following review of the
Scope 3 data, we modified our investments policy to eliminate investing in Energy
and Utilities sector bonds unless the associated issuance is identified as a
Green, Social or Sustainability (GSS) Bond. The analysis showed we could adjust
our approach without any expected impact to our returns, helping to green ourinvestments without financial impact.

Learn more about our supplier engagement efforts in the
Responsible Supply Chain section of the Integrity chapter.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

84%

More Sustainable
Business Travel
Illumina enables employees to effectively
avert travel for business meetings with ahost of digital and virtual tools, reducing
carbon emissions associated with businesstravel. For our highest traveled routes, weare curating preferred partnerships withairlines where sustainable aviation fuel andincreased aircraft efficiency are options.

48

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Leveraging Genomics
for a Healthier Planet
The positive power of genomics is helping
solve some of the world’s most challenging andpressing issues for human health and beyond.
Today, scientists are using our technology to research climatechange adaptation, study conservation, and utilize environmental
DNA (eDNA) to gain insights to develop innovative environmental
solutions. Genomics is proving to be an invaluable tool to understandhow climate change is impacting biodiversity, such as cataloging
endangered species and identifying new ones.
Conservation Genomics focuses on characterizing genetic diversityof endangered species and applying molecular tools like Illumina
sequencing to support sustainable management of threatened
species and populations. For agricultural genomics, Illumina
technologies help researchers on everything from developing moreheat-resistant crops to helping breeders raise healthier livestock.
As we address the carbon footprint of our business, we alsoseek to support a collective global improvement. To ensure a justtransition to a decarbonized future, we have added an element ofphilanthropic and community investment.

2030 Target
Invest$20M
in philanthropic contributions to sustainability
initiatives and projects to ensure a justtransition to a decarbonized future.
Learn more in the Community section.

Honoring a Just Transition
to a Carbon Free Future
GRID Alternatives helps advance economicand environmental justice in the US throughrenewable energy projects. We partnered with
GRID Alternatives on projects near each of ourmain campus locations to provide clean energy,
solar industry job training, and job placement to
low-income and tribal communities in San Diego,
the San Francisco Bay Area, Washington DC,
and Wisconsin.

The University of Sydney’s Australasian Wildlife Genomics
Group is using genomics to battle decreased genetic
diversity threatening koalas. Illumina whole genome
sequencing technology provides insights to researchers to
help protect the species from climate change, disease, andother risks.
Learn more

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

49

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Climate Action | Facilities | Products | Value Chain | Sustainability Applications

Leveraging Genomics for a Healthier Planet

Accelerating Conservation
with Illumina iConserve

How Illumina Technology Is Helping to Support
Biodiversity and Sustainable Agriculture

Our philanthropic initiative iConserve seeks to bring the community
together to accelerate wildlife conservation. This year, the teamis partnering with Dr. Tomas Marques-Bonet at the Universitat
Pompeu Fabra in Barcelona to map the genetic variability of gorilla
populations across their habitat range. Despite international laws ofprotection, illegal trafficking of great apes is an ongoing challenge.
Once gorillas are confiscated, it is challenging to genotype andidentify their source of origin to facilitate reintroduction to the wild.

Returning Turtles Home
with Genomics
The Turtle Survival Alliance (TSA) is using
genomics to save endangered turtles fromextinction. 20% of global turtle diversity lies within
the US, making it an ideal hub for trafficking. Over
10,000 trafficked turtles from unknown locations
have been confiscated by US authorities. We
contributed two iSeq™ and one MiSeq™ platforms
along with reagents for fast processing of gene
samples enabling TSA to return up to 5,000 more
turtles to their original homes each year.

Profiling Endangered Plants
California State University, East Bay, located in the same community
as our Hayward manufacturing location, has launched the Green
Biome Institute using genomics to profile California’s endangered
plants. The Institute aims to create molecular profiles of nearly 380
threatened or endangered plant species to promote conservationand document their biology, ecological interactions, and potential
human benefits.
The Illumina Corporate Foundation provided the Institute with a$50,000 grant for the advancement of genomic literacy and STEM
education through hands-on genomics research for high school,
undergraduate, and graduate students, while contributing to theknowledge and preservation of California’s endangered flora.
2022 CORPORATE SOCIAL RESPONSIBILITY REPORTThe project will determine the geographical origins to create afirst-of-its-kind atlas of individual apes confiscated over the last
decade and now living in sanctuaries, maximizing the probabilities
of reintroduction to the wild. This project will also serve to boost
regions in Africa as centers of excellence in conservation genomics.
Learn more about this iConserve project here. Explore additional
initiatives below:• Bottlenose Dolphin Genome Made Available to Researchers

Illumina Agricultural
Greater Good Grant
The most recent awardee of our annual
Agricultural Greater Good Initiative grant
program funded a project by the International
Institute of Tropical Agriculture (IITA) todevelop genomic resources for yams, asignificant agricultural crop and a rich sourceof nutrition. The IITA aims to conduct WGSof guinea yams from Nigeria and Benin to
investigate their evolutionary development
and to tap into specific genes for optimizing
hybrids in the breeding program.

• Sequencing to Save the Lemurs

Sequencing Genomesof All Species
We are a contributing member of the
Earth Biogenome Project, a massive
undertaking that aims to sequence
the genomes of all species on Earthto help uncover the solutions forpreserving and restoring biodiversity.
We have provided an in-kind donationof 100 reference-quality genomes
and participated in the developmentof technology for the sequencing ofgenomes from single-cell and small
multicellular organisms.

50

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Nurturing
Our People51Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Nurturing Our People:

Our Strategic Approach
We are committed to engaging extraordinary talent and helping
them thrive. Together our impact is amplified, and our potential
is unlimited.
Overview

Our Objectives

Every day at Illumina, we have the chance to do once-in-a-lifetime work, transforming humanhealth and driving scientific innovation. With an extraordinary mission comes the need forextraordinary people and leaders at every level. By nurturing a culture of care, we enable
Illumina employees to fully contribute to our Mission and deliver on the transformative powerof genomics.

We strive to embody a culture of care that is fueled by supporting one
another, promoting collaboration, inspiring innovation, and advancing
diversity, equity, and inclusion.

By focusing on inclusion and enabling a culture of care, we amplify the value of collaboration
and building community. Fostering an inclusive and healthy workforce is a foundational
principle and essential for innovation. We invest in our people, offer flexible working
conditions, and provide a portfolio of benefits that support the variety of their personal needs.

• Relentlessly practice diversity and inclusion in all that we do toadvance equity and belonging

Our shared purpose and collective efforts result in common bonds and pride among all at
Illumina as we help drive the positive progress of genomics for all.

• Offer employees the resources and support they need to bring
their personal best every day• Foster an environment where people feel Illumina is a greatplace to work for everyone• Acquire, invest, and grow extraordinary talent, leaders, andteams to create a deep and diverse pipeline• Steward employee safety and well-being

The COVID-19 pandemic created extraordinary
opportunities for reinvention. Our foundation of innovationand our culture of care set us up well for recovery andbeyond to continue allowing us to thrive into the future.”

Contributing to UN SDGs

Aimee Hoyt, Chief People Officer

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

52

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Nurturing Our People:

Measuring Our Impact
2030 Targets
Increase gender
representation in
global leadership1
2021 PROGRESS

42%

Increase representation
Black, Native,
Pacific Islander,
Hispanic or Latino,
2 or more in
leadership1 (US)2021 PROGRESS

12%

Increase representation
Black, Native,
Pacific Islander,
Hispanic or Latino,
2 or more in our
workforce (US)2021 Highlights
Increase minority
representationin executive
leadership (US)1,2

female workforce representation

5%

Maintain zero net
pay gap3

50%2021 PROGRESS

increase in female executive leadershipin last three years

minority representation in US workforce

Zero Net
Pay Gap>4,000

Reduce recordable
injury & illness rate5>1,0002021 PROGRESS.54

2021 PROGRESS

17%

Leadership = Manager, equivalent, and above
2
Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more3
Zero net pay gap: no statistically significant difference in pay for the same or similar work, regardless of gender ethnicity, or race
4
ERG: Employee Resource Group
5
Rate calculated using total hours worked from employees + contingent workers. Incident per 100 employees based on 200,000 hours worked.
1

45%2021 PROGRESS

27%

2021 Recognition

participants in ERG4 programming

new roles added for growth2%

increase in representation ofBlack, Native, Pacific Islander, Hispanic
or Latino, 2 or more communities inleadership1 since 20196%

increase in minority representation in
executive leadership (US)1,2 since 201953

Illumina

AccessCommunity

PeopleEnvironment

Integrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Our People
Everyone at Illumina is driven by the power of genomics to positively
impact the world. We seek opportunities. We embrace challenges. We
work tirelessly to move genomics and humanity forward. Together, ourteam of passionate people amplify impact and unleash unlimited potential.

We regularly ask our employees to complete our survey and in 2021, we surveyed
quarterly. These insights help leaders, at all levels, better understand and respond to
employees’ needs.

Trust and Engagement

At Illumina, you will do more and become more than you ever thought possible.

We create worldchanging impact

Listening to our Employees

90%
Illumina is a placefor everyone

I have confidence in the continued
growth and success of Illumina

Diversity, Equity, and Inclusion

92%
Innovative thinking
is our way

We achieve
more together

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT93%

I am proud to work for Illumina

84%

I feel that Illumina values diversityI would gladly recommend Illumina as
a great place to work to people I know
and respect

86%

83%

I feel like I belong
at Illumina

Opportunity
for growth iseverywhere

What Our Employees Think
About Illumina

Illumina really cares about
my well‑being

Our work is
deeply rewarding54

Illumina

AccessCommunity

PeopleEnvironment

Integrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Workforce Demographics
Gender Representation

Regional Employee Distribution

55%

1,285

AMR

45%

2,238

15%
Over 50

20%
Under 30

female

APAC

5%

50%

65%
30–50

male

EMEA

5,668

Minority Representation Workforce (US)

Employee Age Distribution

Declined
to state

Minority
representation

45%

Self identified
as white

38% Female Director and above(5% increase from 2019)

9,191

Representation of Black, Native, Pacific Islander,
Hispanic or Latino, 2 or more communities (US)total global employees (FTE)

10%2021 US Minority Data By Level1

Executive

12%

Leadership

17%

Workforce

Support to Entry Professional
Intermediate to Senior Professional

Minority Representation in LeadershipManager to Associate Director

27%

Director and Above
0%

1

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

White/CaucasianAmerican Indian/Native Alaskan

Hispanic/Latino

2 or More

Native, Hawaiian/Other Pacific Islander

AsianBlack/African American

Not Disclosed or additional data points on EEOC, refer to ESG Appendix. Though we do not use the Federal Employer Information Report EEO-1
F
to measure progress, we publish our most recent filing.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTIn the last three years:

6%

Increase at Executive level

8%

Increase at Leader level

Executive: Director and above
Leadership: Manager, equivalent, and above
Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more

55

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Advancing Diversity, Equity, and Inclusion
Inclusion is core to our purpose. It is essential to the work we do, thecommunities we serve, the partners we choose, and the teams we build.
We relentlessly practice diversity and inclusion in all
we do to advance equity and belonging. We strive
to foster an inclusive and diverse culture in which
all employees feel valued and appreciated. This kindof environment helps people engage at their best,
knowing they have an equal opportunity to growand succeed based on their performance, fueledby their individual differences. We know our path
to creating and sustaining a fully inclusive culture
requires investment in our employees with a keen
focus on inviting diverse perspectives, experiences,and opportunities to learn from one another. We
celebrate our employees’ unique life experiences,backgrounds, talents, passions, and contributions
to innovation.
Diverse perspectives are valued and needed todrive discovery and innovation. As a business
committed to advancing genomic technologies
and pushing science to new limits, we depend on
harnessing the full engagement of employees andtheir most creative ideas. We appreciate theseoutcomes are achieved when everyone feels safe,
respected, valued, and supported.

In addition to the reported workforce demographics,
we also collect self-reported employee data for theidentities such as LGBTQIA+, people with a disability,and veteran status in the US workforce. This isimportant because providing the option to identify
provides the message: “we see you” and that we are
actively welcoming those who often feel marginalized
in the broader society into our community. We are
expanding this effort and aim to create a working
environment where neurodiversity and people withdisabilities can thrive. We will continue seeking
opportunities to help us get better at our practice ofinclusion and building community.
Our strategy is integrated across the following
areas: our employees and culture; our suppliers andbusiness partners; and our community. Learn more
about our supplier diversity program in the Integrity
chapter, our philanthropy to increase equitable
access in the Access chapter, and STEM for all
in the Community chapter.

As part of our commitment to DEI,
we are the proud signatories of:• UN Women Empowerment Principles• CEO Action for Diversity and Inclusion• UN Global Compact

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

56

Illumina

AccessCommunity

PeopleEnvironment

Integrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Advancing Diversity, Equity, and Inclusion

Our DEI Focus Areas

Diversity, equity, and inclusion are important
aspirations that are only built over time throughpractice. We relentlessly work to get better andcelebrate the milestones.”

Our efforts to practice DEI include setting targets, investing in programs to drive improvement,
and expanding the transparency of diversity data. We aim to:• Build our global workforce to represent the communities where we operate and the world we are working to serve• Create a working environment where neurodiversity and people with disabilities can thrive

Dr. Lisa Toppin, Global Head of Diversity, Equity, and Inclusion• Create an innovative organization where young and mature talent feel involved, respected, connected, and inspired to contribute new ideas• Establish a culture where minorities can thrive and progress with the company as we build a strong pipeline of diverse talentAcquire and Develop Diverse Talent

Build Inclusive Leadership• Advance DEI in talent initiatives and HR processes• Build and practice leadership inclusion capability amongst our teams• Create strong, mutually beneficial relationships with HBCUs1,

minority and women employees

Our DEI• Commit to diverse candidate pools (final slates) for Director and above

Focus Areas• Launch DEI learning journey for leaders empowering their use of thetalent cycle• Provide assessment tools to help leaders understand opportunities
for themselves and the team• Recognize leaders making a difference in DEI

Pr

sp

ar
en

oc

n
Tra

ess

• Build ERG groups as diverse pipeline of leadership

Communicate with Transparency

racial/ethnic minorities in senior leadership roles globallyes• Expand formal mentorships and add sponsorship programs supportive of• Provide opportunities for representation of women and

Inclu
siv
eL
p
rshi
de
ea

and networks

Div
er
se

other educational institutions, diversity groups, professional organizations,

t
len
Ta

cy

E qui

ta b

le

Enhance Equitable Processes• Disclose commitments and measurements, and celebrate successes• Reduce bias in people processes and strengthen DEI outcomes• Share data to inspire trust and action on key processes• Leverage data and consistent structure to make people processes• Publish DEI goals and commitments externallymore equitable• Spotlight diverse employee stories of inclusion and belonging• Embed DEI lens in promotion and mobility process• Maximize impact of leader DEI dashboards to deliver insights• Continue momentum on net zero pay gap policy and outcomes

and drive change

1

HBCU: Historically black colleges and universities

57

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Advancing Diversity, Equity, and Inclusion

Equal Opportunity
Pay Equity
We strive to offer meaningful development opportunities and rewards for impact,
performance, and potential to attract and retain outstanding and diverse talent. Our
pay practices are designed to compensate employees based on factors such as job
performance, expertise, and experience relevant to individual geography. Everyone
should be paid equitably, regardless of gender, race, age, ethnicity, sexual orientation,or national origin. We monitor our pay equity status and market competitiveness onan annual basis.1 Our 2021 global compensation cycle once again confirmed a zeronet gap2 in pay.
When we examine the average pay3 between women and men in our organization, we
recognize opportunities still exist to improve. Our objective is to achieve equality withwomen’s representation in senior roles. We acknowledge that senior positions typically pay
more and we will reach parity when women hold as many of the higher paying roles as theirmale counterparts.

Flexible
workplace policies

GenderGender Representation by Level
Female
Male

67%

66%

neutral policies

100%

64%

57%

56%

52%

44%

44%

Supervisor to
Associate
Director

Intermediate
to SeniorProfessional

43%

48%

36%

34%

33%

56%

employees eligible forbonus plan
Board ofDirectors

SVP/
C-Suite5%

VP

Director & Sr.
Director

Supportto Entry
Professional

Increase in Female Executive Leadership4 since 2019

Equal Opportunity andNondiscrimination Policies

Gender Representation

2019

2020

2021

% of women in management positions inrevenue-generating function

35%

36%

42%

We support the elimination of discriminatory practices with respect toemployment. We are committed to fair and respectful treatment of all
employees, promoting equal opportunity and diversity in the workplace andin all aspects of our business. Our policies prohibit discrimination based on
race, color, age, gender, sexual orientation, marital status, gender identity andexpression, ethnicity, religion, physical or mental disability, medical condition,
genetic information, veteran status, national origin, or any protected class.

% of revenue-generating roles held by women

41%

36%

48%

% of women in STEM-related positions(as % of total STEM positions)

37%

37%

39%

% of IT workforce that are women

24%

23%

24%

% of engineering workforce that are women

37%

36%

29%

Equal pay refers to paying a woman and man equally for the same or similar work
Zero net gap in pay means no statistically significant difference in pay for the same or similar work,
regardless of gender, ethnicity, or race3
A pay gap is the difference in average pay between women and men in an organization
4
Executive Leadership: Director and above
1

2

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

58

Illumina

AccessCommunity

PeopleEnvironment

Integrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Advancing Diversity, Equity, and Inclusion

Our ERG Program Philosophy

Employee Resource Groups
We celebrate and connect employees through our
Employee Resource Groups (ERGs). ERGs deepen
our respectful, inclusive culture by engaging
employees around issues they care about.
Our ERGs are the cornerstone of DEI at Illumina.
They provide a formal way to engage employees
on diversity and create a positive impact for thecompany. The ERGs are a key lever to identify,
develop, and retain untapped, early in career
talent for future senior level roles. They help
employees develop connections with theirpeers and allies, and collectively advocate fordiversity initiatives. Our growing ERGs also deliver
expanded career and development experiences.
We are proud to have ERGs represented globallythat support young professionals, LGBTQIA+,
veterans, people of color, minorities, and women.

In 2021, we launched two new ERGs: iLatinx
for employees who identify as Latinx and their
allies and Green Team EMEA for employees
in the EMEA region who are committed toadvancing sustainability at Illumina by improving
awareness and promoting practices that havea positive impact on our environment. We also
expanded our core ERGs to additional regions
around the globe, taking our count of chaptersfrom six to eleven.
This year, we deepened the connections
between ERGs and our CSR program. Each ERG
completed a social impact project and provided
a donation to a local organization aligned with
their mission. Our ERGs created meaningfulbusiness and social impact, as well as directing
over $50,000 of CSR funds to their local chosencharities. To read more about our philanthropic
efforts, see the Access and Community
chapters.

Our four contribution pillars ensure programming supports ERG member needs and aligns with Illumina values.
This focused work educates our teams about the value of difference and uses the power of diversity to drive
innovative problem-solving for our business. Our ERG program aims to:

Develop diverse leaders

COMMUNITY SERVICECAREER DEVELOPMENT• Support our communities
with social impact
projects• Strengthen employee
engagement and Illuminaawareness• Building the skills of• Educate thediverse employees asorganization about
future leaders
our values• Identify internal talent• Create morefrom many different
understanding, deeper
backgrounds andcollaboration, and moredevelop them
meaningful work
• Offer specificprogramming to ERG
participants and exposure
to executives

SHADES: Employees of color fromdiverse backgrounds and allies

Horizons: Employees early in theircareers and allies

EDUCATION

iLatinx: Employees connected to theLatin-American/Hispanic culture

Green Team: Dedicated to educating
employees on how to be more sustainable

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Enable skills practice

BUSINESS IMPACT• Leverage thepower of diversity
to drive imaginative
problem‑solving• Enhance innovation
with diverse teams
identifying andsolving businesschallenges

iServed: Employees who served or
currently serve in the military and allies

iPride: Employees of the LGBTQIA+
community and allies

WIN: Women at all levels and stagesof their careers and allies

BE GREAT: Dedicated to Black/African
American employees and allies

59Illumina

AccessCommunity

PeopleEnvironment

Integrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Advancing Diversity, Equity, and Inclusion

Increasing DEI Awareness and Engagement

Raising Awareness of Asian Hate

Enabling Supplier Diversity
Program Improvements
The SHADES ERG, which is a group of
employees of color and allies, has worked tostrengthen our supplier diversity program. ERG
members volunteered their time to identify,
research, and verify over 400 diverse suppliers,
improving the accuracy of our supplier data.
They also increased outreach to diverse
suppliers to provide new opportunities to workwith Illumina.

The US has seen a deeply unsettling rise in racism andviolence against members of the Asian community. Illumina
condemns all racism and stands with our Asian community.
To provide awareness and strengthen our internal community,
our ERGs hosted listening sessions as a safe space to sharethoughts and feelings, hear the voices of others, and learn
about their experiences.

Monthly D&I Sessions
In 2021, we began hosting a monthly speaker
series on diversity and inclusion to further
integrate D&I into our company culture,spread awareness of important issues, andaddress unconscious bias. Approximately 500
employees tuned in to hear sessions on:• Understanding Masculine and Feminine
Communications Styles• What You Need to Know About Caregiving• How to Be an Ally
• Disability Employment and Awareness• Understanding Neurodiversity—Autism

Inclusive Leadership Training
In 2021, 200 employees trained on
The Fundamentals of Inclusive Leadership,a strengths-based training.
2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Celebrating Black
History MonthOur BE GREAT ERG coordinated
STEM volunteer activities.

Enabling Inclusive Representation
Labels and signals can be a source of unconscious
bias in society. With that in mind, leaders of iPride,our LGBTQIA+ ERG selected a project for theirbusiness impact initiative that coordinated the
addition of Mx (pronounced “mix”) to the Illumina
Salesforce customer interface and internal HR
platforms. ‘Mx’ is a widely used gender neutral
honorific.
“When we launched the project idea, we were met
with support from our internal allies and externalbusiness partners. This project signals that as acompany, Illumina is sensitive to the diverse needsof our community, and we are fully committed
to being a safe space for all,” explained Shadow
Seacliff, a staff web designer and iPride leader.

Walk the Talk on DEI
In 2021, we invited our employees to support theirwell‑being and give back by connecting charity to a fitness
challenge. The “Walking the Talk on Inclusion” challenge
helped raise awareness about ‘power and privilege’ while
encouraging active, healthy lifestyles. Collectively, ouremployees walked over 100 million steps—and raised$25,000, which was donated through the Illumina Corporate
Foundation to five charities around the world that help makean impact on DEI in their communities.

60

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Investing in Our People
We are committed to engaging extraordinary talent and helping them thrive.
Our vison requires a People strategy that attracts,
nurtures, and retains industry-leading talentand leaders.
To ensure that our employees enjoy long andfulfilling careers at Illumina, we invest in recruiting
extraordinary talent, providing varied training anddevelopment opportunities, and rewarding our
employees meaningfully for their contributions.
The path to realizing the world-changing
possibilities of genomics is both challenging andrewarding. Our dedicated and brilliant professionals
each do their part to create this future. We seek
opportunities. We persevere together. And we
support one another in delivering innovations thatmove humanity forward.

We believe in the importance of creating aworkplace in which all employees:• Are empowered to grow, contribute, and makean impact• Work in a culture that prioritizes learning andcontinuous improvement• Collaborate and build relationships withcolleagues, regardless of their positionor seniority• Embrace our culture of innovation and respect• Are rewarded and recognized for theircontributions• Participate in giving back to the communities andcauses that matter most to them
• Understand that diversity is strength

There isn’t just one career path at Illumina. In every role, we
approach our work with curiosity, and apply our passions to
support a mission that truly matters. We work to create a space
where there is unwavering support to grow as an individual andbring out the best of our teams.”
Karen Wetherholt, Head of Global Talent

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

61

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Investing in Our People

Opportunity Is Everywhere at Illumina
The exponential growth of our business means there is no shortage of opportunities
for those who continue to challenge themselves. We encourage employees topursue their passions, learn beyond their discipline, and create their own path.
Our training and development programs embody our belief that opportunities
always exist to grow and to learn regardless of where you are on your career
path. From soft skills to technical knowledge, online learning to coaching clinics,
we empower our employees to shape their own careers, taking advantage of theopportunities to progress at Illumina.
We have enhanced our people development and training programs to effectively
serve the dual purpose of growing the overall workforce capabilities and elevating
the skills of unique talents and roles.
The right tools are critical in navigating career development. Through regularperformance conversations, employees have meaningful discussions about theirwork, their aspirations, and their development. Development resources are curated
so that employees can explore, share, plan, and act to get on the path that is thebest fit for them.
• External speaker series• Open career panel discussions• TEK Talks (technical education knowledge)• 360-degree and 180-degree assessments for individual and team feedback• Tuition assistance/financial assistance for job-related education• LinkedIn learning, an on-demand learning resource

100%

employees are provided opportunities
for regular performance and careerdevelopment reviews

64

average hours of annual
training per employee

11%

roles filled with internal
candidates

27%

new hires referred by
Illumina employees

Quarterly

career development andperformance review cycles

Quarterly
promotion cycles

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

62

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Investing in Our People

Supporting the Full Career Journey
We are investing in the growth and development ofour people at every stage of their career journey.
Opportunity is everywhere for our early in career, ourscientific and technical tracks, and our leadershippaths.

Internship Program

We provide several paid internship opportunities
around the world, enabling students to grow and makean impact by working on business-critical projects.
Working alongside our engineers, scientists, andcorporate employees, our internships span multiple
business functions and varying academic levels(Bachelor’s, Master’s, and PhD). We actively nurture
a diverse early in their career talent pipeline who canhelp advance the future of genomics. These are thefuture innovators, leaders, and game changers.

Leadership at Illumina
We care for each other in service of our Mission. Our
exceptional leaders inspire confidence, lead change,
and foster an environment where we can collectively
deliver results. They continuously inspire others to live
their passion and achieve their own career goals. We
provide a series of leadership programs for both newand experienced leaders:• Power Hours: A leadership development programfor frontline leaders, run by subject matter experts,
to develop the skills and knowledge required tolead teams effectively.
• Discussion and Lean In Circles: Our businessleaders host discussions on important topics suchas “Moving into Management” and “Managing Your
Career.” We also support Lean in Circles throughour Women at Illumina (WIN) ERG.

Intern Cohort

68%

Conversion
Rate (US)57%

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTAMR Women• Mentoring Programs: The Horizons ERG hosts
Jedi-Padawan buddy programs, connecting early
career professionals with seasoned employees,
and the Women in Illumina (WIN) ERG offers amentor program called iMentor.
• Culture of Coaching: Our Coaching Learning Pathhighlights a variety of options to help leaderslearn, practice, and build their coaching skills.
• Crucial Conversations: We facilitate workshopsthat teach communication skills for a variety
of situations in which opinions may differ
significantly, and emotions run high.
• Leaders in Action: Leaders helping leaders growtheir skills and expand their impact.
• Thrive New Leader Orientation: Targeted to newly
hired and promoted leaders at Illumina, this takes
our global new leaders and provides insight into
leading at Illumina and our leadership philosophy.
• Ignite: Leadership training series bringing
contemporary topics to provide ongoing andregular development.

63%

Minorities
(US)

46%

EMEA Women• Elevate for Executive Leaders: Over a several
week journey, Directors and Sr. Directors engage
with peers around the globe in a cutting-edge
social and interactive learning experience.
Leaders learn from other executives throughactivities and guided discussions, shareexpertise, and deepen insights with a dedicatedexecutive coach.

Distinguished Scientists,Engineers, and Medical
Scientists
We are proud to support our Distinguished
Scientists and Distinguished Engineers, whohave risen through our leadership track thatemphasizes the highest level of scientific andtechnical contributions. These leaders are
our internal experts in key areas of scienceand technology. They drive ground-breaking
innovations, make the big calls on researchand development directions, lead focusedteams pushing the envelope to create ournext products, represent us in the scientificcommunity, and mentor future talent.

6

promotions to the VP level ofDistinguished Scientist in 2021
63

Illumina

AccessCommunity

PeopleEnvironment

Integrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Investing in Our People

Recognizing Success
We have designed several award programs to recognize employees’ outstandingachievements, including:• Values Award: presented to individuals and teams nominated bytheir peers for exemplifying our values• Innovation Award: recognizes this core element of our culture andsuccess by annually celebrating our pioneering scientists for their
extraordinary contributions• Inventor Award: recognizes employee inventors who annually contributeto our patent applications

Illumina Inventors by the Numbers

In 2021, Illumina employees filed a record 171 new patent applications, a 69% increase over theprevious year.

328

total inventors

43%

first time inventors

UK inventors
are female

37%

Illumina female
inventors comparedto the national rateof women receiving
patents1

31%

29%

40%

130

female inventors

Singapore inventors
are female

2x

US inventors
are female

US inventors
are minority2

From Patents to Patients: Meet a Few of
the Women Making a Difference at Illumina
Sarah Munchel, Associate Principal Scientist, has filed 13 patent applications
and Suzanne Rohrback, Senior Scientist, has filed three. They were both partof a team of Illumina employees whose recent work contributed to a patentapplication for a circulating RNA signature they discovered in early-onset
preeclampsia. Learn more about how they fell in love with genomics, making
discoveries, and what’s ahead in the years to come.
1

USPTO: Women inventor rate is 12.8% as of 20192

US Minority: Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

64

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Caring for Our Employees
Our goal is for everyone to feel valued in the way that resonates
most with them. This means investing to create an inspiring work
environment, unmatched experiences, and meaningful benefits.
Building extraordinary teams starts with caring forour employees and putting their welfare at the heartof all we do by:• Offering a world-class portfolio of employee
benefits and wellness programs• Caring for our employees through life events

Through our partner, Progyny, we offer acomprehensive fertility benefit program to eligible
US-based employees that provides coverage for
fertility preservation, providing equitable accessto care for our diverse employees, including thosepursuing nontraditional paths to parenthood.

Fostering Wellness Inside and Out

Medical, dental, and vision
Flexible spending accounts
Health savings accounts
Employee Assistance program (EAP)Wellness rooms for nursing, meditation,and prayer
Business travel medical insurance
Gym access or membershipOnsite health screenings, blood pressure monitoring, andflu shots
Offices equipped with ergonomic workstations, abundantnatural light, and opportunities to work outdoorsCafeterias offering sustainable, healthy food options,
including vegetarian choices
Genetic counseling
Global well-being program
Mental health advocates and first aiders (EMEA)• Supporting their diverse personal needs

Workplace Genomics Program (US)• Extending all our benefits to employees, spouses,
domestic partners, and dependents

Through our partner, Genome Medical, we provide
access to genetic experts who can provide
consultations, guidance, and facilitate testing for
employees and their families. In addition, we offer
financial support for cancer tests, reproductive
health tests, and clinical whole genome sequencing(cWGS) for rare and undiagnosed diseases.

Health Solutions

Cancer Testing Benefit

Supporting Growing Families

Our employee benefits program recognizes thetremendous value our people bring to the business.
While benefits vary by country and region, we provide
all employees with an array of meaningful programs.

Reproductive Health Program
Employees, their spouses, and domestic partners
may be eligible for the company-sponsored
reproductive health program either throughinsurance or financial support:• In vitro fertilization• Pre-implantation Genetic Screening• Pre-implantation Genetic Diagnoses• Non-invasive prenatal testing2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Every day, our technology is being used to improve
human health—enabling advancements thatwere not possible just a few years ago. It seems
only fitting that our employees be able to accessthese new technologies to help better inform theirhealthcare decisions. GRAIL’s multi-cancer early
detection test Galleri® is available at no cost to
eligible US employees and their dependents as partof our Workplace Genomics Program.

Cancer support and expert advisory review throughAccess Hope (US)Expert guidance for diagnosis, treatment, or finding thebest physician through Included Health (US)Comprehensive musculoskeletal (MSK) care solution
through Hinge Health (US)Providing Time to Recharge

Flexible time off
20 days of paid time off (non-exempt US)
Two days of paid volunteer time off
Minimum 10 days of holiday paid time off

Investing for the Future

Employee stock purchase program
Retirement savings plans
Pensions (EMEA)Life and accident insurance
Disability insurance
Independent financial advice
Tuition assistance

Additional Perks and BenefitsSite amenities, including car washing, dry cleaning,mobile hair salons, food service, mindfulness, andself‑improvement courses
Employee referral program
Donation matching program
Special interest clubs
Commuter support
Broadband allowance (hybrid + remote employees)

Up to six weeks of paid parental leave
Comprehensive family support system through Cleo
Bring Your Child to Work Day
Back-up care with Bright Horizons forchild and elder care
Flexible work schedules and remote working
opportunities
Gender-neutral parental leave policies

65

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Caring for Our Employees

We Recognize the Importance ofPromoting Well-being

APJ Spotlight: Fitness Challenge for
Charity for Singapore Red Cross

To help our employees thrive, we provide activities
to help meet their physical, mental, and social
well‑being needs.

Our Steps for Charity initiative motivatedemployees to get moving while staying safe fromCOVID-19 and supporting their local community.
APJ employees registered for the challengethrough our well-being portal app, synced theirwearable fitness devices with the app, and thengot busy walking, running, and even sprinting. The
challenge attracted 131 participants who took over
15 million steps, earning a $15,000 donation fromthe Illumina Corporate Foundation to the Singapore
Red Cross Society.

We offer a free digital wellness platform to all
full‑time and part-time employees. This platform
enables them to track well-being related
activities, as well as participate in quarterly
fitness challenges, and build healthy habits.
Though the pandemic has altered many aspects ofworking, our culture of giving back and commitment
to employee well-being has remained strong. We
addressed both as part of our 2021 employee
fitness challenges.

US Spotlight: Virtual Wellness Fair

Global Spotlight: 2nd Annual Virtual 5K

As many of our employees continued to work from
home, our Wellness Day provided employees achance to explore and experience our well‑being
offerings virtually. We hosted sessions withphysicians, meditation gurus, well-being experts,
and even an employee panel.

Over 2,000 employees joined the annual charity
virtual 5K raising over $5,000 for the Ronald
McDonald House Charities.

Healthy Selfie
To promote self care for our employees and their loved ones we offer an annual $500 Health and Lifestyle
Allowance to all employees globally. To help build excitement around this annual event, we held a#HealthySelfie campaign to have employees share how they plan to use the allowance.

EMEA Spotlight: Wellness Wednesdays
and Mental Health Advocacy
Our EMEA team members continued to focus on
mental health in 2021 including holding workshops
and mental health drop-in sessions. Over 20
mental health advocates and 8 mental health firstaiders support the region.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

66

Illumina

AccessCommunity

PeopleEnvironment

Integrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Committed to Workplace
Health and Safety

2021 Safety Performance

1,452

We are committed to a safe and healthy work environment for all our
employees, contractors, and the communities in which we operate.

EHS Management System
We continue to work under an integrated management
system framework to measure performance andcontinually seek improvement. Our Singapore siteattained recertification to ISO 14001 and ISO 45001
and our other manufacturing locations continue towork toward conformance. Due to COVID-19 relateddelays, the goals for conformance by 2021 wereextended until the end of 2023.

EHS Programs
Creating an environment of collaboration among
all to identify safety risks, we have establisheda series of grassroots safety culture teams thatdrive continuous improvement projects. We apply
software tools to manage incidents and assess risks,enabling employees to easily report and measuresafety performance focusing on prevention.

214

324

>43,000.53

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Evaluate and manage the EHS
aspects and risks of our processes,
equipment, and services based onhierarchy of control

Environment, Health and Safety

14001 Certificate

Recordable Injury & Illness Rate calculated using total hours worked from employees + contingent workers. Incident per 100 employees. Lost Time
Incident rate calculated using total hours worked from employees + contingent workers. Rates have been calculated based on 200,000 hours worked.

Provide an environment for open
communication and collaborationfor employees at all levels

recordable injury and illness rate

Recordable
Injury &Illness Rate2

Program (IIPP)

2

Review and improve our EHS
processes while meeting or
exceeding compliance and otherobligations

hours of EHS-related training

EHS Policy

The UN Global Compact Principle 7 and The UN Global Compact Principle 15 state in order to protect the environment, the precautionary approach
shall be applied.

Respect and protect theenvironment by preventing
pollution, minimizing waste, andconserving resources

ergonomic evaluations completed   Learn More

1Prevent injury, illness, or ill healthby proactively managing risk
through minimizing health andsafety risks in the workplace

EHS risk assessments completed globally

EHS’s Global IIPP describes basic processes
our employees can take to maintain a safe andcompliant workplace. Our Emergency Action
teams work together to create awareness andlead regular preparedness drills and activities.
The precautionary approach1 is embedded in ourrisk assessments, our environmental aspects/
impacts, our EHS Policy, Product Stewardship,
and the engagement of our people.

Injury & Illness Prevention

We embrace our Mission through theestablishment, implementation, andmaintenance of an integrated EHS
management system. This commits us to:prevention reports

Prevention andPreparedness

45001 Certificate

Environment, Health and Safety(EHS) Policy

Lost Time
Illness Rate

.52

2019
.34

2020
2021

.53
.74

2019
2020
2021

.18
.23

Measure and enhance EHS
performance and provide aframework for setting objectives toachieve continual improvement
Require all employees to beaccountable for their commitment
to our EHS policy

67

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Committed to Workplace Health and Safety

Ergonomics
We provide a number of prevention-based
ergonomic resources:• Implementation of EHS Global Standards forergonomics• Maintain effective management of inherently
high-risk operations• Ergonomic and material handling training• In-person and virtual ergonomic evaluations• Proactive processes and ergonomic assessmentsof equipment• EHS Guidance for working from home

Singapore Spotlight:

National “Safety Starts with Me” Competition
Every year, the Safety Starts with Me Competition is organized to provide a platform for members of
the public to showcase their creativity in promoting workplace safety and health (WSH) through art,
design, photography, film, and writing. We are thrilled to announce that two of our employees, Lee
Hong Kwan and Ahmad Mustaqim bin Md Abdul Bakki each won an award for their entry this year!
As winners in this national competition, their works will be featured on the WSH Council website,
exhibitions, and their social media channels.

• Workplace Safety and Health Performance Awards–Silver• Workplace Safety and Health Innovation Awards–Gold for Vega lifter• Workplace Safety and Health Innovation Awards–Silver for SAFE platform• BizSAFE Star Certification• National Safety Starts with Me Competition

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

China Spotlight:

Safety and Wellness
Week in China
At Illumina, everyone is a Safety Leader.
The safety and health of our employees arealways the top priority of our work. During
the China National Safe Production Month inJune, the Greater China EHS and Facilities
teams jointly planned and successfullyorganized the first Illumina (China) Safety
Week series. This series included a richand diverse teaching practice, knowledge
competition, professional safety, and firstaid training.

68Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Our People | Diversity, Equity, and Inclusion | Investing in Our People | Caring for Our Employees | Workplace Health and Safety

Together we’readvancinggenomics for all.

Join us, and you can make a difference!

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

69

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

OperatingResponsibly70Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Operating Responsibly:

Our Strategic Approach
We are committed to conducting ourselves with honesty, integrity,
and respect for all.
Overview

Our Objectives

Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring thatthe technology we create and the data we collect are used safely, ethically, and responsibly.

The tenets of strong governance are foundational to doing business responsibly. We put
this into action through our Code of Conduct and compliance programs.

That responsibility starts within our own business and is the foundation for magnifying our positive impact
on humanity. For us, doing the right thing is more than just compliance. It is having a deep sense of integrity
and honoring the trust placed in us by employees, patients, customers, shareholders, and communities. We
recognize that the longevity of our success is linked to creating sustainable value for our shareholders andsociety. As our business and genomics continues to evolve, we strive to set the highest standard for ethicaluse of our technology, as well as the security and privacy of data.

• Maintain a corporate governance framework to promote ethics and integrity in all we do• Ensure all Illumina political activities promote ethical and transparent engagement,
advance the company purpose, and comply with applicable laws and reporting
requirements• Continue working to ensure human rights are respected in our workplace,our supply chain, and the marketplace• Achieve a mix of Board members that represents a diversity of backgrounds andexperience, including age, gender, ethnicity, race, and specialized experience• Demonstrate responsible data stewardship with strong privacy andcybersecurity practices

At Illumina, as we unlock the power of the genome, we act withintegrity in all that we do—interacting with customers and suppliers;
bravely advocating on behalf of patients and our unwaveringcommitment to health equality.”

Contributing to UN SDGs

Gwen Chapman, Chief Compliance Officer

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT71

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Operating Responsibly:

Measuring Our Impact
2030 Targets
100% strategic suppliers committed to reducing
their environmental footprint
2021 PROGRESS

2021 Highlights

33%

Board members women

84%

33%

Expand green travel policy governance to support
reduction of emissions associated with businesstravel$209M

2021 PROGRESS

Initiated

Achieve 20% spend with diverse suppliers (US)2021 PROGRESS

17%

Position Illumina as the most trusted company ingenomic privacy and ethics
2021 PROGRESS

Ongoing

2021 Recognition

Board members represent racial/ethnic diversity

diverse supplier spend

100%

Illumina facilities participated in third-party
audit programs

97%

Tier 1 suppliers participated in third-party
audit programs
Initiated
Human Rights Assessment
and updated human rights policy
Published first annual
Privacy Transparency Report
Developed and disclosed
Ethical Artificial Intelligence Principles

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

72

Illumina

AccessCommunity

Environment

Integrity

PeopleAppendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Guiding Genomics into the Future
By creating a culture of compliance, strong corporate governance,and ethical leadership, we aim to inspire confidence in the work
we do and in our company’s future.

Board of Directors
Our culture of compliance and ethics starts at theBoard level and is incorporated into every levelof our business. We put that strong governancefoundation in action through our Code of Conductand compliance programs. We anchor to that
Code in how we run the company, and require
annual certification. Our Board of Directors is adiverse group of leaders who champion scientificinnovation. The Board’s aim is to ensure thecompany is equipped with the tools it needs toaccelerate the power of genomics. The Board
has adopted Corporate Governance Guidelines
which are founded on a commitment to building
shareholder value, with an emphasis on responsible
governance. These guidelines, together with theCode of Conduct and Board Committee Charters,
provide the framework for corporate governanceat Illumina.

Diverse and Independent Board

As stipulated in our Corporate Governance
Guidelines, our company seeks to achieve a mixof Board members that represents a diversity ofbackground and experience, including with respect
to age, gender, international background, race, andspecialized experience. Our Corporate Governance10%> >10+
10%
10+
years
10%
> years
10+
years
Guidelines also require that independent
directors
20%
6-10
years
20%
6-10
years
20%
6-10
years
constitute at least a majority of the Board.
In orderto70%
1-1-5 5years
70%
years
70%
15
years
be independent directors of the Company, directors
must meet the criteria for director independence
established by the Nasdaq Stock Market.
Our Board has established four committees.
Learn more in each committee charter:• Audit Committee

Board of Directors

10% > 10+ years
20% 6-10 years
70% 1- 5 years
John W.
ThompsonFrancisdeSouza

Frances
Arnold, PhD

Caroline
Dorsa

Gary S.
Guthart, PhD

PhilipSchillerSue
SiegelRobert S.
Epstein, MD(Chair)Scott
Gottlieb, MD

Board Profile
Independent Directors

Female Directors

Ethnic/Racial Minority Representation

Tenure5
4• Compensation Committee• Nominating/Corporate Governance Committee• Science and Technology Committee

89%

33%

33%
1-5
years

6-10
years

More details about the Board can be found in our Proxy and on our corporate website
73

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT
555Illumina

AccessCommunity

Environment

Integrity

PeopleAppendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Ethics and Compliance
We are committed to reflecting the very best of our people,
practices, and purpose. We take pride in conducting our businesswith honesty, transparency, and in accordance with legal standards
and ethical principles.

Compliance Model

A Culture of Compliance

Compliance Committee

Our policies guide employees on how to apply
a culture of compliance to their daily work. The
Illumina Code of Conduct promotes honest andethical conduct, compliance with applicablelaws and regulations, and protection of ourbusiness interests. The Code applies to all Illumina
employees, consultants, temporary workers,
officers, and members of the Board of Directors,
regardless of location, seniority level, business
unit, function, or region. Key topics of our Codeof Conduct include fraud prevention, bribery andcorruption, anti-discrimination, anti-harassment,
human rights, diversity and inclusion, employee
safety, corporate social responsibility, marketingand sales claims, and government interaction.
We uphold the rigor and fulfillment of our Codeof Conduct with written programs, training,
investigations, root cause analysis, risk assessment,
and monitoring. We provide annual training on our
Code of Conduct and Anti-Bribery and Anti-Corruption
Policies for all employees globally and more focusedtraining on other Illumina compliance-related policies.
2022 CORPORATE SOCIAL RESPONSIBILITY REPORTAll employees receive training when onboarded andannually through our enterprise learning management
system. Employees must acknowledge in writingthat they have read, understood, and will abide by
our Code of Conduct.
At Illumina, we are at the forefront of theevolution of genomics from pure research toin vitro diagnostic (IVD) medical devices. With
this evolution we operate in the ever-changing,highly regulated IVD market and often interact
with healthcare professionals and government
officials, representatives, and agencies that regulate
the markets in which we do business. Illumina iscommitted to high standards of ethical businessconduct, including compliance with all applicableanti-bribery/corruption and anti-kickback laws, aswell as relevant medical device industry codes.
Based on this commitment, Illumina has adopted a
Code of Conduct and implements a robust anticorruption Compliance Program aimed at ensuringthat every employee has the knowledge andawareness to operate appropriately in this market.

Board of Directors
CEOInternal Audit

Committee Members
Chief
Compliance
Officer

GeneralCounselChief
Operations
Officer

Chief
Medical
Officer

Chief
Commercial
Officer

Chief
Financial
Officer

ChiefMarketing
Officer

Chief
PeopleOfficerCompliance Director, Secretary to Committee

Code of Conduct

8

languages
Employees
certified to thecode annuallyCompliance Committee
Illumina has established a Compliance Committee to direct and oversee ourcompliance activities, including administration of the Code of Conduct andCompliance Program. The Committee is composed of senior executives
and chaired by the Chief Compliance Officer. It is the responsibility of theCompliance Committee to foster a culture of ethics and compliance andpromote global awareness of the company’s compliance program efforts.
The committee has also adopted a program framework based upon the sevenfundamental elements of an effective compliance program established by the
US Office of Inspector General.

74Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Ethics and Compliance

Ethics and Compliance Reporting

Ethics Advisory Board

We are committed to fostering a culture in which
employees feel comfortable raising complianceand ethics concerns without fear of retaliation. We
promote an open-door policy that encourages our
employees to raise concerns to their managers, HR,
and the Compliance Department directly and haveestablished a third-party Compliance and Fraud
Prevention Hotline that Illumina employees and third
parties may use to report concerns anonymously.

We seek guidance from our Ethics Advisory
Board on a range of strategic issues, including
recommendations on emerging ethics matters,
policies, and regulations that are relevant to the
genomics industry. We meet with the Ethics
Advisory Board on a quarterly basis. Work includes
providing strategic advice to Illumina about:

To facilitate the reporting of good faith concerns,
we have a third-party operated hotline and websitethat Illumina employees and others may use
to report concerns. Our nonretaliation policies,
confidentiality policies, and mechanisms ensure

anonymity and protect employees. Callers may
choose to self-identify or remain anonymous,
where permitted by law, when reporting.
We track and respond to all compliance concerns
raised, acting promptly to identify offenses andtake corrective action when necessary whileobserving a strict non-retaliation policy. Whenan actual or potential instance of noncomplianceor ethics violation is identified, our ComplianceDepartment investigates. They swiftly address
instances of noncompliance and engage relevant
stakeholders to develop risk mitigation andmonitoring plans, as appropriate.

• Emerging policies and regulations relevant to the
genomics industry and the company’s interests• Ethical issues arising from specific technology
or products   Learn More
Code of Conduct
Compliance Program Framework
Anti-Corruption/Anti-Bribery
Anti-Competitive Behavior
Interactions with Healthcare Professionals
Compliance Information
Ethics Information
Ethics Advisory Board Charter
Ethics Advisory Board Members

The Compliance and Fraud Prevention

Ethics Advisory Board

reporting resources are available to both
employees and third-party partners, 24/7
at (800-461-9330), or electronically atCompliance and Fraud Prevention Reporting.

1:1
Clement
LeslieAdebamowo, Biesecker, MD
BM, ChB, ScD,FWACS, FACS

Glenn
Cohen, JD

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Freda
Nita Farahany,
Lewis‑Hall, MD,
JD, PhD
DFAPA, MFPM

CharmaineRoyal, MS,
PhD

Ratio of women to men on
Ethics Advisory Board

75

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Ethics and Compliance

Affordability and Pricing
Transparency
Illumina is committed to offering prices that enablebroad access to genomic technology. We maintain a
responsible approach to pricing our products. We
negotiate and partner with healthcare systems,
payers, and research institutions to provide availabilityof our products at a fair net price. As in past years,
we limited our annual aggregate list price increase
while continuing to offer new technologies thatlower our customers’ costs per genome and provide
increasing access.
In 2021, in response to the COVID-19 pandemic,
Illumina offered direct, simple, transparent pricing
to non-governmental organizations (NGOs) andnon-profit public health organizations in low andmiddle income countries for pathogen surveillanceand early detection.
In the interest of ensuring continued access tosequencing technology and a level playing fieldin the clinical oncology NGS market, Illumina madean open offer to its oncology customers thatguarantees supply of sequencing instruments andconsumables on the same terms as GRAIL (Illumina’s
recently acquired cancer screening company).
Prices are available to customers through theiraccount managers or online on myIllumina.com.
Customers can and are encouraged to place orders
electronically. Prices are also visible to customers on
their invoices and billing statements. Most Illumina
2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

customers are not on a supply/purchasing agreement.
When such an agreement is in place, Illumina uses
general confidentiality clauses in most cases. Examplesof factors that may affect price include region andvolume. Illumina sets and adjusts list prices basedon several factors, including but not limited to costs,
inflation, and market dynamics. In 2021, the Illumina
annual price change was below the U.S. Consumer
Price Index (CPI).
Illumina pricing reflects its value proposition andenables Illumina to continue to innovate for ourcustomers and accelerate access to genomics for all.

Risk Management
Illumina has adopted a company-wide approach,through various mechanisms, to assess and manage
risks. We endeavor to ensure that all employees
adhere to our ethics and compliance protocols.

Additionally, the Internal Audit Department
independently and objectively assesses risk andreports insights to the Audit Committee of the Boardof Directors on a quarterly cadence.

Our risk assessments consider various
quantitative and qualitative inputs, including:Business
and Finance

Product Quality

Operational

Employee

Legal and
Regulatory

Environmental,
Health and Safety

Brand and
Reputation

Climate (physicaland transition)

Climate Resilience
At Illumina, we believe addressing climate change
is one of the key topics to achieving a sustainable,
just, and resilient future for all. We are committed toclimate action and the integration of climate resilienceplanning into our risk management program.
See the Appendix for additional details on our
Task Force on Climate-related Financial Disclosures(TCFD) index and climate scenario insights and theEnvironment section for additional information.

Our Enterprise Risk Management (ERM) frameworkhas been established to anticipate, assess, monitor,
manage and report on risks that could impede ourbusiness, and to identify emerging issues andopportunities.
We have implemented a corporate, global, BusinessContinuity Planning (BCP) program to reduce risk
exposure and mitigate negative events to business
operations. The ISO 22301:2019 standard is used asa business continuity framework for this program.

76

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Upholding Human Rights
for All Stakeholders
We are committed to respecting human rights and treating every
stakeholder with dignity and respect.
Integrity and fairness are central to our values, how we operate in the workplace, and the marketplace. We
acknowledge and respect the fundamental principles contained in both the Universal Declaration of Human
Rights and the United Nations Global Compact. We are committed to integrating these principles into ourstrategy, our culture, and our operations.

Key Pledges of Our Human Rights Policy
Ethical business conduct

Protection of privacy

Supplier Code of Conduct

Safe workplace

Right to exercise freedom of association
Fair wages and working hours

Elimination of child and forced labor
Equal opportunity

Human Rights Impact
Assessment

Ethical Use of Genomic
Technologies

In 2021, we initiated a human rights impact
assessment in alignment with the UN Guiding
Principles as a framework for review. The
assessment will continue in 2022 as we evaluate
internal policies, external disclosures, and work to
map actual and potential human rights impacts.

Illumina is steadfast in our commitment that genomic
technologies should be used to benefit humanity, andwe will only work with partners who further thismission. Our Human Rights Policy and customer
agreements outline our expectations regarding ethicalbusiness conduct, the use of our technology, and thesteps we can take in the event of a possible violation.
We have expanded and enhanced our oversight andaccountability processes to monitor and enforce
these commitments and prevent sales that could
result in misuse or human rights concerns before
they happen. Illumina is committed to investigating
potential reports of product misuse and will not
hesitate to cease sales to business partners in theevent of a confirmed ethics or human rights concern.

Ethical Artificial
Intelligence Principles
Illumina is dedicated to improving human healthby unlocking the power of the genome. That
mission drives everything that we do, including
the technology that we develop. Illumina createsand uses artificial intelligence (AI) systems topower industry-leading sequencing quality, fueldata insights, improve understanding of genomic
variation in relation to health and disease and toadvance genomic science. We define AI systems
to include machine learning, deep learning andpredictive modeling. Illumina is committed todeveloping and using artificial intelligence (AI)according to applicable laws and the following
guiding principles:• Transparency• Diversity, non discrimination, and fairness• Values-driven design• Accountability

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT   Learn More
Human Rights Policy
Human Rights Policy—Japanese
Conflict-Free Minerals Policy
California Transparency in Supply Chain
and Modern Slavery
Responsible Stem Cell Use Position
Statement
Animal Testing Position Statement
Ethical Artificial Intelligence Principles

77Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Protecting the Privacyof Those We Serve
As we expand access to genomics around the world, we must also
respect and properly secure the resulting data.
We are committed to developing, upholding, andpromoting the highest standards for genomic data
privacy. Our Privacy Policy defines the way we use,maintain, protect, disclose, and transfer personal
information. Genomics data is powering positive
progress around the world.

   Learn More
Privacy Policy
Privacy Principles
Privacy Transparency Report

Our Privacy Principles
Our Privacy Policy defines how we may use,maintain, protect, disclose, or transfer certain
types of personal information in the provision of our
products and services. How we handle personal
information is aligned to our four fundamental
privacy guiding principles:• Transparency• Ethical Use• Responsible Stewardship• Accountability

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

78

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Protecting the Privacy of Those We Serve

The Five Pillars of Our Cybersecurity Commitment

Cybersecurity Framework
Our technologies and services inherently involve
handling large amounts of genomic and healthdata that must be protected, making cybersecurity
integral to achieving our company’s mission.
All Illumina instruments are equipped with an
instrument control computer, and users are offeredprotection guidance.

Key References• NIST Cybersecurity Framework• ISO 27001• ISO 13485• General Data Protection Regulation(GDPR)• California Consumer Privacy Act (CCPA)

Program GovernancePartnerships• Led by Chief Information
Security Officer (CISO)• Healthcare Information
Sharing and Analysis
Center (H-ISAC)• CISO reports at least
quarterly to the Board of
Directors’ Audit Committee• Annual assessment against
National Institute ofStandards and Technology(NIST) Cybersecurity
Framework• Employees and contractors
trained annually• Third-party workrequires cybersecurity
risk assessment prior to
engagement• Domestic Security AllianceCouncil (DSAC)• Information 2 Systems
Security Association
International (ISSA)• Society for Information
Management San Diego (SIM)• Chief Information Security
Officer Roundtable• InfraGard

Secure Product
Design and Placement

Risk Analysis andSecurity Testing• Products and systems
secured and maintained
throughout life cycle• Continuously assesscybersecurity risk

• Risk mitigation at earliest
stages of product design
and placement• Security design
requirements• Cloud-based productsaligned with ISO 27001• Privacy by design• Strong encryption
standards• Strict data access controls• Perform internal and external
security testing for all cloud
software products• Regularly put cloud software
products through static
analysis• Incident response plan andteam in place to handle
cyber-related disruption,with business continuity andcontingency plans• Internal vulnerability analysis
conducted• Internal tests deployed torepresent simulated hacker
attacks• Health Insurance Portability andAccountability Act (HIPAA)• Clinical Laboratory Improvement
Amendments (CLIA)

Data Protection• Data protected in compliancewith applicable laws andcybersecurity best practices• Data privacy and data protectionalign with standards set by GDPR,
CCPA, HIPAA, other regulations,and our Privacy Policy• CLIA laboratories ensure data
quality and security with CLIA
and regular HIPAA frameworkassessments• Backup capabilities encrypt andstore data in immutable formats
for data confidentiality andintegrity• Amazon Web Services (AWS)
hosts the Illumina BaseSpace
Suite, with additional security
features   Learn More
Cybersecurity Illumina Security
Resources and Best Practices

2,2502022 CORPORATE SOCIAL RESPONSIBILITY REPORT

employees participated in
our Cybersecurity AwarenessMonth activities

Cybersecurity Awareness Week
Each October, we recognize Cybersecurity Awareness Month (CSAM), which provides heightenedawareness regarding cybersecurity events, threats, attacks, and best practices that all employees
can follow to help keep Illumina and its data safe from cyberthreats.

79

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Public Policy
Proactive, responsible engagement with public policy stakeholders
enables sharing accurate and reliable information about genomics andadvocating for policies that ensure and promote broad access.
Illumina participates in the political andpublic policy process with governments andorganizations around the world to engage andeducate policymakers and key stakeholders on
issues that impact our Mission and business.
Our interactions with policymakers must align withour core values, ethical responsibilities, and legal
obligations. The Illumina Nominating/Corporate
Governance Committee of our Board of Directors
oversees our political policies and contribution
practices. The Committee maintains responsibility
for ensuring all Illumina political activities
promote ethical and transparent engagement,
advance the company’s mission, and comply
with applicable laws and reporting requirements.
On an annual basis, we provide an update on

our public policy priorities, political contributions,lobbying expenditures, and information aboutsignificant memberships. Our Global Government
Affairs team is responsible for advocacy activities.
Illumina does not have a Political Action Committee
but does retain outside strategic advisors who
support our global engagement with policymakers
and key stakeholders. These advisors may
also provide expertise on policy and specificregional issues.
Illumina complies with all applicable laws andrequirements in connection with our global
political and public policy activities. These laws
generally require reporting on lobbying activities
and compliance with applicable gift laws.

Reports filed on behalf of Illumina are publicly
available in the following government-hosted
databases:
Office of the Clerk, US House of Representatives
Secretary of the Senate, US Senate
Lobbying Disclosure, California Secretary of State
Transparency Register, European Commission
Texas Ethics Commission
Advocating for public policies that ensure andenable broad access to genomic technologies isa priority. In 2021, we focused engagement withpublic policy stakeholders around:• Advancement of precision medicine• Adoption and reimbursement for genetic testing• Adoption and reimbursement for NIPT
• Adoption and funding for genomic infectious
disease surveillance“We are dedicated and committed to expanding access to the powerof genomics to patients across the globe through constructive andtransparent engagement with governments.”
Brian Toohey, Global Head of Government Affairs

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT• Promoting STEM opportunities

Trade Associations
and Memberships
Illumina participates in various trade associations
for collaboration and the exchange of ideas. We
pay annual dues to a number of trade and industry
associations, some of which use a portion ofmembership dues for nondeductible state and federal
lobbying and political expenditures. We disclose
memberships in trade associations for which we
contributed over $5,000 in the immediately preceding
year, as well as the total amount of such dues.
For trade association payments in excess of$50,000, we also disclose the portion of paymentsthat are nondeductible under Section 162(e)(1)(B)of the Internal Revenue Code, such as payments toorganizations designated as 501(c)(4) and 501(c)(6).

   Learn More
Political Contribution Policy
Political Contributions Spend Report,
Trade Association and Significant
Membership Report80Illumina

AccessCommunity

Environment

Integrity

PeopleAppendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Responsible Supply Chain
Our suppliers are critical to our Mission. Together, we magnify the
positive impact to the scientists and clinicians we serve and thecommunities where we operate.

Supply Chain Overview• Uphold their employees’ human rights and theIllumina Human Rights Policy

llumina’s global supply chain consists of suppliers,sub-contractors, channel partners, manufacturing
sites, distribution centers, and customers. We
consider it business critical to work with suppliers
who share our commitment to integrity, andwho support an ethical and compliant culture.
We view our suppliers as partners in our effort
to work toward a more equitable and sustainable
future for all.

• Ensure a safe and healthy workplace

We hold our suppliers to the same standards ofbusiness conduct that we set for ourselves. We
require them to comply with the standards of
behavior outlined in our Supplier Code of Conduct
and exhibit social responsibility and environmental
stewardship. The Supplier Code of Conduct isconsistent with commitments we made both asa signatory of the United Nations Global Compact
and as a member of the Dow Jones Sustainability
World Index.
We expect our suppliers to:• Comply with local regulations and applicable
US and international regulations
2022 CORPORATE SOCIAL RESPONSIBILITY REPORTOur Supply Chain

3,798

>$1B

suppliers across theestimated payments

supply chain

to suppliers

517• Demonstrate social and environmental responsibility

active diverse suppliers• Conduct business in an ethical manner$585M

direct supplier spend$209M

diverse supplier spend

Social impact and environmental screening are
included in our Request for Information (RFI) tools
when evaluating potential suppliers.
All new suppliers are required to acknowledge
the Supplier Code of Conduct to complete theonboarding process.
Our suppliers range from off-the-shelf packaging
material to highly sophisticated reagents. We define
our supplier base by categories, segments, andclassification. The categories include direct andindirect with subcategories within each. Suppliers
are then segmented. A sample segment definition
includes Strategic Suppliers. Classifications ofsuppliers depend on the product or service they
provide such as finished medical devices, spec, off
the shelf, and services. We source components,
software, equipment, and services from 48 countries
across the Americas, Asia, Europe, and Africa.

2030 Target

100%

strategic suppliers to commit toreduce their environmental footprint

2021 PROGRESS

84%

   Learn More
Supplier Code of Conduct

81

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Responsible Supply Chain

Supplier Diversity
Our supplier diversity efforts aim to cultivate a supplier base that reflects the diversity of
our communities, customers, employees, and the local economies where we operate.
We recognize that a diverse supplier base provides a competitive business advantage by
harnessing suppliers’ unique experiences and creative solutions. Our program, overseen
by a Supplier Diversity Governance Committee, promotes partnership opportunities for
suppliers in the US that are at least 51% owned, managed, and controlled by a qualifying
diverse group.
These include, but are not limited to:• Woman-owned• LGBTQ-owned• Minority-owned• Veteran-owned• Socially and economicallydisadvantaged-owned businesses• Disabled person-owned• Certified small businessSupplier Diversity Highlights
2030 Target

20%

spend with diverse
suppliers (US)2021 PROGRESS

20%

of total diverse supplier spend attributed towoman-owned business30%

of total diverse supplier spend attributed tominority-owned business

17%

Globally, we encourage the use of local businesses wherever possible to support theeconomies where our employees work and live. Our program is expanding to include
woman-owned businesses in APAC and small businesses in Great Britain.
In 2021, we rolled out a mandatory internal training certification on supplier diversity
for our procurement sourcing managers through our learning management system(LMS). The core intent of this training is to ensure the Illumina Sourcing & Procurement
team leverages our robust Diverse Supplier Network to purchase goods and services.
To further support our diverse suppliers, the Employee Resource Group, SHADES
partnered with the Supplier Diversity team to verify address and contact information
for close to 500 diverse suppliers in our network, while raising internal awareness about
the benefits of utilizing diverse suppliers. Read more about their efforts and contributionsin People. In 2021, we included diversity screening in our Request for Information andRequest for Proposal process. In 2022, we plan to start gathering Tier 2 diversity
spend from select suppliers in an effort to magnify potential impact and reach.

   Learn More
Supplier Code of Conduct

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTSupplier Diversity Program82

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Responsible Supply Chain

Modern Slavery
Illumina is committed to conducting its businesslawfully and with integrity. We work to continuallystrengthen our practices to ensure no humantrafficking, slavery, or forced or compulsory labor
occurs in any part of our supply chains and global
operations. We also seek to ensure that our global
business partners do not use modern slavery in
any of its forms in providing goods or services.
Additional information is available in our California
Transparency in Supply Chains Act & UK Modern
Slavery Act disclosure statements.

Conflict-Free Minerals
Illumina supports international efforts to ensure
no conflict minerals directly or indirectly benefit
armed groups in the Democratic Republic ofCongo or adjoining countries. To this end, Illumina
expects all suppliers to commit to the Responsible
Business Alliance (RBA) Code of Conduct. Throughour Conflict-Free Minerals Policy we expect all our
suppliers to establish their own due diligenceprogram to ensure supply chains are free of conflictminerals and make those due diligence measuresavailable to us upon request. Illumina routinely
evaluates its suppliers to ensure they are adhering
to our expectations and values.

   Learn More
Channel Partner Code of Conduct
California Transparency in Supply Chains Act &UK Modern Slavery Act Disclosure Statement
Conflict-Free Minerals Policy

Verification and
Due Process
We only build relationships with business partners
that share our commitment to fulfilling all legal
and ethical obligations. We never knowingly
conduct business with business partners that
employ underage individuals, employ forcedlabor, or use corporal punishment to discipline
employees, regardless of whether such practices
are permitted by law.
We perform due diligence on new business
partners to verify that they meet our standards.
This process involves conducting initial risk
assessments when onboarding new suppliers andconducting periodic assessments of performance.
In addition, for supply chain areas of higher risk,
we take steps to enhance our risk mitigation
strategies. Prior to engaging in business with any
supplier, we utilize tools that provide up-to-datesanction lists from governments around the worldthat identify companies and individuals involvedin criminal activities such as money laundering,financing paramilitary groups, etc. In addition, we
utilize tools to continuously monitor our supplierbase on potential risk elements such as financial
stability, leadership changes, global news,
and other.
We encourage all employees and business
partners to report potential violations or concerns
through a variety of formal channels, including
our Legal team and/or our Compliance and Fraud
Prevention Reporting website or hotline.

Channel Partners
Our products are available around the globe througha robust channel partner network. Our partners not
only offer critical access to our products throughout
the world but also provide the same level of sales,
marketing, service, and support that we offer tocustomers directly. The Illumina Channel Partner
Code of Conduct requires that channel partners
match the Illumina commitment to business integrity,
ethical conduct in the marketplace, adherence toall applicable laws, and the fundamental elements ofhuman rights. Illumina is a member ofthe Advanced Medical Technology Association(AdvaMed) and MedTech Europe. Channel Partners
are required to adhere to the applicable provisionsof the AdvaMed Code of Ethics and MedTech Europe
Code of Ethical Business Practice.

Supplier Sustainability
In 2021 we assessed 100% of our supply chain
for environmental impact as part of our Scope 3
data collection.
In 2022, as part of our supplier engagement weplan to share our Net Zero goals with our entire
supplier base and invite them to join us in ourrace to zero. We will require acknowledgmentof all our strategic suppliers.
Through our supplier scorecard program, we haveidentified 84% of our strategic suppliers havecommitted to reduce their environmental footprint
with our goal to achieve 100% by 2030.
83Illumina

AccessCommunity

Environment

Integrity

PeopleAppendix

Strategic Approach and Impact | Corporate Governance | Ethics and Compliance | Human Rights | Data Security and Privacy | Public Policy | Responsible Supply Chain

Responsible Supply Chain

Quality Management Systems
The following locations are certified to the ISO
13485 Standard, which specifically covers thequality of medical devices:• Foster City, CA• Netherlands• San Diego, CA• Singapore• Hayward, CA• Cambridge, UK• Madison, WI

To ensure the quality of our products, we haveto ensure the quality of the components that wesource. That is the rationale behind the Illumina
Supplier Quality Vision, which is to construct andfoster a leading supplier base that ensures safe andquality products every time.

A quality management system is a critical aspect at every stage of the product life cycle to ensurethat policies and objectives are in place and product quality standards are of the highest caliber.

• Initial risk assessments• Audits• Qualification• Monitoring

Working with our suppliers, we focus on thecustomer experience, continual improvement,
effectiveness of our quality management system,
and compliance. In 2021, 100% of Illumina-owned
or -operated facilities participated in third-party
audit programs. Additionally, 97% of Tier 1
suppliers participate in some form of third-party
audit program, based on our supplier qualification
requirements. All products have traceability andinventory is tracked via our inventory management
system, SAP. Products may contain bar code, lot
numbers, and/or unique identifiers.

• Supplier selection• Supplier evaluationt i onlec onSe uatilSupplier Monitoring• Non-conformance
management• Supplier Corrective
Action Request (SCAR)Qu Supali
fi

Supplier
Quality
Management
Life Cycleplt o i er
ri n
g

p
m
C o ali f
Qu• Change notificationagreement• Quality agreement• Qualification audit

Component Qualification• First article inspection• Measurement systemanalysis• Process capability• Performance management• Process Failure Modeand Effects Analysis(PFMEA)• Business reviews• Scorecard• Control plan
• Sub-tier supplier control

Quality Control in Product Life Cycle
Quality teams play a role throughout the product life cycle.

   Learn More
Supplier Quality Manual
Quality Policy Statement

2022 CORPORATE SOCIAL RESPONSIBILITY REPORTSupplier Qualificationo
ic n e n
at
io n tThe supplier quality management life cycle
incorporates the following phases:

Supplier Selection
and Evaluation

p
Su ni
Mo

During 2021, we issued zero medical device
product recalls that were reported to the FDA.
There was one medical device voluntary recall
that was not required to be reported to the FDA.
There were four voluntary medical device recalls/
field action that were reported to non-US national
regulatory authorities and removed from the market
or corrected.

Supplier Quality Management Cycleier npl atioc

Quality Policy: Illumina is dedicated to being
the leading provider of integrated solutions that
advance the understanding of genetics andhealth. We achieve this through our focus on thecustomer experience, our commitment to continual
improvement, maintaining the effectiveness of ourquality management system, and complying withregulatory requirements.

Supplier Quality Vision and ValuesSuppand lierEvaProduct Quality

Concept

Feasibility
and Planning

Development

Pilot

Transfer

Sustaining84

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Appendix85

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Reporting Overview
About This Report

Signatories

Assurance

Our report has been designed to provide acomprehensive and integrated view of ourcommitments, progress, and activities related
to our corporate social responsibility programand most material environmental, social, andgovernance themes.

• UN Global Compact• We Mean Business Coalition 1.5º
• UN Race to Zero
• CEO Action for Diversity & Inclusion• UN Women Empowerment Principles

Limited assurance has been provided in accordancewith ISAE 3000 and ISAE 3410 on the following topics• Scope 1, 2, and 3 GHG emissions data
• Energy data
• Water data
• Human capital data

Our voluntary reporting is informed by thefollowing frameworks:• In accordance with the GRI Standards:
Comprehensive• Sustainability Accounting Standards Board (SASB)• Task Force on Climate-related Financial
Disclosures (TCFD)• UN Sustainable Development Goals• UN Global Compact• UN Universal Declaration of Human Rights• Dow Jones Sustainability Index• CDP• Bloomberg Gender Equality Index• HRC Corporate Equality Index
We also recognize ISO 26000 as a reference
document that provides guidance for integration ofsocial responsibility.

ESG Appendix Contents
86

Reporting Overview

87K ey Performance Indicators

87

About Illumina

87

Expanding Access to Genomics

87

Empowering Our Communities

88

Integrating Environmental Sustainability

Re-statements

91

Nurturing Our People

98

Operating Responsibly

January 1, 2021, to December 31, 2021, unlessotherwise indicated.

We conduct ongoing data review to ensure accuracy
and consistency. Any material data changes quoted
in the current CSR report that reflect a revision fromprevious reports have been adjusted and are calledout with the symbol ‘†’.

Baseline Year

Contact

106 TCFD Index

2019, unless otherwise indicated.

We welcome your feedback at csr@illumina.com

107 UNGC Communication on ProgressMateriality

Learn More

Based on the materiality assessment refreshcompleted in 2021.

www.illumina.com/csr
ESG reporting hub

Entities Excluded in This Report
In 2021, Illumina acquired GRAIL. Pending the outcomeof the European Commission’s review of the acquisition,
GRAIL is required to be held and operated separately.
Data contained in this report does not reflect any GRAIL
operations, financial results, or ESG data.

Reporting Period

Currency References
US Dollars

100 Indices100 GRI Index
105 SASB Index

108 SDG Index and Goals
109 Assurance Statements
111

Disclosures

CSR and ESG Industry Peer Groups• Business for Social Responsibility (BSR)• Association of Corporate CitizenshipProfessionals (ACCP)• Chief Executives for Corporate Purpose (CECP)• CSR Board• World 50• Sustainable Packaging Coalition• My Green Labs
86

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicator Summary
About Illumina

Empowering Our Communities

General2021

Total Giving

2019

2020

2021

Name of organization

Illumina, Inc.

$13,829,496$14,966,331

San Diego, California, US

Illumina, Inc. + Illumina Corporate Foundation +employee giving$1,185,088

Location of headquarters
Number of global locations

28

Illumina, Inc. + Illumina Corporate Foundation$873,088$13,255,768$14,446,500

Nature of ownership and legal form

Public Corporation

Number of causes supported4

1,021

1,034

1,345

Revenue$4.52 billion

Total capitalization (stockholder’s equity) market value as of 12/31/2021$10.74 billion$560,088$7,146,450$9,409,966

5Y CAGR

14%

Illumina Corporate Foundation Giving

10Y CAGR

16%

Employee giving$312,000$573,728$519,831

R&D % revenue investment

20%

Employee participation (giving)

19%

20%

26%

R&D spend$885 million

Foundation match & volunteer rewards (Dollars for Doers)$208,000$721,111$546,884

Building footprint1

2,541,548 square feet

Charitable grants$105,000$5,388,207$4,489,650

Facility additions2

3

Total Foundation giving (not including employees)$313,000$6,109,318$5,036,534

Facility closures3

1

Employee hours

13,980

4,236

8,772

Employee volunteering

29%

5%

10%

Intern hours

140

1,237

800

40%

24%

31%

Illumina, Inc.

NA

$2,894,129$7,044,842

Illumina Corporate Foundation

NA$635,126$1,089,892

Number of countries

24

29

44

306,170

195,000

315,000

Expanding Access to Genomics
Access to Genomics

2021

Cost per genome$600

iHope™ patients supported in 2021

300

Total iHope™ patients supported since program inception

1,150

Clinical iHope™ network sites

24

Professional healthcare learners

30,000Illumina Accelerator companies funded through December 2021

63

NGS coverage outlook: Total insured lives>1 billion

Illumina, Inc. Giving
In-kind product donations + cash grants

Volunteer Hours

Employee Participation
Total employee participation (giving + volunteering)

Summary of International Giving (Outside US)

STEM
Number of teachers and students engaged in Illumina
STEM programs

Notes:
1
Average square feet during reporting year.
2
Emedgene Acquisition, new commercial office in Dubai, and new distribution center in Steenhoven.
Moved out of Eindhoven distribution center into larger distribution center in Steenoven.
In order to be included in the Causes Database, an organization must meet their country’s NGO guidelines. Organizations are then evaluated against 1,200 watch lists and a number of National Taxonomy of Exempt Entities Codes (NTEE) that arealso excluded from matching eligibility. Illumina currently blocks charitable organizations that have been found to discriminate against a specific race, religion, ethnicity, sexual orientation, or gender identity.

3
42022 CORPORATE SOCIAL RESPONSIBILITY REPORT

87

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Integrating Environmental Sustainability
Energy Consumption (Units: Gigajoules)

2019

2020*

2021*

Emissions (Units: Metric Tons CO2e)

2019

2020*

2021*

Total fuel consumption from non-renewable sources

247,576

390,564

403,211

Total Scope 1 & 2 (market-based) GHG emissions

34,40436,57326,265

Total fuel consumption from renewable sources

0

0

0

Generation from renewable sources consumed by the organization

1,566

3,333

2,417

Total Scope 1 & 2 (location-based) GHG emissions

34,40436,57336,914

Total energy consumption from non-renewable sources

503,658

561,258

581,067

Gross direct GHG emissions (Scope 1)

12,48919,701

20,296

Total energy consumption from renewable sources

1,566

3,333

9,077

Gross market-based energy indirect GHG emissions (Scope 2)

21,915

16,872

5,968

Total energy consumption

505,224564,591

590,144

Energy Consumption by Activity and Region (Units: Gigajoules)

2019

2020*

2021*

Total electricity (purchased + generated)

257,648

174,028

187,297

Purchased electricity

256,082

170,694

184,882

1,566

3,333

2,417

Total fuel247,576

390,564

403,211Natural gas

247,576

390,564

403,211

Total steam

0

0

0

Electricity, heating, cooling, steam sold

0

0

0

380,106

445,190

469,104

47,77935,07236,358Generated electricity (on-site solar)

Total energy consumption AMR region
Total energy consumption EMEA region

Gross location-based energy indirect GHG emissions (Scope 2)

21,915

16,872

16,618

Regional Emissions (Units: Metric Tons CO2e)

2019

2020

*

2021*

Scope 1 & 2 market-based emissions AMR region

22,90325,20725,060

Scope 1 & 2 market-based emissions EMEA region

3,014

2,253

864

Scope 1 & 2 market-based emissions APAC region

8,488

9,113

Country-Specific Scope 1 (Units: Metric Tons CO2e)

2019

2020

China

0

0

0

Netherlands

73

73

74

Singapore000United Kingdom of Great Britain and Northern Ireland

1,132

801

768

United States of America

11,284

18,827

19,454

Country-Specific Scope 2 Market-Based (Units: Metric Tons CO2e)

2019

2020

2021*

China

388

518

0

341
*

*

2021*

Total energy consumption APAC region

75,75280,996

84,681

Renewable Electricity Consumption

2019

2020

2021*

Percentage of global electricity consumption that is renewable

0.6%

2%

59%

Netherlands

384

368

8

8,099

8,595

341

On-site solar generation

0.6%

2%

1%

Singapore

Renewable electricity purchased

0%

0%

3%

United Kingdom of Great Britain and Northern Ireland

1,425

1,011

14

Covered by Renewable Energy Credits

0%

0%

55%

United States of America

11,619

6,380

5,605

Notes:* Denotes data has been assured.
• Boundary definition for energy and Scope 1 & 2 emission inventory: sites >30,000 square feet or contain manufacturing, distribution, or significant R&D activities. These sites represent our jurisdictional control plus material locations. This scope accounts for 96% of our total 2019 baseline footprint.
• The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard is utilized as the methodology to calculate Scope 1 and Scope 2 emissions.
• Some segments may not add up to total due to rounding.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT88

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Integrating Environmental Sustainability continued
Facility-Specific Emissions (Units: Metric Tons CO2e)12021 Scope 1*

2021 Scope 2
Market-Based*

2021 Scope 2
Location-Based*

Scope 3 Emissions (Units: Metric Tons CO2e)

2019

2020

2021*

Purchased Goods and Services (Category 1)3

72,915

100,351

138,563

Capital Goods (Category 2)3

Cambridge, United Kingdom

749

0

903

Eindhoven, Netherlands

72

0

203

39,94044,057

79,530

Foster City, California

Fuel- and Energy-Related Activities (Category 3)

1,359

1,403

1,403

6,956

5,785

9,048

Hayward, California

Upstream Transportation & Distribution (Category 4)3

634

592

592

46,32748,256

68,934Madison, Wisconsin

Waste Generated in Operations (Category 5)

1,458

2,138

2,138

236

617

1,055

Business Travel (Category 6)3

San Diego Headquarters, California

19,350

8,913

3,959

15,248

1,291

1,580

Employee Commuting (Category 7)

San Diego i3, California

18,012

7,567

7,616

756

134

200

Upstream Leased Assets (Category 8)

San Diego Warehouse, California

733

547

0

47

74

Downstream Transportation & Distribution (Category 9)

Shanghai, China

0

0

358

Processing of Sold Products (Category 10)

Steenoven, Netherlands

2

8

218

Use of Sold Products (Category 11)

Watson, United Kingdom

6,968

19

14

23

End-of-Life Treatment of Sold Products (Category 12)

Woodlands, Singapore

2,368

0

341

8,927

Downstream Leased Assets (Category 13)

Greenhouse Gas Breakdown (Units:  Metric Tons CO2e)

Assessed, not relevant

2019

2020*

2021*

Franchises (Category 14)

Assessed, not relevant

CO2 Scope 1

12,475

19,681

19,884

Investments (Category 15)3

23,55919,0380

CH4 Scope1

7

10

375

Total Scope 3 Emissions

238,110242,411

323,702

N20 Scope 1

6

10

37

Scope 3 Emissions: % of Total Scope 3 Emissions

2019

2020

2021*

Emission Intensity Ratios

2019

2020*

2021*

Purchased Goods and Services (Category 1)3

31%

41%

43%

Capital Goods (Category 2)3

17%

18%

25%

Scope 1 and 2 Emissions

3

1,480

Assessed, not relevant
Assessed, not relevant
4,850

9,221

2,245

5,230

GHG emission intensity per million dollars revenue

9.8

11.4

5.8

Fuel- and Energy-Related Activities (Category 3)

3%

2%

3%

GHG emission intensity kgCO2e/square feet

13.8

15.1

10.4

Upstream Transportation & Distribution (Category 4)3

19%

20%

21%

GHG emission intensity per employee

4.4

4.7

2.9

Scope 3 Emissions2

Notes:
1
Facilities included in Scope 1 & 2 emission boundary.
2
Emission intensity for Scope 3 categories included in 2050 net zero target.
3
Categories included in 2050 net zero target.
* Denotes data has been assured.
• Some segments may not add up to total due to rounding.
• The Greenhouse Gas Protocol: A Corporate Value Chain (Scope 3) Accounting and Reporting Standard.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

Waste Generated in Operations (Category 5)

0.1%

0.3%

0.3%

Business Travel (Category 6)3

8%

4%

1%

Employee Commuting (Category 7)3

8%

3%

2%

Upstream Leased Assets (Category 8)

0.6%

0.3%

0.2%

Use of Sold Products (Category 11)

3%

2%

3%

End-of-Life Treatment of Sold Products (Category 12)

1%

0.9%

2%

Investments (Category 15)3

10%

8%

0%

89

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Integrating Environmental Sustainability continued
Water (Units: Megaliters)

2019

2020

2021*

Effluent & Waste by Type and Disposal Method (Units: Metric Tons)

Interactions with water: total water withdrawal (potable source + recycled source)

225

†

294

†

268

Non-Hazardous Waste

Water withdrawal (potable)

147†

208†

195

Water withdrawal (recycled)

78

86

2019

2020

2021

Non-hazardous waste total

3,494

3,703

4,421

74

Reuse

0

0

0

1

63%

62%

70%

Recycling

887

872

937

Water intensity (kiloliters normalized by rentable square feet forcore site locations)2

†

0.10

†

0.12

0.11

Composting

149

203

259

% water withdrawal in AMR

97%

97%

97%

Recovery (including energy recovery)

760

729

977

% water withdrawal in EMEA

2%

1%

1%

Incineration

0

0

0

% water withdrawal in APAC

1%

2%

2%

Deep well injection

0

0

0

Total Waste (Units: Metric Tons)

2019

2020

2021

Landfill

1,698

1,899

2,247

Total (hazardous + non-hazardous)

4,934

4,979

5,975

On-site storage

0

0

0

Global average non-hazardous diversion from landfill

51%

49%

49%

Other

0

0

0

Regional Waste Data AMR (Units: Metric Tons)

2019

2020

2021

Non-hazardous waste total

2,619

2,869

3,326

Hazardous waste total

1,440

1,276

1,554

Hazardous waste total

902

699

605

Reuse

0

0

0

Madison Site % diversion3

39%

43%

43%

Recycling

413

489

332

Foster City % diversion

54%

48%

49%

Composting

0

0

0

32%

22%

22%

Recovery (including energy recovery)

850

707

1,169

Incineration

62

34

41

Deep well injection

0

0

0

Percentage of total water withdrawal in water stressed regions

3

Hayward % diversion3

Hazardous Waste

San Diego % diversion3

33%

36%†

31%

Regional Waste Data EMEA (Units: Metric Tons)

2019

2020

2021

Non-hazardous waste total

451

397

590

Landfill

37

20

6

0

0

0

77

26

4

Hazardous waste total
Cambridge, UK % diversion
Netherlands % diversion

3

67

35

55

On-site storage

100%

100%

100%

Other

100%

100%

100%

Regional Waste Data APAC (Units: Metric Tons)

2019

2020

2021

Non-hazardous waste total

424

437

504

Hazardous waste total

471

542

894

Singapore % diversion

100%

100%

100%

3

3

Notes:
1
Water stressed regions listed on page 44.
2Core site locations: San Diego HQ, i3 and Warehouse, Hayward, Foster City, Madison, Netherlands, Cambridge, and Singapore Woodlands.
3
% Diversion calculated using non-hazardous waste and % diverted from landfill.
* Denotes data has been assured.
† Updated data to reflect most current information.

90

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Nurturing Our People
Workforce Data

2019

2020

2021*

Gender Data

Total employees

7,802

7,828

9,191

Workforce

Full-time employees

7,749

7,782

9,137

Total womenPart-time employees

53

46

54

Contingent workers

1,247

1,459

1,647

Full-time women

Age Group
Employees under 30

Part-time women1

1,527

1,363

1,820

20%

17%

20%

5,090

5,235

5,992

65%

67%

65%

1,185

1,230

1,379

Leadership

15%

16%

15%

Women in leadership2

Total employees

4,973

4,937

5,668

Women in executive leadership3

Full-time employees

4,954

4,918

5,650

Employees 30–50
Employees over 50

Temporary women

AMR

Part-time employees
Contingent workers

19

19

18

Women on Board of Directors

2019

2020

2021*

3,334

3,342

4,076

43%

43%

45%

3,293

3,305

4,036

43%

43%

45%

41

37

40

79%

80%

76%

N/A

N/A

N/A

N/A

N/A

N/A

571

610

746

39%

40%

42%

112

136

174

33%

36%

38%

3

3

3

33%

30%

33%

971

1,182

884

Total employees

1,883

1,871

2,238

AMR

2,071

2,067

2,474

Full-time employees

1,882

1,871

2,238

APAC

847

826

1,037

416

449

565

AMR

404

421

506

APAC

95

104

135

72

85

105

Total Women by Region

APAC

Part-time employees

1

0

0

EMEA

Contingent workers

164

146

588

Women in Leadership by Region

Total employees

946

1,020

1,285

Full-time employees

913

993

1,249

EMEA

Part-time employees

33

27

36

Functional Group

Contingent workers

112

131

175

Women in revenue-generating roles

41%

36%

48%

Women in revenue-generating roles—management

35%

36%

42%

Women in STEM-related roles (% of total STEM roles)

37%

37%

39%

Women in IT roles

24%

23%

24%

Women in engineering roles

37%

36%

29%

EMEA

Notes:
1
Percentage of all part-time employees.
2
Leadership: Manager, equivalent, and above.
3
Executive leadership: Director and above.
* Denotes data has been assured.
• For all people metrics unless specified, the values include only regular Illumina employees, not contingent workers.
• Some segments may not add up to total due to rounding.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT91

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Nurturing Our People continued
Percentage Female of Each EEOC Category (US)

2019

2020

2021*

EEOC Minority Summary (US)

2019

2020

2021*

White/Caucasian

41%

41%

43%

Total employees identifying in minority race and ethnicity statistics

2,429

2,422

2,830

Native Hawaiian or Other Pacific Islander

31%

27%

33%

Minority of total employees

49%

49%

50%

American Indian or Native Alaskan

50%

45%

50%

46%

46%

45%

Asian

44%

44%

45%

Non-Minority of total employees

Hispanic or Latino

39%

40%

44%

Decline to state of total employees

5%

5%

5%

Black or African American

37%

41%

45%

Representation of Black, Native, Pacific Islander, Hispanic or Latino, 2 or morecommunities in workforce

17%

17%

17%

2 or More

45%

46%

51%

11%

12%

40%

40%

41%

Representation of Black, Native, Pacific Islander, Hispanic or Latino, 2 or morecommunities in leadership

10%

Choose not to self disclose

Percentage Male of Each EEOC Category (US)

2019

2020

2021*

White/Caucasian

59%

59%

57%

Native Hawaiian or Other Pacific Islander

69%

73%

67%

American Indian or Native Alaskan

50%

55%

50%

Asian

56%

56%

55%

Hispanic or Latino

61%

60%

56%

Black or African American

63%

60%

55%

2 or More

55%

54%

49%

Choose not to self disclose

60%

60%

59%

EEOC Minority by Category (US)

2019

2020

2021*

White/Caucasian

2,284

2,253

2,514

46%

46%

45%

62

56

67

1%

1%

1%

10

11

13

<1%

<1%

<1%

1,601

1,601

1,863

32%

33%

33%

447

435

510

9%

9%

9%

121

121

130

2%

2%

2%

188

198

248

4%

4%

4%

240

238

294

5%

5%

5%

143

141

145

3%

3%

3%

248

235

230

5%

5%

4%

Native Hawaiian or Other Pacific Islander
American Indian or Native Alaskan
Asian
Hispanic or Latino
Black or African American
2 or More
Choose not to self disclose
VeteranDisabled

Notes:* Denotes data has been assured.
• Minority defined as any EEOC category that is non-white/non-Caucasian. Does not include those who choose not to specify a race/ethnicity.
• Some segments may not add up to total due to rounding.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

92

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Nurturing Our People continued
EEOC Data by Level (US)

2019

2020

2021*

2019

2020

2021*

White/Caucasian

261

226

264

Native Hawaiian or Other Pacific Islander

24%
29

23%
31

23%
34

White/Caucasian

413

421

452

Native Hawaiian or Other Pacific Islander

54%
11

56%
9

55%
11

American Indian or Native Alaskan

3%
3

3%
2

3%
3

American Indian or Native Alaskan

1%
2

1%
2

1%
1

Asian

<1%
489

<1%
452

<1%
514

Asian

<1%
182

<1%
174

<1%
214

Hispanic or Latino

45%
173

45%
160

45%
185

Hispanic or Latino

24%
65

23%
61

26%
70

Black or African American

16%
48

16%
38

16%
38

Black or African American

9%
17

8%
21

8%
22

2 or More

4%
57

4%
56

3%
65

2 or More

2%
22

3%
21

3%
23

5%

6%

6%

38

34

35

Choose not to self disclose

3%
46

3%
48

3%
51

3%

3%

3%

6%

6%

6%

Support to Entry Professional

Choose not to self disclose

EEOC Data by Level (US)Manager to Associate Director

Director and Above

Intermediate to Senior Professional
White/Caucasian

1,403

1,389

1,555

White/Caucasian

207

217

243

Native Hawaiian or Other Pacific Islander

50%
22

48%
16

48%
21

Native Hawaiian or Other Pacific Islander

75%
0

75%
0

70%
1

American Indian or Native Alaskan

1%
4

1%
6

1%
7

American Indian or Native Alaskan

0%
1

0%
1

<1%
2

Asian

<1%
895

<1%
938

<1%
1,078

Asian

<1%
35

<1%
37

1%
57

33%
201

33%
243

13%

13%

16%

Hispanic or Latino

32%
199

Hispanic or Latino

10

13

12

Black or African American

7%
51

7%
56

7%
63

Black or African American

4%
5

4%
6

3%
7

2 or More

2%
105

2%
115

2%
150

2 or More

2%
4

2%
6

2%
10

4%
146

5%
191

1%

2%

3%

Choose not to self disclose

4%143

Choose not to self disclose

13

10

17

5%

5%

6%

5%

3%

5%

Notes:* Denotes data has been assured.
• Some segments may not add up to total due to rounding.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT   Learn More Federal Employer Information EEO-1 Report93Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Nurturing Our People continued
New Hire Data

2019

2020

2021*

Promotion Data

2019

2020

2021*

458

380

990

Total number of employees promoted

1,502

1,568

2,583

Promotion Rate by EEOC (US)

2019

2020

30%

28%

2021*

54%

716

White/Caucasian

22%

20%

34%

586

1,358

Native Hawaiian or Other Pacific Islander

19%

10%

34%

14%

11%

23%

American Indian or Native Alaskan

0%

29%

33%

89

88

156

Asian

23%

20%

37%

8%

7%

11%

Hispanic or Latino

19%

19%

34%

Black or African American

14%

15%

33%

New Hire by Age Group
Employees under 30
Employees 30–50
Employees over 50
New Hire by Gender
New female employee hires1

566

490

1,185

2 or More

20%

18%

37%

17%

15%

29%

Choose not to self disclose

21%

22%

35%

684

560

1,262

Veteran Data (US)

2019

2020

2021*

15%

12%

25%

Number of US employees, regardless of whether they have any
military connection

4,908

4,866

5,561

707

629

1,479

87

87

90

14%

13%

26%

Number of employees as defined by the federal government as meeting thecriteria for protected veteran status

376

249

621

Number of veteran and active duty employees, regardless of protected status

143

141

145

20%

13%

28%

Number of disabled veteran employees

2

2

3

180

176

404

Number of women veteran employees

24

20

26

19%

17%

31%

Number of minority veteran employees—minority veterans include, but are notlimited to, people of color, women, LGBTQIA+, and (non) religious minorities

67

68

75

White/Caucasian

44%

47%

40%

Native Hawaiian or Other Pacific Islander

1%

<1%

1%

American Indian or Native Alaskan

<1%

<1%

<1%

Asian

32%

33%

34%

Hispanic or Latino

10%

7%

10%

Black or African American

2%

4%

2%

2 or More

7%

6%

7%

Choose not to self disclose

5%

3%

6%

New male employee hires1
New Hire by Region
AMR new employee hires1
APAC new employee hires1
EMEA new employee hires1

Percentage New Hire per EEOC (US)

Notes:
1% data for new hire by age represents the percentage of the total age group headcount for the reporting year.
* Denotes data has been assured.
• For all gender statistics, percentage of women is based on number of employees who identify as male or female, not total number of Illumina employees.
• Some segments may not add up to total due to rounding.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

94

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Nurturing Our People continued
Employee Turnover Data

2019

2020

2021*

Total number of employee turnover

856

1,028

1,154

Rate of employee turnover

11%

14%

14%

Total number of voluntary terminations

644

714

1,048

Rate of voluntary terminations

9%

9%

12%

Total Turnover

Employees 30–50
Employees over 50
Voluntary employee turnover under 30
Voluntary employee turnover 30–50
Voluntary employee turnover over 50

2019

2020

2021*

530

666

763

11%

13%

14%

223

261

251

12%

14%

12%

103

101

140

11%

10%

12%

384

442

701

8%

9%

13%

188

207

224

10%

11%

11%

72

65

123

8%

7%

11%

Total Turnover by Region

Turnover by Age
Employees under 30

Employee Turnover Data
AMR
APAC
EMEA

229

224

246

15%

16%

15%

Voluntary Turnover by Region

489

638

749

AMR

10%

12%

13%

138

166

159

12%

14%

12%

195

182

233

13%

13%

15%

366

456

686

Voluntary Turnover Percentage by EEOC (US)

7%

9%

12%

White/Caucasian

8%

10%

13%

82

76

129

Native Hawaiian or Other Pacific Islander

11%

10%

5%

7%

6%

10%

American Indian or Native Alaskan

0%

0%

25%

Asian

7%

8%

13%

Turnover by Level

APAC
EMEA

Voluntary turnover support to entry professional

11%

11%

14%

Hispanic or Latino

8%

7%

14%

Involuntary turnover support to entry professional

3%

5%

1%

Black or African American

11%

12%

16%

Voluntary turnover intermediate to senior professional

8%

8%

12%

2 or More

6%

11%

21%

Involuntary turnover intermediate to senior professional

2%

4%

1%

Choose not to self disclose

6%

8%

13%

Voluntary turnover manager to associate director

6%

8%

11%

Involuntary turnover manager to associate director

4%

4%

2%

Voluntary turnover director and above

6%

13%

17%

Involuntary turnover director and above

4%

4%

3%

Notes:* Denotes data has been assured.
• Some segments may not add up to total due to rounding.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

95

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Nurturing Our People continued
Parental Leave1

2019

2020

2021

Average Compensation Ratio—Women to Men

2019

2020

2021

Total number of employees who were entitled to parental leave

4,714

4,900

5,302

Across all employee categories

100%

100%

100%

Total number of employees who took parental leave, by gender

Female 116
Male 65

Female 181
Male 121
Blank 1

Female 173
Male 89

Support to entry professional

102%

102%

101%

Intermediate to senior professional

100%

100%

99%

Female 116
Male 65

Female 191
Male 138
Blank 1

Female 166
Male 123

Supervisor to associate director

98%

99%

100%

Director and above

101%

98%

99%

Annual Compensation Ratio

2019

2020

2021

Ratio of annual total compensation for the organization's highest-paid individual ineach region to the median annual total compensation for all employees

Refer toProxy Filing

Refer toProxy Filing

Refer toProxy Filing

Total number of employees who returned to work in thereporting period after parental leave ended, by gender
Total number of employees who returned to work after parental
leave ended that were still employed 12 months after theirreturn to work, by gender

Female 100
Male 54

Female 177
Male 123
Blank 1

Female 150
Male 107

Return to work and retention rates of employees who tookparental leave, by gender

Return to Work:
Female 100%
Male 98%

Return to Work:
Female 100%
Male 98%

Return to Work:
Female 98%
Male 99%

Training

2019

2020

2021

Average hours of training per employee per year

60

64

64

Hours of training by gender: Male

60

66

66

Retention:
Female 86%
Male 83%

Retention:
Female 86%
Male 83%

Retention:
Female 93%
Male 89%

Hours of training by gender: Female

61

61

63

Hours of training by employee category: Individual Contributor

64

68

68

Benefit Plan and Other Retirement

2019

2020

2021

Hours of training by employee category: Middle Management

71

76

76

Percentage of salary contributed by employee or employer

US 401(k): Employee elected between 0–80%, Illumina
matching contribution of 50% up to the first 6% employee
election (3% of eligible salary)

Hours of training by employee category: Senior Management

38

38

44

Hours of training by employee category: Executive Leadership

22

24

30

Hours of training by functional category: Commercial Operations

50

46

52

Hours of training by functional category: General Operations

23

25

27

Hours of training by functional category: Manufacturing

91

104

98

Hours of training by functional category: Research & Development

53

57

62

Total number of hours devoted to training on human rights

1,737

5,578

3,333

Applicable employees certified to Code of Conduct

99%†

98%†

97%

Level of participation in retirement plans, such as participationin mandatory or voluntary schemes, regional or country-based
schemes, or those with financial impact

Employee Bonus and Stock Program

US 401(k): 97% employee
voluntary participation

2019

2020

Employees eligible for annual VCP bonus

All employees

Employees eligible to participate in employee stock purchase plan

All employees

US 401(k):98% employee
voluntary participation

2021

Performance & Career Development Review

2019

2020

2021

Percentage of employees receiving regular performanceand career development reviews (includes all administrative,
production, technical, middle management, andsenior management)

100%

100%

100%

Employee Survey2

2019

2020

2021

Participation rate for employee iPulse survey

89%

79%

80%

Notes:
1
Following the birth of a child or placement of a child for adoption or foster care, we provide 100% pay continuity to eligible US-based employees for up to six weeks to help ensure peace of mind during this essential time. In some cases, a mother could receive up to 28 weeks of pay continuity depending on the combination of leaves
associated with childbirth. Our parental leave policies in the other locations where we operate either meet or exceed local legal entitlements.
2
Employee survey participation rates in 2019 are calculated using an average of two surveys per year (Q2 and Q4 of each year). For 2020, the participation rate is based on an average of three quarterly surveys (Q2–Q4). For 2021, the participation rate is based on an average of four quarterly surveys (Q1-Q4).
• For all training hour metrics, the values include only regular Illumina employees, not contingent workers.
† Updated data to reflect most current information.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

96

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Nurturing Our People continued
Health & Safety

2019

2020

2021

Global recordable injury or illness incident rate (incident
per 100 employees)

0.52

0.34

0.54

Lost time incident rate

0.74

0.18

0.23

Environment, Health & Safety notices of violations

0

0

0

Environmental fines

0

0

0

Prevention reporting statistics

3,611

3,018

1,452

Employee Safety

2019

2020

2021

Number of work-related fatalities

0

0

0

Rate of work-related fatalities

0

0

0

The number of high-consequence work-related injuries
and illnesses (excluding fatalities)

49

29

51

The rate of high-consequence work-related injuries andillnesses (excluding fatalities)

0.62

0.39

0.16

The number of recordable work-related injuries
and illnesses

49

29

51

The rate of recordable work-related injuries and illnesses

0.62

The main types of work-related injury and illness
The number of hours worked

0.39

Ergonomics (repetitive stress injury),strain, contusion, and sprain
15,647,395

15,344,520

0.16

Safety Workers Who Are Not Employees but
Whose Work and/or Workplace is Controlled
by the Organization

2019

2020

2021

Number of work-related fatalities

0

0

0

Rate of work-related fatalities

0

0

0

The number of high-consequence work-related injuries
and illnesses (excluding fatalities)

0

3

2

The rate of high-consequence work-related injuries andillnesses (excluding fatalities)

0

0.07

0.13

The number of recordable work-related injuries
and illnesses

0

3

2

The rate of recordable work-related injuries and illnesses

0

0.07

0.13

The main types of work-related injury and illness
The number of hours worked

Ergonomics (repetitive stress injury),strain, contusion, and sprain

Fracture and strains

2,741,396

2,798,888

2,986,473

Total hours of EHS training

26,75830,05443,066

Average hours per employee

3.7

3.4

4.1

Environmental, Health & Safety Training

Repetitive stressinjury and strains
15,946,780

Notes:• Recordable injury & illness rate calculated using total hours worked from employees + contingent workers.
• Contingent workers: workers who are not employees but whose work and/or workplace is controlled by the organization.
• Lost time incident rate calculated using total hours worked from employees—contingent workers.
• High-consequence work-related injuries are defined as all recordable injuries.
• Rates have been calculated based on 200,000 hours worked.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

97

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Operating Responsibly
Governance

2019

2020

2021

Board of Directors (BoD)

2019

2020

2021

Non-compliance with environmental laws and regulations;
Significant fines and non-monetary sanctions for noncompliance with environmental laws and/or regulations# of FDA recalls

0

0

0

Yes

Yes

Yes

0

0

0

BoD level oversight for CSR and ESG (including themes of sustainability andclimate action; diversity, equity, and inclusion; human rights; cybersecurity;
data privacy; and ethical and responsible business practices)

Number of substantiated complaints concerning breachesof customer privacy and losses of customer data
Number of public legal cases regarding corruption
brought against the organization or its employees during
the reporting period
Anti-competitive

0

0

0

Clawback provision

Yes

Yes

Yes

Commitment to gender diversity on BoD

Yes

Yes

Yes

BoD composition by gender (% female)

33%

30%

33%

BoD composition by racial/ethnic minority representation

N/A

N/A

33%

0

0

0

2

0

See notes 1 and 2

Nature and total number of critical concerns
communicated to highest governance body regarding
CSR topics
Total employees covered by collective
bargaining agreements
Incidents of discrimination and corrective actions taken

0

0

0

Transparency Reporting Law Enforcement & National
Security Requests

N/A

0

Supply Chain

2019

2020

2021

Quantity of product shipped

3,118,142 units

3,297,561 units

3,862,839 units

Spend with direct suppliers$440 million$396 million$585 million

Supplier Code of Conduct in place002020 Privacy
Transparency
Report2021 Privacy
Transparency
Report

2. On March 30, 2021, the United States Federal Trade Commission filed an administrative complaint alleging that Illumina’s acquisition of GRAIL, Inc. violates
federal antitrust laws. Illumina denies the allegations, which are without merit, and will vigorously defend the case.
3. During the past twelve years, neither the EEOC nor any court or administrative agency has issued a finding against Illumina in a claim involving discrimination.
No incidents were filed during the reporting period. The matters that were pending during the last reporting period have been resolved.
We do not tolerate acts of discrimination, and promote an open culture to report concerns (including anonymously). Illumina takes all reports of misconduct
seriously and has a strict non-retaliation policy. If a report is substantiated, the company would respond as it deems appropriate or necessary, consistent withthe law, and will act swiftly to correct the problem and deter future occurrences. Depending on the circumstances, this may include training and/or disciplinary
action up to, and including, termination. Individuals may also be subject to civil or criminal prosecution for violating the law.

Countries: AE, AM, AR, AU,
AU, BE, BR, BY, CA, CH, CL,
CN, CR, CZ, DE, DK, EE, ES,
FI, FR, GB, GH, HK, ID, IE, IL,
IND, IS, IT, JP, KR, LT, LU,
MY, MX, NL, NO, NZ, PE,
PH, PL, PT, RU, SA, SE, SG,
TH, TR, TW, UA, US,
UY, ZACountries: AE, AM, AR,
AT, AU, BE, BG, BR, CA,
CH, CN, CO, CZ, DE, DK,
ES, FI, FR, GB, GH, HK,
ID, IE, IL, IN, IT, JP, KR,
LK, LT, LU, LV, MY, NL,
NO, NZ, PL, RO, RU, SA,
SE, SG, SI, TH, TR, TW,
US, ZA

Geographic location of suppliersCountries: AE, AM, AR, AT,
AU, BE, BS, CA, CH, CL, CN,
CO, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HK, ID, IE, IL, IN,
IS, IT, JP, KR, LT, LU, MO,
MX, MY, NL, NO, NZ, PA, PE,
PH, PL, PT, RO, RU, SE, SG,
SI, TH, TR, TW, UA, US, UY,
VN, ZAA description of the organization’s
supply chain

Illumina’s global supply chain consists of suppliers, sub-contractors, channel partners,
manufacturing sites, distribution centers, and customers

Types of suppliers

Direct, indirect, strategic, finished medical device, custom spec, off the shelf, and services

Number of suppliers engaged
by organization

3,891

3,704

3,798

Estimated monetary value of
payments made to suppliers>$1 billion$935 million>$1 billion

Number of active diverse
suppliers (US)

>400

334

517

See note 3

1. On January 11, 2021, Complete Genomics, Inc., BGI Americas Corp., and MGI Americas, Inc. (collectively BGI) filed a complaint in the US District Court for the
Northern District of California alleging that Illumina violated federal antitrust and state unfair competition laws, based on a patent infringement suit Illumina
filed against BGI in the same court. Illumina denies the allegations, which are without merit, and will vigorously defend the case.

Yes

ESG Governance Topics

Position

Level from CEO

Level from Board

Corporate Social Responsibility

SVP, Chief Financial Officer

12

Environment, Health & Safety, Supply Chain,
Facilities, Operations

SVP, Chief of Global Operations

1

2

Diverse supplier spend$190 million$152 million$209 million

19%

16%

17%

People, Employment, Diversity, Equity,and Inclusion

SVP, Chief People Officer

12Percentage of total PO spend withdiverse suppliers

75%

84%

SVP, General Counsel

1

2

Product

SVP, Chief Technology Officer

12Percentage of strategic suppliers thathave committed to minimizing theirenvironmental footprint

N/A

Compliance, Ethics, Legal

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

98

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Key Performance Indicators

Operating Responsibly continued
Political Contributions

2019

2020

2021

Total monetary value of financial and in-kind political contributions made directly and indirectly by the organization by country and recipient/beneficiary$50,000$0$0

Trade Association & Memberships

2021

Trade Association & Memberships

Illumina participates in various trade associations and industry memberships for collaboration and exchange of ideas. Some of theseorganizations may utilize a portion of membership fees for non-deductible state and federal lobbying and political expenditures. As partof our transparency practices, we disclose trade memberships for which we contribute at least $5,000 annually in fees.

Trade and Industry Group Memberships Above $5,000 Threshold Annually
GlobalWorld Economic Forum$330,000

U.S. Trade Association Memberships
World 50, Inc$393,766

US Chamber of Commerce$150,000

Coalition for Access to Prenatal Screening (CAPS)$100,000

Access to Comprehensive Genomic Profiling Coalition$80,813

Procurement Leaders$57,000

Biocom$56,300

American Clinical Laboratory Association (ACLA)$50,000

Coalition for 21st Century Medicine$50,000

Personalized Medicine Coalition (PMC)$32,000

California Chamber of Commerce$25,000

San Diego Economic Development Corp. (SDEDC)$25,000

National Association of Manufacturers (NAM)$24,500

AdvaMed$19,950

American Cancer Society—Cancer Action Network (ACS-CAN)*$10,000

San Diego Regional Chamber of Commcerce (SD Chamber)$7,650Industrial Environmental Association (IEA)$6,000

Healthcare Businesswomen's Association (HBA)$5,000Organization

Total Annual Membership Fee

2021

EMEA Trade Association Memberships
All.Can (ASBL)$35,000

EUCOPE$27,892

US Qatar Business Council$10,000

US Saudi Arabian Business Council$10,000

US UAE Business Council$10,000

International Quality Network for Pathology (IQN Path)$5,000

APJ and Greater China Trade Association Memberships
US India Business Council$27,500

US Chamber — China$25,000

US-China Business Council (USCBC)$15,000

US-ASEAN$11,686

AmCham China$7,413

Pathology Technology Australia$7,309% Membership Fees Used for State or Federal Lobbying

Dollars Applied to State or Federal Lobbying From Membership Fees

For the trade associations with membership fees greater than $50,000, the portion of such payments that is non-deductible under Section 162(e)(1)(B) of the Internal Revenue Code, such as payments to organizations designated as 501(c)(4) and 501(c)(6) associated with stateand federal lobbying efforts annually.

US Chamber of Commerce$161,625

25%$40,406

Coalition for Access to Prenatal Screening (CAPS)$100,00025%$25,000

American Clinical Laboratory Association (ACLA)$50,000

33%$16,500

Biocom$56,300

10%$5,6302022 CORPORATE SOCIAL RESPONSIBILITY REPORT

99

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

GRI Index
GRI Description

GRI Section

Illumina CSR Report Section

Page Number

GENERAL: DISCLOSURE 102
Organizational Profile
Name of organization

GRI 102-1

Illumina, Appendix

7, 87

Activities, brands, products and services

GRI 102-2

Illumina

7, 9Location of headquarters

GRI 102-3

Illumina, Appendix

8, 87

Location of all operations

GRI 102-4

Illumina

8

Ownership & legal form

GRI 102-5

Appendix87

Markets served

GRI 102-6

Illumina, Appendix

7-9, 87

Scale of organization

GRI 102-7

Illumina, People, Appendix

8-9, 55, 87, 91, 98

Information on employees and other workers

GRI 102-8

Illumina, People, Appendix

8-9, 53, 55, 58, 63-64, 87, 91-95

Supply chain

GRI 102-9

Integrity, Appendix

72, 81-84, 98

Significant changes to organization and its supply chain

GRI 102-10

Integrity, Appendix

72, 81-84, 86, 98

Precautionary principle or approach

GRI 102-11

Environment, People, Integrity

39, 42, 45-48, 81-83

External initiatives

GRI 102-12

Illumina, Environment, Integrity, Appendix

12, 41, 56, 79, 86

Membership of associations

GRI 102-13

Illumina, Integrity, Appendix

12, 79-80, 86, 99, 106

StrategyStatement from senior decision maker/CEO

GRI 102-14

Illumina

2-3

Key impacts, risks, and opportunities

GRI 102-15

Illumina, Access, Community, Environment, People, Integrity, Appendix

2-3, 7, 10-13, 15-16, 31-32, 39-40, 52-53, 71-72, 98,
106, 108

Ethics & Integrity
Values, principles, standards, and norms of behavior

GRI 102-16

Illumina, Access, Community, Environment, People, Integrity

7, 15, 31, 39, 52-68, 71-84

Mechanisms for advice and concern about ethics

GRI 102-17

Integrity

71-77, 81-83

Governance structure

GRI 102-18

Illumina, Integrity, Appendix

11, 73-75, 97

Delegating authority

GRI 102-19

Illumina, Appendix

11, 97

Executive level responsibility for economic, environmental, and social topics

GRI 102-20

Illumina, Integrity, Appendix

10-11, 73-75, 98

Consulting stakeholders on economic, environmental, and social topics

GRI 102-21

Illumina

11-12

Composition of the highest governance body and its committees

GRI 102-22

Illumina, Integrity, Appendix

11, 73-75, 98

Chair of the highest governance body

GRI 102-23

Illumina, Integrity, Appendix

11, 73-75, 98

Nominating and selecting the highest governance body

GRI 102-24

Illumina, Integrity, Appendix

11, 73-75, 98

Conflicts of interest

GRI 102-25

Integrity

73-75

Role of highest governance body in setting purpose, values, and strategy

GRI 102-26

Illumina, Integrity, Appendix

11, 73-75, 98

Governance2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

100

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

GRI Index

GRI Description

GRI Section

Illumina CSR Report Section

Page Number

GENERAL: DISCLOSURE 102 (cont.)
Governance (cont.)
Collective knowledge of highest governance body

GRI 102-27

Illumina, Integrity, Appendix

11, 73-75, 98

Evaluating the highest governance body’s performance

GRI 102-28

Integrity

73

Identifying and managing economic, environmental, and social impacts

GRI 102-29

Illumina, Integrity, Appendix

12-13, 73, 98

Effectiveness of risk management processes

GRI 102-30

Illumina, Integrity, Appendix

11, 73, 98, 106

Review of economic, environmental, and social topics

GRI 102-31

Illumina, Integrity, Appendix

11, 73, 98

Highest governance body’s role in sustainability reporting

GRI 102-32

Illumina, Integrity, Appendix

11, 73, 98

Communicating critical concerns

GRI 102-33

Illumina, Integrity, Appendix

11, 73, 98

Nature and total number of critical concerns

GRI 102-34

Illumina, Integrity, Appendix

11, 73, 98

Remuneration policies

GRI 102-35

People, Appendix

56-58, 98

Process for determining remuneration

GRI 102-36

People, Appendix

56-58, 98

Stakeholders’ involvement in remuneration

GRI 102-37

People, Appendix

56-59, 98

Annual total compensation ratio

GRI 102-38

Appendix

96

Percentage increase in annual total compensation ratio

GRI 102-39

Appendix

96

List of stakeholder groups

GRI 102-40

Illumina, Appendix

12, 86

Collective bargaining agreements

GRI 102-41

Integrity, Appendix

77, 98

Identifying and selecting stakeholders

GRI 102-42

Illumina

12

Approach to stakeholder engagement

GRI 102-43

Illumina

12

Key topics and concerns raised

GRI 102-44

Illumina

12-13

Stakeholder Engagement

Reporting Practice
Entities included in the consolidated financial statements

GRI 102-45

Appendix86

Defining report content and topic Boundaries

GRI 102-46

Appendix86

List of material topics

GRI 102-47

Illumina

12

Restatements of information

GRI 102-48

Appendix

86

Changes in reporting

GRI 102-49

Appendix

86

Reporting period

GRI 102-50

Appendix86

Date of most recent report

GRI 102-51

Appendix

86

Reporting cycle

GRI 102-52

Illumina, Appendix

1, 86Contact point for questions regarding the report

GRI 102-53

Appendix

86, 109-110

Claims of reporting in accordance with the GRI Standards

GRI 102-54

Appendix86

GRI content index

GRI 102-55

Appendix100-104

External Assurance

GRI 102-56

Appendix

109

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

101

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

GRI Index

GRI Description

GRI Section

Illumina CSR Report Section

Page Number

Management Approach: Economic Performance

GRI 103-1, 103-2, 103-3

Illumina, Access, Community, Environment, People, Integrity

6-10, 15-16, 31-32, 39-40, 52-53, 71-72

Direct economic value generated and distributed

GRI 201-1

Illumina, Appendix

8-9, 87

Financial implications and other risks and opportunities due to climate change

GRI 201-2

Environment, Integrity, Appendix: TCFD Index

39-50, 81, 83, 106

Defined benefit plan obligations and other retirement plans

GRI 201-3

People, Appendix

65, 96

Management Approach: Indirect Economic Impact

GRI 103-1, 103-2, 103-3

Access, Community, Environment, Integrity, Appendix

15-16, 31-32, 39-40, 71-72

Significant indirect economic impacts

GRI 203-2

Access, Community, Environment, Integrity, Appendix

15-29, 31-37, 39-40, 49-50, 71-72, 81-83

ECONOMIC: DISCLOSURE 200
Economic Performance

Indirect Economic Impact

Anti-Corruption Behavior
Management Approach: Anti-Corruption

GRI 103-1, 103-2, 103-3

Integrity, Appendix

71-72, 74-77, 81, 83

Operations assessed for risks related to corruption

GRI 205-1

Integrity, Appendix

71-72, 74-77, 81, 83

Communication and training about anti-corruption policies and procedures

GRI 205-2

Integrity, Appendix

71-72, 74-77, 81, 83

Confirmed incidents of corruption and actions taken

GRI 205-3

Appendix98

Management Approach: Anti-Competitive Behavior

GRI 103-1, 103-2, 103-3

Integrity, Appendix

74-77, 81-84, 98

Legal actions for anti-competitive behavior, anti-trust, and monopoly practices

GRI 206-1

Appendix98

Management Approach: Energy

GRI 103-1, 103-2, 103-3

Environment, Integrity, Appendix

39-43, 47-48, 81, 83

Energy consumption within the organization

GRI 302-1

Illumina, Environment, Integrity, Appendix

8, 39-43, 83, 88

Energy consumption outside of the organization

GRI 302-2

Environment, Integrity, Appendix

39-41, 47-48, 81, 83, 89

Energy intensity

GRI 302-3

Environment, Appendix

43, 88-89

Reduction of energy consumption

GRI 302-4

Environment, Appendix

39-43, 47-48, 88-89

Management Approach: Water

GRI 103-1, 103-2, 103-3

Environment, Integrity

39-40, 43-44, 81

Interactions with water as a shared resource

GRI 303-1

Community, Environment, Appendix

33-34, 39-40, 43-44, 47-49, 81-82

Water withdrawal

GRI 303-3

Environment, Appendix

40, 44, 90

Management Approach: Biodiversity

GRI 103-1, 103-2, 103-3

Illumina, Community, Environment

8, 31, 33-34, 39-40, 42

Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of highbiodiversity value outside protected areas

GIR 304-1

Illumina, Environment

8, 42-44, 49-50

Habitats protected or restored

GRI 304-3

Community, Environment

33-34, 42-44, 49-50

Anti-Competitive Behavior

ENVIRONMENTAL: DISCLOSURE 300
EnergyWater

Biodiversity

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

102

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

GRI Index

GRI Description

GRI Section

Illumina CSR Report Section

Page Number

ENVIRONMENTAL: DISCLOSURE 300 (cont.)
EmissionsManagement Approach: Emissions

GRI 103-1, 103-2, 103-3

Environment, Integrity

39-41, 43, 47-48, 81, 83

Direct (Scope 1) GHG Emissions

GRI 305-1

Illumina, Environment, Appendix

8, 39-41, 43, 88-89

Energy indirect (Scope 2) GHG emissions

GRI 305-2

Illumina, Environment, Appendix

8, 39-41, 43, 88-89

Other indirect (Scope 3) GHG emissions

GRI-305-3

Environment, Integrity, Appendix

39-41, 47-48, 81, 83, 89

GHG emissions intensity

GRI 305-4

Environment, Integrity, Appendix

43, 89Reduction of GHG emissions

GRI 305-5

Illumina, Environment, Integrity, Appendix

8, 40-41, 43, 47-48, 81, 83, 88-89

Management Approach: Effluent and Waste

GRI 103-1, 103-2, 103-3

Environment, People, Integrity

39-40, 43-44, 45-49, 67, 81, 83

Waste by type and disposal method

GRI 306-2

Environment, Integrity, Appendix

40, 44, 45-46, 90

Management Approach: Environmental Laws & Regulations

GRI 103-1, 103-2, 103-3

Environment, People, Integrity, Appendix

39-42, 67-68, 81, 83

Non-compliance with environmental laws and regulations

GRI 307-1

Environment, People, Integrity, Appendix

39-42, 44, 67-68, 81, 83, 97

Management Approach: Supplier Environmental Assessment

GRI 103-1, 103-2, 103-3

Environment, Integrity, Appendix

39-41, 47-48, 81, 83

New suppliers that were screened using environmental criteria

GRI 308-1

Integrity, Appendix

40, 47-48, 81, 83, 89

Management Approach: Employment

GRI 103-1, 103-2, 103-3

People, Integrity

52-69, 71-77

New employee hires and employee turnover

GRI 401-1

People, Appendix

53, 55, 57, 62-63, 94-95

Benefits provided to full-time employees that are not provided to temporary or part-time employees

GRI 401-2

People, Appendix

61-66, 96

Parental leave

GRI 401-3

People, Appendix

65, 96

Effluent and Waste

Environmental Compliance

Supplier Environmental Assessment

SOCIAL: DISCLOSURE 400
Employment

Occupational Health & Safety
Management Approach: Occupational Health & Safety

GRI 103-1, 103-2, 103-3

People, Appendix

52-53, 67-68, 97

Occupational health and safety management system

GRI 403-1

People, Appendix

52-53, 67-68, 97

Hazard identification, risk assessment, and incident investigation

GRI 403-2

People, Appendix

52-53, 67-68, 97

Worker participation, consultation, and communication on occupational health and safety

GRI 403-4

People, Appendix

52-53, 67-68, 97

Worker training on occupational health and safety

GRI 403-5

People, Appendix

52-53, 67-68, 97

Promotion of worker health

GRI 403-6

People, Appendix

52-53, 67-68, 97

Workers covered by an occupational health and safety management system

GRI 403-8

People, Appendix

52-53, 67-68, 97

Work-related injuries

GRI 403-9

People, Appendix

52-53, 67-68, 97

Work-related illness

GRI 403-10

People, Appendix

52-53, 67-68, 97

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

103

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

GRI Index

GRI Description

GRI Section

Illumina CSR Report Section

Page Number

SOCIAL: DISCLOSURE 400 (cont.)
Training & Education
Management Approach: Training & Education

GRI 103-1, 103-2, 103-3

People, Integrity, Appendix

52-54, 56-65, 67, 71-72

Average hours of training per year per employee

GRI 404-1

Illumina, People, Integrity, Appendix

8, 52-53, 62, 67, 74, 96-97

Programs for upgrading employee skills and transition assistance programs

GRI 404-2

People59-65

Percentage of employees receiving regular performance and career development reviews

GRI 404-3

People, Appendix

62, 96

Management Approach: Diversity & Equal Opportunity

GRI 103-1, 103-2, 103-3

Community, People, Integrity

31-37, 52-53, 56-60, 71-73, 82

Diversity of governance bodies and employees

GRI 405-1

Illumina, People, Integrity, Appendix

5, 8, 53, 55, 58, 63-64, 72-73, 75, 82, 91-95

Ratio of basic salary and remuneration of women to men

GRI 405-2

Illumina, People, Appendix

4, 8, 53, 58, 96

Management Approach: Child LaborGRI 103-1, 103-2, 103-3

Integrity

71-72, 77, 81, 83

Operations and suppliers at significant risk for incidents of child labor

GRI 408-1

Integrity, Appendix

71-72, 77, 81, 83, 98

Management Approach: Forced or Compulsory LaborGRI 103-1, 103-2, 103-3

Integrity

71-72, 77, 81, 83

Operations and suppliers at significant risk for incidents of forced or compulsory labor

GRI 409-1

Integrity, Appendix

71-72, 77, 81, 83, 98

Management Approach: Human Rights

GRI 103-1, 103-2, 103-3

Integrity

71-72, 77, 81, 83

Operations that have been subject to human rights reviews or impact assessments

GRI 412-1

Integrity, Appendix

71-72, 77, 81, 83, 98

Employee training on human rights policies or procedures

GRI 412-2

Integrity, Appendix

77, 96Significant investment agreements and contracts that include human rights clauses or that
underwent human rights screening

GRI 412-3

Integrity, Appendix

71-72, 77, 81, 83, 98

Management Approach: Local Communities

GRI 103-1, 103-2, 103-3

Access, Community, Environment, Integrity

15-16, 31-32, 39-40, 71-72

Operations with local community engagement, impact assessments, and development programs

GRI 413-1

Illumina, Access, Community, Environment, Integrity

4, 11-13, 15-16, 21-27, 31-37, 39-42, 47-50, 71-72, 77, 81-83

Diversity & Equal Opportunity

Child Labor

Forced or Compulsory Labor

Human Rights

Local Communities

Supplier Social Criteria Screening
Management Approach: Supplier Social Criteria Screening

GRI 103-1, 103-2, 103-3

Integrity

81-83

New suppliers that were screened using social criteria

GRI 414-1

Integrity, Appendix

81-83, 98

Management Approach: Public Policy

GRI 103-1, 103-2, 103-3

Integrity, Appendix

71-72, 80, 99

Political contributions

GRI 415-1

Integrity, Appendix

71, 80, 99

Management Approach: Customer Privacy

GRI 103-1, 103-2, 103-3

Integrity

71-72, 78-79

Substantiated complaints concerning breaches of customer privacy and losses of customer data

GRI 418-1

Integrity, Appendix

71, 78-79, 98

Public Policy

Customer Privacy

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

104

Illumina

AccessCommunity

Environment

PeopleAppendix

Integrity

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

SASB Index
The Sustainability Accounting Standards Board (SASB) is an independent standards-setting organization that promotes disclosure of material sustainability information to meet investor needs. Illumina is classified officially in
the Health Care Sector and Medical Equipment & Supply Industry. We have also chosen to add relevant sections from the industry categories of Biotechnology & Pharmaceuticals as well as Software & IT Services.
Dimension

General Issue Category Disclosure Topic

Code

Accounting MetricResponse

PRIMARY SICS SECTOR: HEALTHCARE | PRIMARY SICS INDUSTRY: MEDICAL EQUIPMENT & SUPPLIESSocialCapitalAccess & Affordability

HC-MS-240a.1

Ratio of weighted average rate of net price increases to the annual increase in the U.S. Consumer Price Index

Integrity, 76

Affordability and Pricing

HC-MS-240a.2

Description of how price information for each product is disclosed to customers or to their agents

Integrity, 76

Product Safety

HC-MS-250a.1

Number of FDA recalls issued, total units recalled

Integrity, 84

Product Safety

HC-MS-250a.2

List of products listed in the FDA’s MedWatch safety alerts for human medical products database0

Product Safety

HC-MS-250a.3

Number of fatalities related to products as reported in FDA Manufacturer and User Facility Device Experience

0

Product Safety

HC-MS-250a.4

Number of FDA enforcement actions taken in response to violations of Current Good Manufacturing Practices (cGMP)

0

Selling Practices &Product Labeling

Ethical Marketing

HC-MS-270a.1

Total amount of monetary losses as a result of legal proceedings associated with false marketing claims

0

Ethical Marketing

HC-MS-270a.2

Description of code of ethics governing promotion of off-label use of products

Integrity, 74-76
Illumina Code of Conduct

Product Design &Lifecycle Management

Product Design &Lifecycle Management

HC-MS-410a.1

Discussion of process to assess and manage environmental and human health considerations associated with chemicals
in products, and meet demand for sustainable products

Environment, 39, 45-48

Product Design &Lifecycle Management

HC-MS-410a.2

Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipmentand (2) supplies

Environment, 44-46
Appendix, 90

SupplyChain Management

HC-MS-430a.1

Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in third-party audit programs for manufacturing
and product quality

Integrity, 84

SupplyChain Management

HC-MS-430a.2

Description of efforts to maintain traceability within the distribution chain

Integrity, 81-84

SupplyChain Management

HC-MS-430a.3

Description of the management of risks associated with the use of critical materials

Integrity, 81-84

Business Ethics

HC-MS-510a.1

Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption

Appendix, 98

Business Ethics

HC-MS-510a.2

Description of code of ethics governing interactions with health care professionals

Integrity, 74-75
HCP Policy

Activity Metrics

HC-MS-000.A

Number of units sold by product category

Illumina, 9Appendix, 98

Employee Recruitment,
Development & Retention

HC-BP-330a.1

Discussion of talent recruitment and retention efforts for scientists and R&D personnel

People, 61

Employee Recruitment,
Development & Retention

HC-BP-330a.2

1) Voluntary and 2) involuntary turnover rate for a) executive/senior managers b) mid-level managers c) professionals d) all others

Appendix, 95

TC -SI-330a.3

Percentage of gender and racial/ethnic group representation for 1) management 2) technical staff 3) all other employees

Appendix, 91-95

Product Quality & Safety

Business
Model &
Innovation

Affordability and Pricing

Supply Chain Management

Leadership &GovernanceBusiness Ethics

Other

Activity Metrics

SUPPLEMENTAL SICS INDUSTRY: BIOTECH & PHARMA
Human
Capital

Employee Engagement,
Diversity & Inclusion

SUPPLEMENTAL SICS INDUSTRY: SOFTWARE & IT SERVICES
Human Capital

Employee Engagement,
Diversity & Inclusion

Recruiting & Managing
a Global, Diverse &Skilled Workforce

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

105

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Task Force on Climate-related Financial Disclosures (TCFD) Index
TCFD voluntary climate-related disclosure recommendations have been used to guide our reporting. We believe addressing climate change is key to achieving a sustainable, just, and resilient future for all. We are committed totransparency and will continue to share progress in our annual CSR Report and CDP submissions.
TCFD Disclosure Element

Description

Illumina CSR Report Section/2021 CDP
Questionnaire Response

Board oversight

Describe Board’s oversight of climate-related risks and opportunities.

Illumina, 11; CDP C1.1, C1.1a, C1.1b

Management role

Describe management’s role in assessing and managing risks and opportunities.

Illumina, 11; Integrity, 73; CDP C1.2, C1.2a

Topic

Governance: Describe organization’s governance around climate-related risks and opportunities.
Governance

Strategy: Describe the actual and potential impacts of climate-change risks and opportunities on the organization’s business, strategy, and financial planning where such information is material.
Strategy

Climate risk and opportunities timeline

Describe the climate-related risks and opportunities the organization has identified overthe short, medium, and long term.

Environment, 39-50; Integrity, 83; CDP C2.1a, C2.1b, C2.2,
C2.2a, C2.3, C2.3a, C2.4, C2.4a

Climate risk and opportunities impact

Describe the impact of climate-related risks and opportunities on the organization’s
businesses, strategy, and financial planning.

Environment, 39-50; Integrity, 76, 81, 83; CDP C2.2, C2.2a,C2.3b, C2.4b, C3.1, C3.1d, C3.1e, C3.1f, C3.3, C3.4

Targets to manage climate risk
and opportunities

Describe the resilience of the organization’s strategy, taking into consideration different
climate-related scenarios, including a 2°C or lower scenario.

Environment, 39-50; Integrity, 76, 81, 83; CDP C2.2, C3.1a,C3.2, C3.2a, C3.3

Process to identify climate risk

Describe the organization’s processes for identifying and assessing climate-related risks.

Illumina, 11-13; Environment, 39-50; Integrity, 71-72, 76, 81,
83; Appendix, 88-90; CDP C2.1, C2.1a, C2.1b, C2.2, C2.2a, C3.2a

Process to manage climate risk

Describe the organization’s processes for managing climate-related risks.

Community, 31-33; Environment, 39-50; Integrity, 71-72, 76,
81, 83; CDP C2.1, C2.1a, C2.2

Process to integrate climate risk in overallrisk management

Describe how processes for identifying, assessing, and managing climate-related risks areintegrated into the organization’s overall risk management.

Environment, 41-42; Integrity, 71-72, 76, 81, 83; CDP C2.2

Risk Management: Disclose how the organization identifies, assesses, and manages climate-related risks.
Risk Management

Metrics & Targets: Disclose the metrics and targets used to assess and manage relevant climate-related risks and opportunities where such information is material.
Metrics & Targets

Climate-related metrics

Disclose the metrics used by the organization to assess climate-related risks andopportunities in line with its strategy and risk management process.

Environment, 39-50; Integrity, 71-72, 81, 83; Appendix, 88-90;
CDP C4.1, C4.1a, C4.2, C4.2a, C4.2b, C9.1

GHG emission data

Disclose Scope 1, Scope 2, and, if appropriate, Scope 3 greenhouse gas (GHG) emissions,and the related risks.

Environment, 39-44, 47-48; Integrity, 81, 83; Appendix, 88-89;
CDP C6.1, C6.3, C6.5, C6.10, C7.2, C7.3b, C7.5, C7.6b

Targets to manage climate risk andperformance to targets

Describe the targets used by the organization to manage climate-related risks andopportunities and performance against targets.

Environment, 39-40; Integrity, 71-72; Appendix, 88-90, 108;
CDP C4.1, C4.1a, C4.1b, C4.2, C4.2a, C4.2b2022 CORPORATE SOCIAL RESPONSIBILITY REPORT106

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

UNGC Communication on ProgressFebruary 17, 2022

United Nations Global Compact Communication on Progress Index: Illumina has been a member of the United Nations
Global Compact (UNGC) since December 2019. We remain committed to aligning our business practices to the 10 UNGC
principles in the areas of human rights, labor, environment, and anti-corruption. This report serves as our annual UNGC
Communication on Progress. The table below shows the reference location of our disclosures against the UNGC.

UN Global Compact Communication on Progress
United Nations Global Compact Support
Secretary-General
United Nations
New York, NY 10017
USA
Dear Mr. Secretary-General,
Illumina, Inc. is proud to be a member of the Global Compact. I am pleased to re-confirm our
support of and continued commitment to the Ten Principles of the United Nations Global
Compact. In this annual Communication on Progress, we describe our actions to integrate the
Global Compact and its principles into our business strategy, culture, and daily operations. We
are also committed to share this information with our stakeholders using our annual Corporate
Social Responsibility report available on our website.
My signature below affirms our company’s ongoing commitment and our intent to support andadvance the Compact’s ten universally accepted principles in the areas of human rights, labor,
environment, and anti-corruption. We are committed to support of achieving the United Nations
Sustainable Development Goals.
Sincerely yours,

Francis de Souza
Chief Executive Officer
Illumina, Inc.

Principle

Response/Illumina
CSR Report section

Cross Reference Applicable
GRI Section
GRI 102, 205, 401, 403, 405,
408, 409, 412, 413, 414

Human Rights
1

Businesses should support and respect the protection ofinternationally proclaimed human rights.

Integrity

2

Businesses should make sure that they are not complicit inhuman rights abuses.

Integrity

3

Businesses should uphold the freedom of association andthe effective recognition of the right to collective bargaining.

Integrity

4

Businesses should uphold the elimination of all forms offorced and compulsory labor.

Integrity

5

Businesses should uphold the effective abolition ofchild labor.

Integrity

6

Businesses should uphold the elimination of discriminationin respect of employment and occupation.

Integrity, People

LabourGRI 401, 402, 405, 408, 409, 412, 414

Environment
7

Businesses should support a precautionary approach toenvironmental challenges.

Environment, Integrity

8

Businesses should undertake initiatives to promote greater
environmental responsibility.

Environment, Integrity

9

Businesses should encourage the development anddiffusion of environmentally friendly technologies.

Environment, Integrity

GRI 302, 303, 305, 306, 308

Anti-Corruption
10

Businesses should work against corruption in all its forms,
including extortion and bribery.

Integrity

GRI 205, 206, 414, 415, 417

Illumina • 5200 Illumina Way • San Diego, CA 92122 • Tel 858.202.4500 • Fax 858.202.4766 • www.illumina.com

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

107

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Our CSR Goals and SDG Connections
We align our priorities and targets to support the 17 United Nations Sustainable Development Goals and have identified eight we can most uniquely impact.

CSR Focus Area

CSR Goal Description

Expanding Accessto Genomics$100 Genome
2 billion covered lives by 2026

SDG Link

CSR Focus Area

CSR Goal Description

Integrating
Environmental
Sustainability

Net Zero in operations and value chain by 2050

SDG Link

46% emission reduction (Scopes 1, 2, and 3)

50,000 patients supported through iHope™ programming

Carbon neutral in direct operations (Scopes 1 and 2) by 2023 beyond SBTi

Enable $60 million PGI philanthropic commitment by 2027

$20 million philanthropic support for sustainability initiatives

Reach over 200 organizations through Illumina for Startups

100% renewable electricity
10% reduction water intensity
90% landfill waste diversion
Green design principles in new construction with LEED elements or equivalent

Empowering
Our Communities

50% employee participation (giving + volunteering)

Reduce energy intensity of sequencers

100,000 volunteer hours

Reduce petroleum-based plastic use

Achieve 90% positive employee survey rate on Illumina Cares programming

Replace chemicals of concern with green alternatives wherever possible

5 million STEM learners reached through direct programming and nonprofit partners

Seek additional opportunities to engage in circular economy
100% of strategic suppliers commit to minimizing their environmental footprint
75% reduction in packaging

Nurturing
Our People

Maintain Net Zero Pay Gap
Increase representation of women in leadership
Increase representation of women in executive leadership
Increase representation of Black, Native, Pacific Islander, Hispanic or Latino, 2 or morecommunities in US workforce and leadership

90% of our secondary and tertiary packaging will be recyclable, reusable or compostable
OperatingResponsibly

20% of yearly spend with diverse suppliers (US)
Demonstrate responsible data stewardship with strong privacy and cybersecurity practices
Position Illumina as the most trusted company in genomic privacy and ethics

Improve representation of Veteran workforce

Continue working to ensure human rights are respected in our workplace, our supply chain,and the marketplace

Improve representation of disability workforce

Maintain a corporate governance framework promoting ethics and integrity in all we do

Increase prevention-based safety reporting and decrease injury and illness rates

Achieve top industry ESG ratings, indices, and rankings

Notes:
12030 target year unless different target date is specified.

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

108

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Independent Limited Assurance
Report to Illumina, Inc.
Background and introduction
ISOS Group, Inc. (“ISOS” or “we”) were engaged by Illumina, Inc. (“Illumina” or “Company”) to undertake a limited
assurance engagement in accordance with ISAE 3000 and ISAE 3410 covering select information reported within
Illumina’s 2022 Corporate Social Responsibility Report (“2022 CSR Report”) for the period beginning January 1, 2021,
and ending December 31, 2021 (“FY21”).
We have performed our limited assurance engagement in accordance with the International Standard on Assurance
Engagements 3000 (ISAE 3000), Assurance other than Audits or Reviews of Historical Financial Information, as wellas the International Standard on Assurance Engagements 3410 (ISAE 3410) Assurance Engagements on Greenhouse
Gas Statements, issued by the International Auditing and Assurance Standards Board. The engagement covered allentities and all facilities under the operational control of Illumina.
Our review was limited to the data reported in the following Key Performance Indicator Summary sections(pages 88 - 95) and marked with the symbol * (“Reported Information”), comprising of:Integrating Environmental Sustainability:

Nurturing Our People:• Energy Consumption• Workforce Data

• Energy Consumption by Activity and Region• Gender Data

• Renewable Electricity Consumption• Percentage Female and Male of Each EEOC
Category (US)• Emissions• Regional Emissions• Greenhouse Gas Breakdown• Country-Specific Scope 1• Country- Specific Scope 2 Market-Based• Facility-Specific Emissions• Emission Intensity Ratios• Scope 3 Emissions• Scope 3 Emissions: % of Total Scope 3 Emissions• Water
2022 CORPORATE SOCIAL RESPONSIBILITY REPORT

We have not performed any procedures with respect to other information included in the Illumina 2022 Corporate
Responsibility Report and, therefore, no conclusion on the Report as a whole is expressed.

Reporting criteria
The reporting criteria are the standards identified in the 2022 CSR Report – Reporting Overview (“Reporting Criteria”).

Inherent uncertainty
The nature of non-financial information and the methods used to determine non-financial information, allow fordifferent, but acceptable measurement techniques, which can result in materially different measurements and can
impact accuracy and comparability. Furthermore, the nature and methods used to determine such information, as
well as the measurement criteria and the precision thereof, may change over time.
The Reported Information has been measured applying the Reporting Criteria, which has been adopted solely forthe purpose of providing this non-financial information. As such the Reported Information may not be suitable foranother purpose. Where significant assumptions or deductions are utilized, they are disclosed. Where direct data
was unavailable, the company used industry standards as estimates. The assurance provided therefore does notguarantee or provide certainty over the completeness of reported data.

• EEOC Minority Summary (US)

Illumina’s responsibilities• EEOC Minority by Category (US)The Company’s management are responsible for:• EEOC Data by Level (US)• The accuracy and completeness of the information contained in the Reported Information.

• New Hire Data

• T he design, implementation, and maintenance of internal controls relevant to the preparation of thereport to provide reasonable assurance that the report is free from material misstatement, whether due
to fraud or error.

• Percentage New Hire per EEOC (US)• Promotion Data
• Promotion Rate by EEOC (US)• E
 nsuring the Reported Information is fairly stated in accordance with the applicable criteria (“Reporting
Criteria”) and for the content and statements contained therein.

• Veteran Data (US)• Employee Turnover Data
109

Illumina

AccessCommunity

Environment

PeopleIntegrity

Appendix

Reporting Overview | Key Performance Indicators | Indices | Assurance Statements | Disclosures

Assurance Statements

Our responsibilities
Our responsibility is to express a limited assurance conclusion in accordance with ISAE 3000 and ISAE 3410 whether
the Reported Information has been properly prepared in accordance with the Reporting Criteria and to provide this ina report to Illumina.

Work performed
The procedures we performed were based on our professional judgment. Our work included, but was not limited to:• Assessing the appropriateness of the Reporting Criteria for the Reported Information.
• C arrying out interviews with key personnel to understand the systems and controls in place during
the reporting period.
• Assessing the systems, processes, and controls to collate, aggregate, validate and report the data.
• R eviewing a selection of factors and formulae used and calculations performed over theReported Information.
• C onsidering the appropriateness of the Reported Information provided by Illumina and any third-party
data management system service providers.
• T esting a sample of records against underlying records, which were either individually material or where
there was potential for errors to accumulate to material amounts included:◦ T esting of energy consumption, scope 1 and 2 emissions, and water consumption at company
facilities across 12 countries in scope of the reporting.
◦ Testing of scope 3 emissions across the 11 calculated scope 3 emissions categories.

The relative effectiveness and significance of specific control procedures at Illumina and their effect on assessment ofcontrol risk at a facility level are dependent on their interaction with the controls and other factors present at individual
facilities. We have not performed any procedures to evaluate the effectiveness of controls at individual facilities. We
have not conducted any work outside the agreed scope and therefore restrict our conclusion to the above-mentioned
subject matter.

Restriction of use
This assurance report is made solely to Illumina in accordance with the terms of our engagement, which include
agreed arrangements for disclosure. Our work has been undertaken so that we might state to Illumina those matters
we have been engaged to state in this limited assurance report and for no other purpose. Our limited assurance
report should not be regarded as suitable to be used or relied on by any party wishing to acquire rights against us
other than Illumina for any purpose or in any context. Any party other than Illumina who obtains access to our limited
assurance report or a copy thereof and chooses to rely on our limited assurance report (or any part thereof) will doso at its own risk. To the fullest extent permitted by law, we accept or assume no responsibility and deny any liability
to any party other than Illumina for our work, for this independent limited assurance report, or for the conclusions wehave reached.

Conclusion
Based on the procedures we have performed and the evidence we have obtained, nothing has come to ourattention that causes us to believe that the Reported Information, noted in the Key Performance Indicator Summary(pages 88 - 95) for FY21 ended on December 31, 2021, has not been prepared, in all material respects, in accordancewith Illumina’s Reporting Criteria.

◦ T esting of human capital data aggregated across three regions and 28 countries where company
operates, including against EEO-1 reporting for US operations.
• Reperforming a selection of calculations of the Reported Information.
Brian Noveck

CSAP Practitioner for, and on behalf of, ISOS Group, Inc.
31 March 2022

2022 CORPORATE SOCIAL RESPONSIBILITY REPORT110

Disclosures
This release may contain forward-looking statements that involve risks and uncertainties.
Among the important factors to which our business is subject that could cause actual
results to differ materially from those in any forward-looking statements are: (i) the impact
to our business and operating results of the COVID-19 pandemic; (ii) changes in the rateof growth in the markets we serve; (iii) the volume, timing and mix of customer orders
among our products and services; (iv) our ability to adjust our operating expenses toalign with our revenue expectations; (v) our ability to manufacture robust instrumentationand consumables; (vi) the success of products and services competitive with our own;(vii) challenges inherent in developing, manufacturing, and launching new products andservices, including expanding or modifying manufacturing operations and reliance onthird-party suppliers for critical components; (viii) the impact of recently launched or
pre-announced products and services on existing products and services; (ix) our ability
to further develop and commercialize our instruments, consumables, and products,
including Galleri®, the cancer screening test developed by GRAIL, to deploy new products,
services, and applications, and to expand the markets for our technology platforms;(x) the risks and costs associated with the integration of, and our ability to integrate,
GRAIL’s business successfully to achieve anticipated synergies, including the restrictions
on integration during the hold separate period or any delay in integration following thehold separate period; (xi) the risk that disruptions from the consummation of our recent
acquisition of GRAIL or any associated legal or regulatory proceedings or obligations will
harm our business, including current plans and operations; (xii) potential adverse reactions
or changes to business relationships resulting from the consummation of our recent
acquisition of GRAIL; (xiii) our ability to obtain approval by third-party payors to reimburse
patients for our products; (xiv) our ability to obtain regulatory clearance for our products
from government agencies; (xv) our ability to successfully partner with other companies
and organizations to develop new products, expand markets, and grow our business;(xvi) our ability to successfully identify and integrate acquired technologies, products,
or businesses; (xvii) the application of generally accepted accounting principles, which
are highly complex and involve many subjective assumptions, estimates, and judgmentsand (xviii) legislative, regulatory and economic developments, together with other factors
detailed in our filings with the Securities and Exchange Commission, including our mostrecent filings on Forms 10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We undertake no obligation,and do not intend, to update these forward-looking statements, to review or confirm
analysts’ expectations, or to provide interim reports or updates on the progress of thecurrent quarter.

Stay up to date on recent news, stories,
and more by connecting with us.

+1.800.809.4566 toll-free (US)+1.858.202.4566 tel
www.illumina.com©2022 Illumina, Inc.
All rights reserved. All other names, logos, and othertrademarks are the property of their respective owners.

Photo Credit: Juanfang Wu
Illumina Staff Engineer
Photo Location: Illumina HQ, San Diego, CA